GlaxoSmithKline_NNP 159_CD Index_NNP page_NN page_NN page_NN A_DT Corporate_JJ Executive_NNP Team_NNP 25,33,34,36,40,42_CD ,_, Forward-looking_VBG statements_NNS 2,64,65_CD Access_NNP to_TO healthcare_NN 27_CD 44,46,50,121_CD G_NNP Accountability_NNP ,_, audit_NN and_CC internal_JJ control_NN 35_CD Corporate_JJ governance_NN 4,34-38_CD ,74_CD Gearing_NNP 52_CD Accounting_NNP policies_NNS 59,83-85_CD Corporate_JJ Social_NNP Responsibility_NNP Committee_NNP 34_CD Global_JJ community_NN partnerships_NNS 4,27-29_CD Accounting_NN standards_NNS 65,72,82-85_CD ,124_CD Critical_JJ accounting_NN policies_NNS 59_CD Global_JJ Supply_NN Network_NNP 14_CD Acquisitions_NNS and_CC disposals_NNS 78,79,108,124_CD Cross_NNP reference_NN to_TO Form_NN 20-F_JJ 157_CD Glossary_NNP of_IN terms_NNS 158_CD ADR_NNP program_NN administrator_NN 153_CD ,_, D_NNP Going_VBG concern_NN basis_NN 37,74_CD inside_IN back_RB cover_VB Derivative_JJ financial_JJ instruments_NNS 62,63,85,111-113_CD ,_, Goodwill_NNP ,_, American_NNP Depositary_NNP Shares_NNP 5,152,153,155_CD 123,124,126-129_CD Animals_NNS and_CC research_NN 22_CD Dermatologicals_NNS 9_CD Governmental_NNP investigations_NNS 65,103,106,107_CD Annual_JJ General_NNP Meeting_VBG 34,35,40,153_CD Description_NN of_IN business_NN 6-29_CD ,82_CD Group_NNP companies_NNS 139-141_CD Antitrust_NNP 37,106_CD Dialogue_NN with_IN shareholders_NNS 34_CD Anti-bacterials_NNS 7,8_CD ,_, Direct-to-consumer_JJR advertising_NN 13_CD H_NNP Anti-virals_NNPS 7,8_CD ,_, Directors_NNS and_CC senior_JJ management_NN 32-33_CD ,45,48_CD ,_, Healthcare_NNP Services_NNPS 58,88,148_CD Associates_NNPS 50,119,120_CD Hedging_NNP Audit_NNP Committee_NNP 34-38_CD ,74_CD Directors_NNS History_NN and_CC development_NN of_IN the_DT company_NN 6_CD Auditors_NNS ,_, independent_JJ 4,34-38_CD ,75_CD interests_NNS 47,49,50_CD HIV_NNP and_CC AIDS_NNP 3,4_CD ,_, 7,8_CD ,_, ,_, interests_NNS in_IN contracts_NNS 50_CD 54-56_CD ,66_CD -69,144_CD -147_CD B_NNP remuneration_NN 39-50_CD Balance_NN sheet_NN ,_, I_PRP report_VBP 2-72_CD 123,125,129_CD Impairment_NN of_IN assets_NNS ,_, responsibility_NN 74_CD Block_NNP Drug_NNP 126,128-130_CD ,132_CD share_NN options_NNS 41,42,48,155_CD 109,122_CD Independent_NNP Auditors_NNS 4,34-38_CD ,75_CD share_NN ownership_NN guidelines_NNS 42_CD Board_NNP and_CC Executive_NNP 34_CD Information_NNP technology_NN 24,37,65_CD terms_NNS and_CC conditions_NNS 43-45_CD Board_NNP committees_NNS 32,34_CD In-licensing_JJ 14,15,18,21,22,57_CD Diversity_NN 25_CD Business_NN and_CC the_DT Community_NNP 26_CD Intangible_JJ assets_NNS ,_, Divested_JJ businesses_NNS 88_CD Business_NN performance_NN ,_, 122,125-133_CD ,137_CD Divested_JJ products_NNS 66,67,69,148_CD Intellectual_NNP property_NN Dividends_NNS ,_, Business_NNP segments_NNS 6,86-88_CD ,132,134,135_CD ,_, Interest_NN cover_NN 52_CD 139-141_CD ,148_CD Interest_NN rate_NN risk_NN management_NN 63,110_CD Internal_NNP control_NN 34,35_CD E_NNP C_NNP Investments_NNP ,_, Earnings_NNS per_IN share_NN ,_, Capital_NNP employed_VBD 80,149,150_CD Capital_NNP expenditure_NN 61,78,79,124,150_CD Investor_NNP information_NN 151-156_CD Employees_NNS Cardiovascular_NNP 7-9_CD ,15_CD costs_NNS 90,114-118_CD Cash_NN flow_NN J_NNP diversity_NN 25 128-132_CD Joint_NNP ventures_NNS and_CC involvement_NN 29_CD Cautionary_JJ statement_NN 2_CD associates_NNS numbers_NNS 114,150_CD Central_NNP nervous_JJ system_NN CNS_NNP 7,8_CD ,_, 10,54-56_CD ,_, 96,134_CD performance_NN and_CC reward_NN 24_CD 66-68_CD ,144_CD -148_JJ share_NN schemes_NNS 118-121_CD Centres_NNS of_IN Excellence_NN for_IN Drug_NN Discovery_NNP CEDD_NNP L_NNP development_NN 25_CD 20,21_CD Leases_NNP Employee_NNP Share_NNP Ownership_NNP Trusts_NNPS ESOTs_NNP 60,61_CD ,_, Chairman_NNP and_CC Chief_NNP Executive_NNP Legal_NNP proceedings_NNS 23,37,64,65,103-107_JJ Officers_NNPS statement_NN 3,4_CD Liquid_NN investments_NNS ,_, Environment_NNP ,_, health_NN and_CC safety_NN 26,37,83,98,107_CD ,_, Charitable_JJ donations_NNS 27-29_JJ 124,126,128_CD 153_CD Chlorofluorocarbons_NNS CFCs_NNP 17-19_CD Loans_NNPS and_CC overdrafts_NNS 80,90,99,110,111_CD Equity_NN risk_NN management_NN 63_CD Combined_NNP Code_NNP 37,40,74_CD Lymphatic_NNP Filariasis_NNP 4,28,29_NNP Exchange_NNP controls_VBZ 155_CD Commitments_NNP Exchange_NNP rates_NNS 2,5_CD ,_, ,_, M_NNP Community_NNP investment_NN 26-29_CD 124,152_CD Malaria_NNP 7,8_CD ,_, 10,15,17,18,21,27-29_CD Competition_NN External_NNP suppliers_NNS 14_CD Manufacture_NN and_CC supply_NN 6,13,14_CD Consumer_NNP Healthcare_NNP Manufacturing_NNP and_CC other_JJ restructuring_NN 82,83_CD ,_, business_NN sector_NN segment_NN 6,86-88_CD ,132,134_CD ,_, F_NN 135,148_CD Fair_NNP values_NNS ,_, Market_NNP capitalization_NN 40,64,152_CD competition_NN 11,57,69_CD 128-133_CD ,137_CD -138_CD Marketing_NNP and_CC distribution_NN 13_CD manufacturing_NN and_CC supply_NN 13_CD Finanial_NNP Results_NNS Committee_NNP 34_CD Maturity_NN and_CC counterparty_NN risk_NN 63_CD marketing_NN and_CC distribution_NN 14_CD Financial_NNP assets_NNS and_CC liabilities_NNS 63,110,111_CD Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP 155_CD products_NNS 9_CD Financial_NNP instruments_NNS 62,63,85,100,110-113_CD Merger_NNP accounting_NN adjustments_NNS 85_CD sales_NNS Financial_JJ period_NN 82,150_CD Metabolic_NNP and_CC gastro-intestinal_JJ 7,8_CD ,_, 10,15,20,21_CD ,_, research_NN and_CC development_NN 22_CD Financial_NNP position_NN 60,137_CD regulation_NN 12_CD Financial_NNP record_NN trade_NN marks_NNS 23_CD N_NNP 5_CD year_NN record_NN 148-150_CD Constant_JJ exchange_NN rate_NN CER_NNP 2,9_CD ,_, 51,55-59_CD ,_, Net_JJ debt_NN quarterly_JJ trend_NN 142-147_CD 64,67,142-148_CD Net_JJ interest_NN payable_JJ ,_, Financial_JJ reporting_NN calendar_NN 153_CD Contact_NN details_NNS inside_IN back_JJ cover_NN 142,149_CD Financial_NNP Reporting_NNP Standards_NNPS FRS_NNP 2,52,58-60_CD ,63_CD ,_, Contaminated_VBN land_NN 65_CD New_NNP products_NNS Contingent_JJ liabilities_NNS 60,61,98,125_CD Nominations_NNPS Committee_NNP 34,40_CD Financial_NNP statements_NNS 73-141_CD Control_NN of_IN company_NN 155_CD Non-Executive_JJ Directors_NNS 32,34,40,45-47_NNP Financial_NNP summary_NN 2_CD Corporate_NNP Administration_NNP &_CC Noon_NNP buying_VBG rate_NN 71_CD Financial_NNP trends_NNS and_CC ratios_NNS 52_CD Transactions_NNS Committee_NNP 34_CD Nutritional_NNP healthcare_NN 6,9_CD ,_, 11,13,14,22,57,69_CD ,_, Fixed_VBN asset_NN investments_NNS 96,97,123_CD 86,148_CD Foreign_JJ exchange_NN risk_NN management_NN 63,110_CD 160_CD GlaxoSmithKline_NNP Index_NNP page_NN page_NN page_NN O_NNP S_NNP V_NNP Oncology_NNP and_CC emesis_NN ,_, Sales_NNS Vaccines_NNS 144-148_CD Consumer_NN Healthcare_NNP 52,57,69,86,134,135_CD ,_, 82,86,105,144-148_CD Operating_NN and_CC financial_JJ review_NN 142,148_CD W_NNP and_CC prospects_NNS 51-72_CD Pharmaceuticals_NNS ,_, World_NNP economy_NN 53_CD Oral_NNP care_NN 6,9_CD ,_, 69,86,142-148_CD World_NNP market_NN 53_CD Other_JJ operating_NN income_NN expense_NN 57,58,69,70_CD ,_, SB_NNP Clinical_NNP laboratories_NNS 107,108_CD 76,89,126,142_CD Segment_NN information_NN 6,86-88_CD ,132,134,135_CD ,_, Outlook_NNP 53,64_CD 139-141_CD ,148_CD Over-the-counter_NN OTC_NNP medicines_NNS 6,9_CD ,_, 11,13,57,69_CD Selected_VBN financial_JJ data_NNS 71_CD 82,86,148_CD Senior_JJ management_NN compensation_NN and_CC interests_NNS 50_CD P_NNP Share_NN buy-back_NN Patents_NNP 3,4_CD ,_, Share_NN capital_NN Payment_NN policies_NNS 62_CD Share_NN premium_NN 80,81,85,101,150_CD Pension_NN and_CC other_JJ post-retirement_JJ Share_NN price_NN 46,48,49,53,152-154_JJ benefits_NNS ,_, Share_NN purchases_NNS 62,63_CD Share_NN statistics_NNS 149_CD Pharmaceuticals_NNS Shareholder_NN information_NN 153_CD approvals_NNS and_CC submissions_NNS 11,12,19_CD Shareholder_NN return_NN 42,119,120,152_CD business_NN sector_NN Shareholders_NNS funds_NNS 60,80,82_CD competition_NN 10_CD Shareholdings_NNS analysis_NN 155_CD manufacturing_NN and_CC supply_NN 13,14_CD Statement_NN of_IN total_JJ marketing_NN and_CC distribution_NN 13_CD recognized_VBN gains_NNS and_CC losses_NNS 76,77_CD products_NNS 7-14_JJ ,19,53,54,58,64_CD sales_NNS ,_, T_NNP 142-148_CD Taxation_NNP ,_, research_NN and_CC development_NN 10,14-22_CD ,25,37,52_CD ,_, ,_, Taxation_NNP information_NN for_IN shareholders_NNS 156_CD 142,150_CD Tax_NNP rate_NN regulation_NN 11-12_CD Trade_NNP marks_NNS 5,23_CD patents_NNS and_CC trade_NN marks_NNS 5,23_CD Treasury_NNP operations_NNS 37,62,85_CD Pipeline_NNP 14-17_CD Treasury_NNP policies_NNS 62,63_CD Presentation_NN of_IN financial_JJ statements_NNS 82_CD Tuberculosis_NNPS 27_CD Price_NN controls_NNS 12,64_CD Profit_NN and_CC loss_NN account_NN ,_, U_NNP UK_NNP segment_NN 88_CD Property_NN ,_, plant_NN and_CC equipment_NN 25,125_CD US_NNP GAAP_NNP reconciliation_NN to_TO US_NNP accounting_NN Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS 60,61,80,90_CD principles_NNS 122-138_JJ consolidated_JJ balance_NN sheet_NN 125_CD R_NN consolidated_JJ income_NN statement_NN 126,127_CD Reconciliation_NNP of_IN equity_NN of_IN movements_NNS comprehensive_JJ income_NN and_CC in_IN equity_NN shareholders_NNS funds_NNS 80,82_CD changes_NNS in_IN shareholders_NNS equity_NN 126,127_CD Registrar_NNP 153_CD consolidated_JJ statement_NN of_IN cash_NN flows_VBZ 124,128_CD Regulation_NN 11,12_CD earnings_NNS per_IN share_NN ADS_NNPS 133_CD Remuneration_NNP Committee_NNP 34,40_CD material_NN differences_NNS between_IN Remuneration_NNP report_NN 39-50_CD UK_NNP and_CC US_NNP GAAP_NNP 122-124_CD Report_NNP of_IN the_DT Directors_NNS 2-72_JJ post-retirement_NN benefits_NNS 123,136-138_CD Research_NNP collaborations_NNS 21,110_CD purchase_NN accounting_NN 130,131_CD Research_NNP and_CC development_NN results_NNS under_IN US_NNP accounting_NN principles_NNS 72_CD accounting_NN policy_NN 83_CD segment_NN information_NN 134,135_CD animals_NNS and_CC research_NN 22_CD selected_VBN financial_JJ data_NNS 71_CD Consumer_NN Healthcare_NNP 22_CD taxation_NN 133_CD diseases_NNS of_IN the_DT developing_VBG world_NN 21,27_CD expenditure_NN Pharmaceuticals_NNS 14-22_JJ pipeline_NN 14-17_CD Respiratory_NNP ,_, 144-148_CD Return_NN on_IN capital_NN employed_VBN 149_CD Revenue_NN accounting_NN policy_NN 83_CD Risk_NN factors_NNS 64,65_CD Risk_NNP Oversight_NNP and_CC Compliance_NNP Council_NNP ROCC_NNP 36_CD Contact_NN details_NNS INTERNET_NNP Information_NNP for_IN investors_NNS and_CC about_IN the_DT company_NN is_VBZ available_JJ on_IN GlaxoSmithKlines_NNP corporate_JJ website_NN at_IN www_NN ._.
com_NN HEAD_NNP OFFICE_NNP AND_CC REGISTERED_NNP OFFICE_NNP GlaxoSmithKline_NNP plc_NN 980_CD Great_NNP West_NNP Road_NNP Brentford_NNP Middlesex_NNP TW8_NNP 9GS_NNP Tel_NNP :_: 44_CD 0_CD 20 8047 5000_CD UNITED_NNP KINGDOM_NNP UNITED_NNP STATES_NNS OF_IN AMERICA_NNP Investor_NNP relations_NNS Investor_NNP relations_NNS 980_CD Great_NNP West_NNP Road_NNP One_CD Franklin_NNP Plaza_NNP Brentford_NNP PO_NNP Box_NNP 7929_CD Middlesex_NNP TW8_NNP 9GS_NNP Philadelphia_NNP Tel_NNP :_: 44_CD 0_CD 20 8047 5557 5558_CD PA_NNP 19101_CD Fax_NNP :_: 44_CD 0_CD 20 8047 7807_CD Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ Tel_NNP :_: 1_CD 215 751 7003_CD outside_IN the_DT USA_NNP Registrar_NNP Fax_NNP :_: 1_CD 215 751 3233_CD Lloyds_NNP TSB_NNP Registrars_NNPS The_DT Causeway_NNP ADR_NNP program_NN administrator_NN Worthing_NNP The_NNP Bank_NNP of_IN New_NNP York_NNP West_NNP Sussex_NNP BN99_NNP 6DA_NNP Shareholder_NN Relations_NNP www_NN ._.
co._FW uk_FW PO_FW Box_NNP 11258_CD Church_NNP Street_NNP Station_NNP General_NNP enquiries_NNS ,_, Annual_JJ Report_NNP orderline_NN and_CC New_NNP York_NNP NY_NNP 10286-1258_CD Corporate_JJ Nominee_NN service_NN www_NN ._.
com_NN Tel_NNP :_: 0870 600 3991_CD inside_IN the_DT UK_NNP Tel_NNP :_: 1_CD 877 353 1154_CD toll_NN free_JJ Tel_NNP :_: 44_CD 0_CD 121 415 7067_CD outside_IN the_DT UK_NNP Tel_NNP :_: 1_CD 610 312 5315_CD outside_IN the_DT USA_NNP Shareholder_NN Investment_NN Plans_NNS Customer_NN response_NN center_NN Dividend_NN re-investment_JJ enquiries_NNS Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ Tel_NNP :_: 0870 241 3018_CD inside_IN the_DT UK_NNP Tel_NNP :_: 44_CD 0_CD 1903 604 516_CD outside_IN the_DT UK_NNP Monthly_JJ Savings_NNPS Plan_NNP enquiries_VBZ Tel_NNP :_: 0870 606 0268_CD inside_IN the_DT UK_NNP Tel_NNP :_: 44_CD 0_CD 131 527 3746_CD outside_IN the_DT UK_NNP ISA_NNP enquiries_VBZ Tel_NNP :_: 0870 242 4244_CD inside_IN the_DT UK_NNP Tel_NNP :_: 44_CD 0_CD 1903 604 594_CD outside_IN the_DT UK_NNP Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP corporate_JJ PEPs_NNS The_DT Share_NN Centre_NNP Limited_NNP Oxford_NNP House_NNP Oxford_NNP Road_NNP Aylesbury_NNP Bucks_NNP HP21_NNP 8SZ_NNP Tel_NNP :_: 44_CD 0_CD 1296 414 144_CD Corporate_JJ share_NN dealing_VBG facility_NN NatWest_NNP Stockbrokers_NNS Corporate_NNP &_CC Employee_NNP Service_NNP 55_CD Mansell_NNP Street_NNP London_NNP E1_NNP 8AN_NNP Tel_NNP :_: 0870 600 3080_CD inside_IN the_DT UK_NNP Tel_NNP :_: 44_CD 0_CD 20 7895 5923_CD outside_IN the_DT UK_NNP email_NN :_: contactces@natwest_JJS ._.
com_NN quoting_VBG GSK_NNP Shareholders_NNP Service_NNP Printed_NNP by_IN St._NNP Ives_NNP Westerham_NNP Press_NNP in_IN the_DT UK_NNP ._.
The_DT paper_NN used_VBN in_IN the_DT production_NN of_IN this_DT document_NN is_VBZ made_VBN from_IN pulp_NN harvested_VBN from_IN sustainable_JJ forests_NNS ,_, also_RB using_VBG sawmill_NN residues_NNS and_CC forest_NN thinnings_NNS ._.
The_DT Impact_NN of_IN Medicines_NNP Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_JJR Annual_JJ Review_NNP 2002_CD Front_NNP cover_NN photograph_NN Although_IN a_DT generation_NN separates_VBZ them_PRP ,_, Bettina_NNP Bartels_NNPS and_CC her_PRP$ son_NN Philippe_NNP are_VBP able_JJ to_TO lead_VB active_JJ lives_NNS despite_IN both_DT suffering_VBG from_IN asthma_NN ._.
Our_PRP$ feature_NN story_NN on_IN pages_NNS 4_CD and_CC 5_CD traces_NNS the_DT advances_NNS in_IN the_DT treatment_NN of_IN asthma_NN ._.
Contents_NNS 01_CD Chairman_NNP and_CC CEOs_NNS statement_NN 17_CD The_DT Corporate_JJ Executive_NNP Team_NNP 04_CD Patients_NNPS and_CC product_NN development_NN 18_CD Business_NN operating_NN review_NN 06_CD R&D_NNP productivity_NN 20_CD Responsibility_NN statements_NNS 08_CD Innovative_JJ science_NN 21_CD Corporate_JJ governance_NN 10_CD Diseases_NNS of_IN the_DT developing_VBG world_NN 22_CD Summary_NNP financial_JJ statements_NNS 12_CD Our_PRP$ people_NNS 24_CD Summary_NNP information_NN under_IN US_NNP GAAP_NNP 14_CD Corporate_JJ and_CC social_JJ responsibility_NN 25_CD Summary_NNP remuneration_NN report_NN 15_CD Product_NNP portfolio_NN 27_CD Shareholder_NN information_NN 16_CD The_NNP Board_NNP 29_CD Contact_NN details_NNS ANNUAL_NNP REVIEW_NNP 2002_CD 01_CD CHAIRMAN_NNP AND_CC CHIEF_JJ EXECUTIVE_NN OFFICERS_NNS STATEMENT_NNP The_DT purpose_NN of_IN GlaxoSmithKline_NNP is_VBZ to_TO deliver_VB medicines_NNS that_WDT have_VBP a_DT positive_JJ impact_NN on_IN the_DT quality_NN of_IN human_JJ life_NN ._.
We_PRP have_VBP chosen_VBN this_DT fundamental_JJ and_CC challenging_JJ objective_NN as_IN the_DT theme_NN of_IN this_DT years_NNS Annual_JJ Review_NNP ._.
We_PRP are_VBP pleased_JJ to_TO report_VB that_DT 2002_CD was_VBD from_IN our_PRP$ key_JJ therapy_NN areas_NNS including_VBG a_DT year_NN of_IN significant_JJ progress_NN in_IN establishing_VBG central_JJ nervous_JJ system_NN ,_, respiratory_JJ ,_, anti-virals_JJ GlaxoSmithKline_NNP as_IN one_CD of_IN the_DT worlds_NNS leading_VBG and_CC vaccines_NNS ._.
We_PRP achieved_VBD strong_JJ financial_JJ results_NNS in_IN 2002_CD ,_, despite_IN the_DT Our_PRP$ business_NN performance_NN earnings_NNS per_IN share_NN entry_NN of_IN generic_JJ competition_NN in_IN the_DT USA_NNP grew_VBD by_IN 13_CD per_IN cent_NN ,_, delivering_VBG on_IN our_PRP$ to_TO Augmentin_NNP ,_, one_CD of_IN our_PRP$ major_JJ products_NNS ._.
guidance_NN and_CC demonstrating_VBG the_DT continuing_VBG financial_JJ strength_NN that_WDT will_MD provide_VB the_DT Group_NNP Our_PRP$ progress_NN stems_VBZ from_IN the_DT Groups_NNS key_JJ with_IN a_DT sound_JJ platform_NN for_IN the_DT future_NN ._.
strengths_NNS :_: a_DT broadly_RB based_VBN product_NN portfolio_NN ,_, strong_JJ financial_JJ capability_NN and_CC a_DT promising_JJ GlaxoSmithKline_NNP has_VBZ made_VBN good_JJ progress_NN early_RB stage_NN pipeline_NN of_IN products_NNS ._.
We_PRP have_VBP with_IN its_PRP$ merger_NN and_CC manufacturing_NN built_VBN on_IN each_DT of_IN these_DT core_NN attributes_VBZ in_IN 2002_CD restructuring_NN plans_NNS and_CC we_PRP remain_VBP on_IN track_NN and_CC we_PRP are_VBP confident_JJ that_IN they_PRP will_MD help_VB to_TO deliver_VB forecast_NN total_JJ annual_JJ merger_NN and_CC GlaxoSmithKline_NNP to_TO continue_VB to_TO deliver_VB manufacturing_VBG restructuring_NN savings_NNS of_IN success_NN in_IN the_DT future_NN ._.
We_PRP are_VBP not_RB stopping_VBG there_RB :_: our_PRP$ continuous_JJ improvement_NN While_IN achieving_VBG business_NN success_NN it_PRP is_VBZ essential_JJ program_NN ,_, Operational_NNP Excellence_NNP ,_, that_IN we_PRP demonstrate_VBP to_TO all_DT our_PRP$ stakeholders_NNS ,_, is_VBZ delivering_VBG additional_JJ savings_NNS and_CC will_MD around_IN the_DT world_NN ,_, how_WRB we_PRP conduct_VBP our_PRP$ continue_VBP to_TO do_VB so_RB ._.
business_NN with_IN integrity_NN and_CC continue_VB to_TO make_VB a_DT positive_JJ contribution_NN to_TO society_NN ._.
NEW_NNP PRODUCT_NNP GROWTH_NN DRIVES_NNP COMMERCIAL_NNP STRENGTH_NNP GOOD_NNP FINANCIAL_NNP PERFORMANCE_NN The_DT success_NN of_IN our_PRP$ new_JJ products_NNS is_VBZ providing_VBG We_PRP delivered_VBD a_DT very_RB solid_JJ financial_JJ the_DT fuel_NN for_IN future_JJ growth_NN ,_, with_IN new_JJ products_NNS performance_NN in_IN 2002_CD in_IN a_DT challenging_JJ now_RB representing_VBG 27_CD per_IN cent_NN of_IN total_JJ operating_NN environment_NN ._.
Global_JJ pharmaceutical_JJ pharmaceutical_JJ sales_NNS ,_, up_RB 36_CD per_IN cent_NN in_IN 2002_CD ._.
sales_NNS grew_VBD eight_CD per_IN cent_NN to_TO nearly_RB 18_CD billion_CD Sales_NNS of_IN Seretide_NNP Advair_NNP for_IN asthma_NN ,_, now_RB our_PRP$ and_CC US_NNP pharmaceutical_JJ sales_NNS grew_VBD 13_CD per_IN cent_NN ,_, second_RB largest_JJS product_NN ,_, continued_VBD to_TO grow_VB despite_IN generic_JJ competition_NN to_TO Augmentin_NNP ._.
impressively_RB ,_, up_RB 96_CD per_IN cent_NN to_TO 1.6_CD billion_CD ._.
The_DT Group_NNP demonstrated_VBD continued_VBN financial_JJ We_PRP recently_RB launched_VBD Avandamet_NNP for_IN type_NN 2_CD strength_NN with_IN total_JJ sales_NNS up_IN seven_CD per_IN cent_NN diabetes_NN and_CC Avodart_NNP for_IN benign_JJ prostatic_JJ and_CC business_NN performance_NN trading_NN profit_NN up_IN hyperplasia_NN ,_, as_RB well_RB as_IN important_JJ line_NN 15_CD per_IN cent_NN ._.
There_EX were_VBD strong_JJ performances_NNS extensions_NNS of_IN Augmentin_NNP and_CC Paxil_NNP ._.
Our_PRP$ global_JJ quest_NN is_VBZ to_TO improve_VB the_DT quality_NN of_IN human_JJ life_NN by_IN enabling_VBG people_NNS to_TO do_VB more_JJR ,_, feel_VB better_JJR and_CC live_VBP longer_RBR ._.
We_PRP at_IN GlaxoSmithKline_NNP will_MD dedicate_VB ourselves_PRP to_TO delivering_VBG innovative_JJ medicines_NNS and_CC products_NNS that_WDT help_VBP millions_NNS of_IN people_NNS around_IN the_DT world_NN live_RB longer_RB ,_, healthier_RBR and_CC happier_JJR lives_NNS ._.
CHAIRMAN_NN AND_CC CHIEF_JJ EXECUTIVE_NN OFFICERS_NNS STATEMENT_NN CONTINUED_VBD During_IN 2003-2004_CD we_PRP look_VBP forward_RB to_TO SUCCESS_NNP AS_NNP PARTNER_NNP OF_IN CHOICE_NNP A_DT federal_JJ judge_NN in_IN Chicago_NNP recently_RB ruled_VBD that_IN launching_VBG 12_CD new_JJ compounds_NNS and_CC line_NN The_DT size_NN and_CC quality_NN of_IN our_PRP$ global_JJ R&D_NNP GlaxoSmithKlines_NNP patent_NN in_IN the_DT USA_NNP covering_VBG extensions_NNS ._.
These_DT include_VBP Levitra_NNP ,_, a_DT new_JJ organization_NN ,_, together_RB with_IN the_DT strength_NN the_DT hemihydrate_JJ form_NN of_IN Paxil_NNP was_VBD valid_JJ but_CC treatment_NN for_IN erectile_JJ dysfunction_NN ,_, which_WDT of_IN our_PRP$ sales_NNS and_CC marketing_NN teams_NNS ,_, have_VBP not_RB infringed_VBN by_IN generics_NNS company_NN Apotexs_NNP we_PRP are_VBP co-promoting_JJ with_IN Bayer_NNP ,_, and_CC enabled_VBD GlaxoSmithKline_NNP to_TO become_VB the_DT product_NN ._.
We_PRP believe_VBP our_PRP$ patent_NN to_TO be_VB infringed_VBN Wellbutrin_NNP XL_NNP ,_, a_DT new_JJ and_CC improved_JJ version_NN partner_NN of_IN choice_NN in_IN the_DT industry_NN ._.
We_PRP have_VBP by_IN Apotexs_NNP product_NN and_CC will_MD appeal_VB against_IN of_IN our_PRP$ successful_JJ anti-depressant_JJ ._.
signed_VBD an_DT unprecedented_JJ 24_CD major_JJ external_JJ the_DT ruling_NN ._.
Also_RB ,_, we_PRP will_MD continue_VB to_TO pursue_VB collaborations_NNS in_IN the_DT last_JJ two_CD years_NNS which_WDT litigation_NN for_IN infringement_NN of_IN other_JJ patents_NNS CREATING_VBG THE_DT MOST_JJS PRODUCTIVE_NN has_VBZ helped_VBN to_TO boost_VB our_PRP$ product_NN portfolio_NN ._.
relating_VBG to_TO Paxil_NNP against_IN Apotex_NNP and_CC other_JJ R&D_NNP ORGANISATION_NNP It_PRP has_VBZ also_RB provided_VBN some_DT exciting_JJ new_JJ generics_NNS companies_NNS in_IN the_DT USA_NNP ._.
At_IN the_DT outset_NN of_IN the_DT merger_NN we_PRP rethought_VBP the_DT opportunities_NNS in_IN a_DT number_NN of_IN areas_NNS of_IN unmet_JJ way_NN R&D_NN was_VBD carried_VBN out_RP at_IN GlaxoSmithKline_NNP ,_, medical_JJ need_NN such_JJ as_IN erectile_JJ dysfunction_NN ,_, As_IN a_DT result_NN of_IN these_DT pending_VBG matters_NNS ,_, the_DT with_IN the_DT aim_NN of_IN creating_VBG the_DT most_RBS productive_JJ obesity_NN and_CC HIV_NNP ._.
possible_JJ timing_NN of_IN generic_JJ competition_NN to_TO R&D_NNP organization_NN in_IN the_DT industry_NN ._.
We_PRP established_VBD Paxil_NNP in_IN the_DT USA_NNP is_VBZ unclear_JJ ._.
Consequently_RB ,_, six_CD therapeutically_RB focused_VBD Centres_NNP of_IN Excellence_NNP PATENT_NNP CHALLENGES_NNP GlaxoSmithKlines_NNPS published_VBD earnings_NNS guidance_NN for_IN Drug_NN Discovery_NNP CEDDs_NNP ._.
The_DT CEDDs_NNS are_VBP Over_IN the_DT last_JJ year_NN there_EX have_VBP been_VBN a_DT number_NN for_IN 2003_CD remains_VBZ as_IN previously_RB stated_VBN ._.
The_DT nimble_JJ and_CC entrepreneurial_JJ with_IN the_DT range_NN of_IN of_IN developments_NNS involving_VBG the_DT patents_NNS on_IN guidance_NN is_VBZ for_IN high_JJ single_JJ digit_NN percentage_NN skills_NNS and_CC scale_NN of_IN resources_NNS required_VBN to_TO drive_VB some_DT of_IN our_PRP$ key_JJ products_NNS ._.
growth_NN in_IN business_NN performance_NN earnings_NNS mid-stage_NN development_NN projects_NNS through_IN to_TO per_IN share_NN at_IN constant_JJ exchange_NN rates_NNS ,_, their_PRP$ key_JJ decision_NN point_NN ,_, proof_NN of_IN concept_NN ,_, In_IN July_NNP ,_, in_IN the_DT USA_NNP ,_, the_DT first_JJ generic_JJ version_NN assuming_VBG there_EX is_VBZ no_DT generic_JJ competition_NN before_IN large-scale_JJ phase_NN III_NNP clinical_JJ trials_NNS ._.
This_DT followed_VBD a_DT to_TO Paxil_NNP in_IN the_DT USA_NNP ._.
If_IN a_DT generic_JJ launch_NN of_IN ruling_NN by_IN a_DT federal_JJ judge_NN that_IN our_PRP$ Augmentin_NNP paroxetine_NN hydrochloride_NN became_VBD imminent_JJ ,_, After_IN two_CD years_NNS of_IN activity_NN by_IN the_DT new_JJ R&D_NNP patents_NNS were_VBD invalid_JJ ._.
We_PRP are_VBP appealing_VBG against_IN GlaxoSmithKline_NNP would_MD reassess_NN this_DT guidance_NN ._.
organization_NN ,_, we_PRP are_VBP seeing_VBG significant_JJ progress_NN this_DT decision_NN ,_, in_IN the_DT firm_NN belief_NN that_WDT our_PRP$ patents_NNS as_IN we_PRP advance_VBP our_PRP$ promising_JJ early_JJ stage_NN are_VBP valid_JJ ._.
Meanwhile_RB ,_, we_PRP have_VBP already_RB offset_VBN Uptake_NNP of_IN Paxil_NNP CR_NNP ,_, our_PRP$ enhanced_JJ form_NN of_IN pipeline_NN of_IN pharmaceutical_JJ products_NNS through_IN some_DT of_IN the_DT impact_NN of_IN generics_NNS with_IN recent_JJ the_DT antidepressant_JJ launched_VBN in_IN 2002_CD ,_, has_VBZ been_VBN clinical_JJ development_NN ._.
successful_JJ launches_NNS of_IN new_JJ improved_VBN versions_NNS excellent_JJ and_CC it_PRP now_RB represents_VBZ over_IN 30_CD per_IN cent_NN of_IN Augmentin_NNP the_DT ES_NNP and_CC XR_NNP formulations_NNS ._.
of_IN Paxils_NNP new_JJ prescriptions_NNS in_IN the_DT USA_NNP ._.
GlaxoSmithKline_NNP has_VBZ 123_CD projects_NNS in_IN clinical_JJ development_NN ,_, of_IN which_WDT 61_CD are_VBP new_JJ chemical_NN GlaxoSmithKline_NNP is_VBZ also_RB involved_VBN in_IN litigation_NN We_PRP also_RB have_VBP patent_NN challenges_NNS to_TO a_DT number_NN entities_NNS in_IN a_DT number_NN of_IN therapy_NN areas_NNS ,_, and_CC over_IN the_DT patents_NNS on_IN Wellbutrin_NNP SR_NNP and_CC Zyban_NNP of_IN other_JJ products_NNS such_JJ as_IN Zofran_NNP and_CC Lamictal_NNP ._.
The_DT number_NN of_IN new_JJ chemical_NN in_IN the_DT USA_NNP ._.
We_PRP are_VBP awaiting_VBG the_DT outcome_NN These_DT cases_NNS illustrate_VBP an_DT industry-wide_JJ trend_NN entities_NNS starting_VBG phase_NN II_NNP clinical_JJ trials_NNS has_VBZ more_JJR of_IN our_PRP$ appeal_NN against_IN a_DT judgement_NN last_JJ year_NN in_IN which_WDT generics_NNS companies_NNS are_VBP filing_VBG more_JJR than_IN doubled_VBD since_IN the_DT merger_NN ._.
We_PRP are_VBP in_IN favor_NN of_IN Andrx_NNP Corporation_NNP ,_, which_WDT patent_NN challenges_NNS earlier_RBR ._.
We_PRP will_MD obviously_RB confident_JJ that_IN ,_, as_IN these_DT and_CC our_PRP$ phase_NN I_PRP has_VBZ applied_VBN to_TO market_NN generic_JJ versions_NNS defend_VBP our_PRP$ intellectual_JJ property_NN vigorously_RB ._.
pipeline_NN move_NN through_IN development_NN ,_, we_PRP will_MD of_IN the_DT products_NNS ._.
build_VB the_DT best_JJS late_JJ stage_NN pharmaceutical_JJ CONTRIBUTION_NNP TO_TO SOCIETY_NNP pipeline_NN in_IN the_DT industry_NN ._.
We_PRP plan_VBP to_TO provide_VB Seroxat_NNP Paxil_NNP continues_VBZ to_TO be_VB subject_JJ to_TO The_DT responsible_JJ behavior_NN of_IN all_DT types_NNS a_DT detailed_JJ update_VBP on_IN progress_NN in_IN R&D_NNP towards_IN threat_NN of_IN generic_JJ competition_NN ,_, particularly_RB of_IN organizations_NNS ,_, including_VBG multinational_JJ the_DT end_NN of_IN 2003_CD ._.
in_IN the_DT USA_NNP ._.
companies_NNS ,_, governments_NNS and_CC charities_NNS ,_, is_VBZ high_JJ Our_PRP$ contribution_NN to_TO society_NN ._.
At_IN GlaxoSmithKline_NNP we_PRP are_VBP fundamentally_RB committed_VBN to_TO making_VBG a_DT significant_JJ contribution_NN to_TO the_DT societies_NNS in_IN which_WDT we_PRP operate_VBP ._.
ANNUAL_JJ REVIEW_NNP 2002_CD 02_CD |_NN 03_CD on_IN the_DT public_JJ agenda_NN ._.
Last_JJ year_NN ,_, in_IN our_PRP$ first_JJ continue_VBP to_TO grow_VB significantly_RB year_NN on_IN year_NN ._.
controls_NNS and_CC a_DT number_NN of_IN governance_NN issues_NNS ._.
report_NN of_IN corporate_JJ and_CC social_JJ responsibility_NN ,_, In_IN September_NNP 2002_CD ,_, we_PRP further_RB reduced_VBD the_DT GlaxoSmithKline_NNP regularly_RB undertakes_VBZ thorough_JJ we_PRP set_VBP out_RP our_PRP$ commitment_NN to_TO reflecting_VBG preferential_JJ prices_NNS of_IN our_PRP$ HIV_NNP AIDS_NNP medicines_NNS reviews_NNS of_IN the_DT Groups_NNS internal_JJ control_NN systems_NNS ethical_JJ ,_, social_JJ and_CC environmental_JJ concerns_NNS by_IN up_RB to_TO 33_CD per_IN cent_NN ._.
and_CC is_VBZ committed_VBN to_TO remaining_VBG a_DT leader_NN in_IN in_IN our_PRP$ business_NN decisions_NNS ._.
Our_PRP$ second_JJ report_NN ,_, governance_NN processes_NNS and_CC structure_NN ._.
updating_VBG our_PRP$ activities_NNS in_IN 2002_CD ,_, is_VBZ being_VBG Positive_NNP Action_NNP ,_, our_PRP$ international_JJ program_NN published_VBN at_IN the_DT same_JJ time_NN as_IN this_DT Annual_JJ of_IN HIV_NNP AIDS_NNP education_NN ,_, care_NN and_CC support_NN has_VBZ ACKNOWLEDGEMENTS_NNP Review_NNP and_CC covers_VBZ the_DT issues_NNS that_WDT have_VBP now_RB been_VBN established_VBN for_IN ten_CD years_NNS backing_VBG Our_PRP$ business_NN is_VBZ to_TO discover_VB effective_JJ medicines_NNS generated_VBD significant_JJ interest_NN from_IN stakeholders_NNS ._.
and_CC healthcare_NN products_NNS for_IN people_NNS throughout_IN the_DT world_NN and_CC ,_, as_IN a_DT result_NN ,_, create_VB shareholder_NN The_DT Corporate_JJ and_CC Social_NNP Responsibility_NNP Report_NNP GlaxoSmithKline_NNP is_VBZ a_DT key_JJ partner_NN in_IN the_DT global_JJ value_NN ._.
We_PRP are_VBP in_IN a_DT great_JJ position_NN to_TO build_VB on_IN also_RB includes_VBZ some_DT indicators_NNS to_TO show_VB our_PRP$ effort_NN to_TO eliminate_VB lymphatic_JJ filariasis_NN ._.
This_DT the_DT success_NN of_IN the_DT last_JJ year_NN ,_, to_TO build_VB the_DT best_JJS progress_NN in_IN addressing_VBG these_DT issues_NNS ._.
disabling_VBG and_CC disfiguring_VBG disease_NN currently_RB pipeline_NN in_IN the_DT industry_NN and_CC launch_NN further_JJ affects_VBZ 120_CD million_CD people_NNS and_CC threatens_VBZ new_JJ products_NNS ._.
We_PRP extend_VBP our_PRP$ thanks_NNS to_TO all_DT Corporate_JJ responsibility_NN is_VBZ an_DT integral_JJ part_NN a_DT further_JJ one_CD billion_CD in_IN some_DT of_IN the_DT poorest_JJS our_PRP$ employees_NNS who_WP are_VBP so_RB committed_JJ to_TO of_IN our_PRP$ business_NN and_CC inherent_JJ in_IN our_PRP$ mission_NN ._.
To_TO date_NN ,_, GlaxoSmithKline_NNP making_VBG this_DT happen_VB ._.
GlaxoSmithKline_NNP makes_VBZ a_DT significant_JJ positive_JJ has_VBZ donated_VBN 145_CD million_CD tablets_NNS as_IN part_NN of_IN our_PRP$ contribution_NN to_TO society_NN around_IN the_DT world_NN ,_, 20-year_JJ commitment_NN to_TO eradicate_VB this_DT disease_NN ._.
Bob_NNP Ingram_NNP ,_, Chief_NNP Operating_NNP Officer_NNP and_CC through_IN the_DT medicines_NNS ,_, vaccines_NNS and_CC President_NNP ,_, Pharmaceutical_NNP Operations_NNP ,_, retired_VBD healthcare_NN products_NNS that_IN we_PRP research_NN ,_, The_DT Guardian_NNP newspapers_NNS Giving_NNP List_NN ,_, at_IN the_DT end_NN of_IN December_NNP but_CC will_MD continue_VB develop_VB ,_, manufacture_VB and_CC sell_VB ._.
recently_RB recognized_VBN that_IN GlaxoSmithKline_NNP 's_POS to_TO work_VB part_NN time_NN as_IN Vice_NNP Chairman_NNP of_IN total_JJ global_JJ community_NN expenditure_NN in_IN 2001_CD Pharmaceuticals_NNS and_CC special_JJ advisor_NN to_TO Our_PRP$ products_NNS must_MD improve_VB peoples_NNS lives_NNS was_VBD greater_JJR than_IN that_DT of_IN any_DT other_JJ British_JJ the_DT Group_NNP ._.
We_PRP would_MD like_VB to_TO express_VB our_PRP$ and_CC ensure_VB a_DT profitable_JJ and_CC sustainable_JJ future_JJ company_NN ._.
We_PRP increased_VBD our_PRP$ comprehensive_JJ appreciation_NN for_IN his_PRP$ contribution_NN to_TO the_DT for_IN our_PRP$ business_NN ._.
We_PRP also_RB understand_VBP that_DT program_NN of_IN social_JJ investment_NN in_IN 2002_CD ,_, company_NN and_CC ,_, in_IN particular_JJ ,_, for_IN his_PRP$ significant_JJ stakeholders_NNS ,_, including_VBG employees_NNS ,_, want_VBP investing_VBG 239_CD million_CD in_IN support_NN of_IN global_JJ role_NN in_IN making_VBG the_DT merger_NN a_DT success_NN ._.
to_TO know_VB how_WRB we_PRP make_VBP this_DT profit_NN ,_, and_CC need_VBP community_NN programs_NNS ,_, product_NN donations_NNS to_TO be_VB reassured_VBN of_IN the_DT sound_JJ ethical_JJ basis_NN for_IN and_CC charitable_JJ contributions_NNS ._.
On_IN behalf_NN of_IN the_DT Board_NNP and_CC the_DT Corporate_JJ our_PRP$ business_NN ._.
Executive_NNP Team_NNP ,_, we_PRP also_RB thank_VBP you_PRP ,_, our_PRP$ CORPORATE_JJ GOVERNANCE_NN shareholders_NNS ,_, for_IN your_PRP$ support_NN and_CC hope_NN Our_PRP$ focus_NN on_IN making_VBG a_DT contribution_NN to_TO Corporate_JJ governance_NN continues_VBZ to_TO be_VB a_DT that_IN you_PRP share_VBP our_PRP$ enthusiasm_NN for_IN the_DT improving_VBG healthcare_NN and_CC alleviating_VBG suffering_VBG high_JJ profile_NN issue_NN with_IN the_DT publication_NN of_IN the_DT company_NN and_CC look_VB forward_RB to_TO its_PRP$ continued_VBN in_IN the_DT developing_VBG world_NN has_VBZ never_RB been_VBN Higgs_NNP Review_NNP of_IN the_DT role_NN and_CC effectiveness_NN of_IN success_NN in_IN 2003_CD ._.
greater_JJR ._.
Significant_JJ progress_NN has_VBZ been_VBN made_VBN Non-Executive_JJ Directors_NNS and_CC Sir_NNP Robert_NNP Smiths_NNP towards_IN tackling_VBG the_DT enormous_JJ challenge_NN Report_NNP on_IN audit_NN committees_NNS ._.
By_IN the_DT end_NN of_IN 2002_CD ,_, we_PRP had_VBD Sarbanes-Oxley_NNP Act_NNP became_VBD law_NN in_IN July_NNP 2002_CD secured_VBN some_DT 120_CD arrangements_NNS to_TO supply_VB and_CC will_MD have_VB an_DT impact_NN on_IN GlaxoSmithKline_NNP HIV_NNP AIDS_NNP medicines_NNS to_TO in_IN relation_NN to_TO certification_NN of_IN the_DT Annual_JJ Report_NNP 50_CD of_IN the_DT worlds_NNS poorest_JJS countries_NNS ._.
Shipments_NNS on_IN Form_NN 20-F_NN ,_, disclosure_NN processes_NNS ,_, our_PRP$ SIR_NNP CHRISTOPHER_NNP HOGG_NNP JP_NNP GARNIER_NNP of_IN these_DT medicines_NNS to_TO the_DT developing_VBG world_NN relationship_NN with_IN external_JJ auditors_NNS ,_, internal_JJ CHAIRMAN_NNP CHIEF_JJ EXECUTIVE_NN OFFICER_NN TRADING_NN PROFIT_NN GROWTH_NN million_CD AN_DT R&D_NN ORGANISATION_NNP ON_NNP TRACK_NNP TO_TO DELIVER_VB A_DT FULL_JJ LATE_JJ STAGE_NN PRODUCT_NN TRADING_NN PROFIT_NN UP_RP 15_CD %_NN TO_TO 00_CD 5,026_CD PIPELINE_NNP ,_, WITH_IN AN_DT R&D_NNP UPDATE_NNP 01_CD 6,053_CD MEETING_NN EXPECTED_VBN TO_TO TAKE_VB PLACE_NN 02_CD 6,694_CD 6.7_CD BILLION_NNP TOWARDS_NNP THE_DT END_NNP OF_IN 2003_CD ._.
Earnings_NNS per_IN share_NN growth_NN of_IN 13_CD %_NN demonstrates_VBZ the_DT continued_JJ financial_JJ strength_NN that_WDT will_MD provide_VB the_DT company_NN with_IN a_DT sound_JJ platform_NN for_IN future_JJ growth_NN ._.
All_DT percentage_NN growth_NN rates_NNS throughout_IN this_DT Review_NNP are_VBP at_IN constant_JJ exchange_NN rates_NNS ,_, unless_IN otherwise_RB stated_VBN see_VBP Business_NN operating_VBG review_NN on_IN page_NN 19_CD ._.
These_DT are_VBP based_VBN on_IN business_NN performance_NN results_NNS ._.
GlaxoSmithKline_NNP is_VBZ instrumental_JJ in_IN improving_VBG the_DT lives_NNS of_IN Bettina_NNP and_CC Philippe_NNP Bartels_NNP Bettina_NNP Bartels_NNP ,_, a_DT physiotherapist_NN from_IN Munich_NNP ,_, Germany_NNP ,_, has_VBZ lived_VBN with_IN asthma_NN from_IN the_DT age_NN of_IN seven_CD ._.
Her_PRP$ condition_NN affected_VBD her_PRP$ involvement_NN in_IN sport_NN and_CC she_PRP also_RB found_VBD it_PRP difficult_JJ to_TO breathe_VB during_IN her_PRP$ favorite_JJ hobby_NN ,_, horse_NN riding_VBG ._.
She_PRP now_RB controls_VBZ her_PRP asthma_NN with_IN an_DT inhaler_NN millions_NNS and_CC is_VBZ able_JJ to_TO take_VB part_NN in_IN activities_NNS such_JJ as_IN swimming_NN with_IN her_PRP$ son_NN ,_, Philippe_NNP ._.
Philippe_NNP ,_, who_WP is_VBZ nearly_RB eight_CD ,_, has_VBZ been_VBN able_JJ of_IN people_NNS around_IN the_DT to_TO take_VB advantage_NN of_IN more_JJR modern_JJ inhalers_NNS and_CC also_RB understands_VBZ his_PRP$ condition_NN much_RB better_RBR as_IN a_DT result_NN of_IN attending_VBG a_DT special_JJ asthma_NN school_NN world_NN every_DT day_NN ._.
where_WRB the_DT disease_NN and_CC its_PRP$ effects_NNS are_VBP explained_VBN ._.
A_DT keen_JJ footballer_NN ,_, Philippe_NNP plays_VBZ three_CD times_NNS a_DT week_NN for_IN a_DT local_JJ team_NN ._.
When_WRB I_PRP was_VBD seven_CD ,_, there_EX was_VBD not_RB a_DT great_JJ deal_NN of_IN information_NN about_IN asthma_NN and_CC how_WRB to_TO live_VB with_IN it_PRP ._.
Today_NN the_DT situation_NN has_VBZ changed_VBN considerably_RB and_CC Philippe_NNP is_VBZ able_JJ to_TO deal_VB much_RB better_RBR with_IN his_PRP$ asthma_NN ,_, said_VBD Bettina_NNP ._.
PATIENTS_NNS AND_CC PRODUCT_NN DEVELOPMENT_NNP GlaxoSmithKline_NNP has_VBZ a_DT tradition_NN of_IN creating_VBG significant_JJ improvements_NNS in_IN asthma_NN healthcare_NN ._.
We_PRP pioneered_VBD the_DT early_JJ standard_NN treatments_NNS such_JJ as_IN Ventolin_NNP in_IN the_DT early_JJ 1970s_NNS and_CC in_IN the_DT last_JJ few_JJ years_NNS have_VBP delivered_VBN another_DT major_JJ leap_NN forward_RB with_IN Seretide_NNP Advair_NNP ,_, the_DT first_JJ product_NN to_TO treat_VB the_DT two_CD main_JJ components_NNS of_IN asthma_NN ,_, inflammation_NN and_CC bronchoconstriction_NN ,_, in_IN one_CD easy-to-use_JJ inhaler_NN ._.
Development_NNP of_IN our_PRP$ inhaled_JJ asthma_NN treatments_NNS Despite_IN these_DT continuous_JJ advances_NNS ,_, however_RB ,_, millions_NNS of_IN people_NNS still_RB suffer_VBP from_IN asthma_NN and_CC ,_, whilst_VB their_PRP$ quality_NN of_IN life_NN has_VBZ improved_VBN ,_, there_EX is_VBZ still_RB a_DT lot_NN of_IN work_NN to_TO do_VB ._.
Whats_NNS more_RBR ,_, the_DT worldwide_JJ incidence_NN of_IN asthma_NN is_VBZ increasing_VBG ._.
1970s_NNS Ventolin_NNP bronchodilator_NN 1970s_CD Becotide_NNP Beclovent_NNP GlaxoSmithKline_NNP is_VBZ still_RB pushing_VBG the_DT boundaries_NNS of_IN science_NN to_TO learn_VB more_JJR corticosteroid_JJ about_IN asthma_NN ._.
An_DT exciting_JJ example_NN of_IN this_DT work_NN is_VBZ the_DT recent_JJ publication_NN 1990s_CD Serevent_NNP bronchodilator_NN by_IN our_PRP$ scientists_NNS of_IN the_DT detailed_JJ structure_NN of_IN a_DT vital_JJ part_NN of_IN the_DT human_JJ glucocorticoid_NN receptor_NN ._.
This_DT receptor_NN is_VBZ known_VBN to_TO control_VB the_DT response_NN 1990s_CD Flixotide_NNP Flovent_NNP corticosteroid_VBD to_TO common_JJ asthma_NN medicines_NNS and_CC so_RB an_DT understanding_NN of_IN its_PRP$ structure_NN Today_NN Seretide_NNP Advair_NNP may_MD lead_VB to_TO still_RB more_RBR innovative_JJ therapies_NNS ._.
bronchodilator_NN corticosteroid_NN In_IN respiratory_JJ medicine_NN ,_, as_IN in_IN our_PRP$ other_JJ therapy_NN areas_NNS ,_, we_PRP strive_VBP to_TO improve_VB peoples_NNS lives_NNS ._.
ANNUAL_JJ REVIEW_NNP 2002_CD 04_CD |_NN 05_CD The_DT incidence_NN of_IN asthma_NN among_IN children_NNS in_IN the_DT UK_NNP is_VBZ now_RB six_CD times_NNS higher_JJR than_IN it_PRP was_VBD 25_CD years_NNS ago_RB ._.
SCALE_VB OF_IN THE_DT PROBLEM_NN GLAXOSMITHKLINE_NNP IS_VBZ COMMITTED_NNP TO_TO DEVELOPING_NNP NEW_NNP RESPIRATORY_NNP PRODUCTS_NNP WITH_IN ,_, WHERE_NNP RELEVANT_NNP ,_, EASY-TO-USE_JJ DEVICES_NNS ._.
DISKUS_NNP ,_, In_NNP Germany_NNP ,_, there_EX are_VBP an_DT estimated_VBN AN_DT AWARD-WINNING_NN DEVICE_NNP ,_, IS_VBZ ONE_CD SUCH_JJ PRODUCT_NN ._.
The_DT number_NN of_IN asthmatics_NNS in_IN the_DT USA_NNP has_VBZ leapt_VBN by_IN over_IN 60_CD per_IN cent_NN since_IN the_DT early_JJ 1980s_CD and_CC deaths_NNS have_VBP doubled_VBN to_TO 5,000_CD a_DT year_NN ._.
In_IN Western_NNP Europe_NNP ,_, cases_NNS of_IN asthma_NN have_VBP doubled_VBN in_IN ten_CD years_NNS ._.
There_EX are_VBP three_CD million_CD asthmatics_NNS in_IN Japan_NNP ._.
In_IN Australia_NNP ,_, one_CD child_NN in_IN six_CD under_IN the_DT age_NN of_IN 16_CD is_VBZ affected_VBN ._.
GlaxoSmithKline_NNP is_VBZ also_RB the_DT CENTRES_NNPS OF_IN EXCELLENCE_NNP leader_NN in_IN in-licensing_JJ deals_NNS ._.
FOR_IN DRUG_NN DISCOVERY_NN 1_CD CARDIOVASCULAR_NNP &_CC UROGENITAL_NNP DISEASES_NNPS 2_CD METABOLIC_NNP &_CC VIRAL_NNP DISEASES_NNPS 24_CD The_DT results_NNS of_IN 1,536_CD single_JJ 3_CD MICROBIAL_NNP ,_, MUSCULOSKELETAL_NNP experiments_NNS can_MD be_VB read_VBN by_IN &_CC PROLIFERATIVE_NNP DISEASES_NNPS major_JJ external_JJ 4_CD NEUROLOGY_NNP our_PRP$ computers_NNS in_IN 0.5_CD seconds_NNS ._.
collaborations_NNS have_VBP 5_CD PSYCHIATRY_NNP been_VBN signed_VBN since_IN 6_CD RESPIRATORY_NNP &_CC INFLAMMATION_NNP GLAXOSMITHKLINE_NNP CURRENTLY_NNP HAS_VBZ MORE_JJR THAN_IN ONE_CD MILLION_NNP December_NNP 2000_CD ._.
HIGH_JJ QUALITY_NN COMPOUNDS_VBZ IN_IN ITS_NNP COLLECTION_NNP ._.
ANNUAL_JJ REVIEW_NNP 2002_CD 06_CD |_NN 07_CD Over_IN ONL10_CD Y_CD %_NN of_IN all_DT drugs_NNS that_WDT reach_VBP clinical_JJ trials_NNS in_IN the_DT pharmaceutical_JJ industry_NN make_VBP it_PRP to_TO the_DT market_NN place_NN ._.
15,000_CD An_DT automated_JJ compound_NN store_NN houses_NNS hundreds_NNS of_IN thousands_NNS of_IN compounds_NNS ._.
A_DT number_NN of_IN R&D_NNP staff_NN are_VBP based_VBN at_IN these_DT will_MD interact_VB with_IN drug_NN targets_NNS during_IN screening_VBG and_CC become_VB potential_JJ medicines_NNS ._.
more_JJR than_IN 20_CD sites_NNS in_IN GlaxoSmithKline_NNP aims_VBZ to_TO have_VB one_CD of_IN the_DT largest_JJS and_CC ,_, more_RBR importantly_RB ,_, the_DT highest_JJS quality_NN collection_NN in_IN the_DT eight_CD countries_NNS ._.
The_DT compound_NN store_NN pictured_VBN here_RB at_IN Stevenage_NNP in_IN the_DT UK_NNP holds_VBZ nearly_RB half_PDT a_DT million_CD compounds_NNS ._.
Work_NN has_VBZ just_RB been_VBN completed_VBN on_IN a_DT stateof-the-art_JJ compound_NN store_NN at_IN Tres_NNP Cantos_NNP in_IN Spain_NNP which_WDT has_VBZ capacity_NN for_IN over_IN two_CD million_CD compounds_NNS ._.
Such_JJ investment_NN in_IN technology_NN is_VBZ already_RB paying_VBG dividends_NNS ._.
GlaxoSmithKline_NNP has_VBZ one_CD of_IN the_DT strongest_JJS early_JJ stage_NN pipelines_NNS in_IN the_DT industry_NN ._.
There_EX are_VBP currently_RB 123_CD projects_NNS in_IN clinical_JJ development_NN ._.
R&D_NNP PRODUCTIVITY_NNP GlaxoSmithKlines_NNPS aim_NN is_VBZ to_TO become_VB the_DT most_RBS productive_JJ R&D_NNP organization_NN in_IN the_DT industry_NN ._.
The_DT merger_NN that_WDT brought_VBD about_RB GlaxoSmithKline_JJ accelerated_VBD a_DT radical_JJ rethink_NN in_IN the_DT way_NN R&D_NN is_VBZ organised_VBN and_CC conducted_VBN ._.
R&D_NNP at_IN GlaxoSmithKline_NNP takes_VBZ advantage_NN of_IN its_PRP$ size_NN in_IN areas_NNS such_JJ as_IN genetics_NNS ,_, molecular_JJ screening_NN and_CC clinical_JJ research_NN ,_, where_WRB scale_NN is_VBZ important_JJ ._.
However_RB ,_, in_IN some_DT areas_NNS of_IN drug_NN discovery_NN ,_, GlaxoSmithKline_NNP has_VBZ formed_VBN six_CD therapy-area_NN focused_VBD and_CC entrepreneurial_JJ units_NNS known_VBN as_IN Centres_NNP of_IN Excellence_NNP for_IN Drug_NNP Discovery_NNP CEDDs_NNP ._.
Their_PRP$ brief_NN is_VBZ to_TO focus_VB on_IN just_RB one_CD thing_NN advancing_VBG lead_NN compounds_NNS to_TO the_DT point_NN where_WRB a_DT therapeutic_JJ concept_NN has_VBZ been_VBN demonstrated_VBN and_CC large-scale_JJ clinical_JJ trials_NNS can_MD begin_VB ._.
The_DT Group_NNP has_VBZ also_RB focused_VBN enormous_JJ amounts_NNS of_IN energy_NN and_CC resource_NN on_IN automation_NN to_TO broaden_VB the_DT scope_NN and_CC quicken_VB the_DT pace_NN of_IN the_DT search_NN for_IN new_JJ medicines_NNS ._.
High_NNP throughput_NN technology_NN ,_, for_IN example_NN ,_, increases_VBZ the_DT number_NN of_IN hits_NNS identified_VBN ,_, improves_VBZ the_DT quality_NN of_IN the_DT lead_NN compounds_NNS and_CC reduces_VBZ the_DT time_NN taken_VBN to_TO optimise_VB them_PRP for_IN further_JJ development_NN ._.
Meanwhile_RB ,_, we_PRP are_VBP scrutinising_VBG each_DT step_NN in_IN the_DT discovery_NN and_CC development_NN process_NN to_TO reduce_VB the_DT element_NN of_IN chance_NN and_CC identify_VB potential_JJ problems_NNS earlier_RBR ._.
USING_NNP INNOVATIVE_NNP SCIENCE_NNP TO_TO ENHANCE_VB R&D_NNP The_DT application_NN of_IN the_DT latest_JJS scientific_JJ advances_NNS to_TO the_DT drug_NN discovery_NN and_CC Kevin_NNP Kershner_NNP ,_, pictured_VBD right_RB ,_, is_VBZ a_DT member_NN of_IN the_DT Transcriptome_NNP development_NN processes_NNS will_MD ensure_VB GlaxoSmithKlines_NNP leadership_NN position_NN ._.
Analysis_NN TA_NNP team_NN at_IN Upper_NNP Merion_NNP ,_, New_NNP technology_NN has_VBZ opened_VBN up_RP novel_NN avenues_NNS of_IN research_NN exploring_VBG the_DT Pennsylvania_NNP ._.
His_PRP$ area_NN of_IN expertise_NN fundamental_JJ bases_NNS of_IN health_NN and_CC disease_NN ._.
is_VBZ robotic_JJ automation_NN to_TO profile_VB gene_NN expression_NN patterns_NNS in_IN normal_JJ and_CC diseased_JJ tissues_NNS ._.
Gene-related_JJ research_NN ,_, in_IN particular_JJ ,_, presents_VBZ an_DT enormous_JJ opportunity_NN ._.
Pharmacogenetics_NNP identifies_VBZ genetic_JJ patterns_NNS to_TO help_VB predict_VB how_WRB individual_JJ Automation_NN decreases_VBZ human_JJ patients_NNS will_MD respond_VB to_TO medicines_NNS ._.
In_IN short_JJ ,_, getting_VBG the_DT right_JJ medicine_NN to_TO interaction_NN and_CC allows_VBZ the_DT robot_NN to_TO produce_VB samples_NNS in_IN a_DT highthe_JJ right_NN patient_NN ._.
Everyone_NN wants_VBZ more_RBR effective_JJ and_CC safer_JJR medicines_NNS and_CC throughput_NN manner_NN ._.
It_PRP also_RB frees_VBZ if_IN we_PRP can_MD easily_RB identify_VB which_WDT patients_NNS respond_VBP well_RB to_TO particular_JJ drugs_NNS we_PRP scientists_NNS to_TO concentrate_VB on_IN other_JJ can_MD use_VB this_DT information_NN to_TO further_JJ refine_VB therapy_NN ._.
challenges_NNS in_IN their_PRP$ research_NN ,_, ultimately_RB increasing_VBG productivity_NN and_CC efficiency_NN in_IN a_DT shorter_JJR time_NN ,_, GlaxoSmithKline_NNP is_VBZ also_RB using_VBG information_NN gleaned_VBN from_IN the_DT human_JJ genome_NN without_IN compromising_VBG data_NNS quality_NN ._.
to_TO identify_VB new_JJ ways_NNS to_TO tackle_VB disease_NN ._.
By_IN finding_VBG out_RP what_WP specific_JJ genes_NNS do_VBP Introducing_VBG robotic_JJ automation_NN and_CC their_PRP$ role_NN in_IN disease_NN ,_, we_PRP can_MD identify_VB whole_JJ new_JJ approaches_NNS to_TO medicine_NN ._.
to_TO the_DT TA_NNP group_NN will_MD help_VB team_NN Our_PRP$ studies_NNS of_IN the_DT human_JJ genome_NN have_VBP identified_VBN new_JJ drug_NN targets_NNS for_IN bone_NN members_NNS become_VBP more_RBR effective_JJ loss_NN and_CC for_IN atherosclerosis_NN ,_, the_DT fundamental_JJ pathology_NN behind_IN most_JJS deaths_NNS and_CC more_RBR productive_JJ ,_, said_VBD Kevin_NNP ._.
Therapies_NNS directed_VBD against_IN these_DT targets_NNS are_VBP now_RB It_PRP will_MD also_RB enable_VB team_NN members_NNS in_IN clinical_JJ studies_NNS ._.
to_TO generate_VB high_JJ quality_NN data_NNS which_WDT will_MD lead_VB to_TO a_DT better_JJR understanding_NN For_IN all_PDT the_DT powerful_JJ capabilities_NNS that_WDT GlaxoSmithKline_NNP has_VBZ built_VBN within_IN its_PRP$ own_JJ of_IN gene_NN expression_NN and_CC disease_NN ._.
R&D_NNP organization_NN ,_, we_PRP recognize_VBP that_IN we_PRP do_VBP not_RB have_VB a_DT monopoly_NN on_IN good_JJ ideas_NNS ._.
To_TO ensure_VB that_IN we_PRP stay_VBP at_IN the_DT leading_VBG edge_NN of_IN biomedical_JJ research_NN ,_, we_PRP have_VBP entered_VBN into_IN hundreds_NNS of_IN collaborations_NNS with_IN other_JJ companies_NNS and_CC academic_JJ and_CC government_NN institutions_NNS ._.
Using_VBG genetic_JJ research_NN will_MD enable_VB us_PRP to_TO get_VB the_DT right_JJ medicine_NN for_IN the_DT right_JJ patient_NN and_CC find_VB new_JJ ways_NNS to_TO tackle_VB disease_NN ._.
ANNUAL_JJ REVIEW_NNP 2002_CD 08_CD |_NN 09_CD FOCUS_NNP ON_IN GENETICS_NNPS AND_CC GENOMICS_NNPS OUR_NNP AREAS_NNPS OF_IN FOCUS_NNP In_IN the_DT 1990s_CD ,_, GlaxoSmithKline_NNP made_VBD a_DT commitment_NN to_TO focus_VB on_IN genetics_NNS Pharmacogenetics_NNP and_CC genomics_NNS in_IN its_PRP$ drug_NN research_NN and_CC development_NN efforts_NNS ,_, making_VBG it_PRP an_DT industry_NN leader_NN ._.
Drug_NN target_NN identification_NN Gene-disease_NN GLAXOSMITHKLINE_NNP GENETIC_NNP RESEARCHERS_NNS associations_NNS HAVE_NNP IDENTIFIED_NNP LIKELY_NNP SUSCEPTIBILITY_NNP GENES_NNP FOR_IN ALZHEIMERS_NNP DISEASE_NNP ,_, PSORIASIS_NNP ,_, MIGRAINE_NNP AND_CC PARKINSONS_NNP DISEASE_NNP ._.
OUR_NNP CONTRIBUTION_NNP 2002_CD HIGHLIGHTS_NNP We_PRP have_VBP 120_CD arrangements_NNS to_TO supply_VB HIV_NNP AIDS_NNP medicines_NNS to_TO 50_CD of_IN the_DT worlds_NNS poorest_JJS countries_NNS ._.
We_PRP commenced_VBD human_JJ clinical_JJ trials_NNS of_IN our_PRP$ HIV_NNP vaccine_NN ._.
Grants_NNPS totalling_VBG 1_CD million_CD awarded_VBN under_IN our_PRP$ African_JJ Malaria_NNP Partnership_NNP ._.
In_IN 2002_CD we_PRP donated_VBD 66_CD million_CD albendazole_NN tablets_NNS to_TO support_VB the_DT Global_JJ Alliance_NNP to_TO Eliminate_VB Lymphatic_NNP Filariasis_NNP ._.
ANNUAL_JJ REVIEW_NNP 2002_CD 10_CD |_NN 11_CD In_IN addition_NN to_TO providing_VBG products_NNS to_TO treat_VB diseases_NNS in_IN the_DT developing_VBG GSK_NNP is_VBZ conducting_VBG world_NN ,_, GlaxoSmithKline_NNP also_RB supports_VBZ charitable_JJ and_CC community_NN work_VBP throughout_IN the_DT world_NN ._.
R&D_NNP for_IN the_DT prevention_NN One_CD such_JJ charity_NN is_VBZ Project_NNP HOPE_NNP which_WDT for_IN the_DT last_JJ 25_CD years_NNS has_VBZ run_VBN health_NN education_NN programs_NNS in_IN and_CC treatment_NN of_IN Guatemala_NNP where_WRB this_DT picture_NN of_IN local_JJ people_NNS in_IN traditional_JJ Mayan_JJ costume_NN was_VBD taken_VBN ._.
all_DT three_CD of_IN the_DT World_NNP Health_NNP Organizations_NNPS top_JJ priorities_NNS :_: HIV_NNP AIDS_NNP ,_, TB_NN and_CC malaria_NN ._.
DISEASES_NNS OF_IN THE_DT DEVELOPING_VBG WORLD_NN GlaxoSmithKline_NN makes_VBZ an_DT innovative_JJ ,_, responsible_JJ and_CC sustainable_JJ contribution_NN to_TO improving_VBG healthcare_NN in_IN the_DT developing_VBG world_NN in_IN four_CD key_JJ areas_NNS ._.
In_IN addition_NN to_TO providing_VBG drugs_NNS and_CC vaccines_NNS for_IN current_JJ needs_NNS ,_, we_PRP invest_VBP in_IN R&D_NNP to_TO meet_VB future_JJ needs_NNS ._.
The_DT Group_NNP also_RB offers_VBZ sustainable_JJ preferential_JJ pricing_NN in_IN the_DT developing_VBG world_NN and_CC works_VBZ in_IN partnership_NN with_IN communities_NNS to_TO foster_VB effective_JJ healthcare_NN ._.
This_DT is_VBZ against_IN a_DT background_NN where_WRB access_NN to_TO the_DT most_JJS basic_JJ healthcare_NN services_NNS does_VBZ not_RB exist_VB for_IN millions_NNS of_IN people_NNS in_IN developing_VBG countries_NNS and_CC where_WRB lifethreatening_VBG diseases_NNS such_JJ as_IN tuberculosis_NN TB_NN ,_, malaria_NN and_CC HIV_NNP AIDS_NNP have_VBP created_VBN a_DT healthcare_NN crisis_NN ._.
GlaxoSmithKline_NNP has_VBZ an_DT extensive_JJ portfolio_NN of_IN research_NN projects_NNS and_CC products_NNS for_IN diseases_NNS of_IN the_DT developing_VBG world_NN DDW_NNP ._.
We_PRP have_VBP created_VBN a_DT dedicated_JJ DDW_NNP It_PRP would_MD be_VB tough_JJ for_IN me_PRP to_TO go_VB home_NN every_DT night_NN and_CC have_VBP to_TO say_VB group_NN within_IN our_PRP$ R&D_NNP organization_NN which_WDT includes_VBZ a_DT facility_NN in_IN Tres_NNP Cantos_NNP ,_, I_PRP know_VBP how_WRB to_TO discover_VB drugs_NNS for_IN Spain_NNP ,_, focused_VBD on_IN drug_NN discovery_NN for_IN malaria_NN and_CC TB_NN ._.
people_NNS who_WP are_VBP dying_VBG but_CC am_VBP not_RB doing_VBG anything_NN about_IN it_PRP ._.
This_DT facility_NN is_VBZ only_RB a_DT part_NN of_IN our_PRP$ wider_JJR R&D_NN activity_NN into_IN diseases_NNS that_WDT affect_VBP We_PRP believe_VB the_DT focused_VBN drug_NN the_DT developing_VBG world_NN ._.
Our_PRP$ effort_NN to_TO discover_VB new_JJ HIV_NNP AIDS_NNP therapies_NNS is_VBZ led_VBN from_IN discovery_NN effort_NN at_IN Tres_NNP Cantos_NNP will_MD Research_NNP Triangle_NNP Park_NNP in_IN the_DT USA_NNP ,_, while_IN GlaxoSmithKline_NNP Biologicals_NNP at_IN Rixensart_NNP ,_, provide_VBP a_DT rich_JJ early_JJ pipeline_NN that_WDT will_MD enable_VB GlaxoSmithKline_NNP to_TO Belgium_NNP ,_, is_VBZ focused_VBN on_IN the_DT discovery_NN and_CC development_NN of_IN vaccines_NNS ,_, including_VBG launch_NN new_JJ products_NNS for_IN diseases_NNS those_DT for_IN malaria_NN ,_, TB_NN and_CC HIV_NNP ._.
We_PRP also_RB have_VBP extensive_JJ clinical_JJ trials_NNS programs_NNS of_IN the_DT developing_VBG world_NN on_IN a_DT across_IN the_DT developing_VBG world_NN ._.
regular_JJ basis_NN in_IN future_JJ years_NNS ._.
Dr_NNP Federico_NNP Gmez_NNP fide_NN las_VBZ Heras_NNP ,_, Owing_NNP to_TO the_DT challenges_NNS of_IN healthcare_NN provision_NN in_IN some_DT developing_VBG countries_NNS Director_NNP Diseases_NNPS of_IN the_DT Developing_VBG World_NNP ,_, Tres_NNP Cantos_NNP ,_, Spain_NNP ._.
and_CC the_DT lack_NN of_IN a_DT commercially-viable_JJ market_NN for_IN DDW_NNP treatments_NNS ,_, public_JJ private_JJ partnerships_NNS and_CC initiatives_NNS are_VBP essential_JJ to_TO direct_JJ resources_NNS effectively_RB and_CC deliver_VB treatments_NNS to_TO those_DT who_WP need_VBP them_PRP ._.
As_IN a_DT result_NN of_IN one_CD effective_JJ public_JJ private_JJ partnership_NN we_PRP have_VBP recently_RB filed_VBN a_DT licence_NN application_NN for_IN a_DT new_JJ anti-malarial_JJ product_NN ,_, Lapdap_NNP ._.
OUR_NNP PEOPLE_NNP Our_PRP$ global_JJ team_NN consists_VBZ of_IN over_IN 100,000_CD people_NNS ._.
Our_PRP$ staff_NN are_VBP dedicated_VBN to_TO our_PRP$ mission_NN and_CC striving_VBG to_TO achieve_VB excellence_NN in_IN every_DT area_NN of_IN our_PRP$ business_NN ._.
We_PRP have_VBP a_DT dynamic_JJ and_CC focused_VBD R&D_NNP operation_NN ,_, a_DT highly_RB efficient_JJ manufacturing_NN system_NN and_CC sales_NNS and_CC marketing_NN teams_NNS that_WDT are_VBP recognized_VBN for_IN their_PRP$ creative_JJ drive_NN and_CC scale_NN of_IN operation_NN ._.
We_PRP are_VBP committed_VBN to_TO the_DT principles_NNS of_IN diversity_NN ,_, equality_NN of_IN opportunity_NN and_CC equal_JJ treatment_NN and_CC we_PRP are_VBP aiming_VBG to_TO attract_VB ,_, retain_VB and_CC motivate_VB the_DT very_RB best_JJS people_NNS at_IN GlaxoSmithKline_NNP ._.
As_IN part_NN of_IN this_DT we_PRP recognize_VBP that_IN our_PRP$ people_NNS choose_VB to_TO work_VB for_IN us_PRP because_IN they_PRP believe_VBP we_PRP play_VB a_DT positive_JJ role_NN in_IN society_NN at_IN large_JJ ._.
This_DT means_VBZ that_IN our_PRP$ corporate_JJ and_CC social_JJ responsibilities_NNS are_VBP embedded_VBN in_IN our_PRP$ decision-making_JJ processes_NNS and_CC practices_NNS ._.
Our_PRP$ global_JJ team_NN is_VBZ aiming_VBG for_IN excellence_NN in_IN performance_NN and_CC excellence_NN in_IN terms_NNS of_IN its_PRP$ contribution_NN to_TO the_DT economies_NNS and_CC the_DT communities_NNS in_IN which_WDT it_PRP operates_VBZ ._.
In_IN sales_NNS terms_NNS ,_, GlaxoSmithKline_NNP is_VBZ the_DT number_NN one_CD pharmaceutical_JJ company_NN in_IN Europe_NNP ._.
By_IN building_VBG on_IN the_DT strengths_NNS of_IN all_DT our_PRP$ employees_NNS ,_, we_PRP can_MD create_VB a_DT new_JJ way_NN of_IN working_VBG OUR_NNP PHARMACEUTICAL_NNP INTERNATIONAL_NNP REGION_NNP COVERS_VBZ 118_CD COUNTRIES_NNS ,_, that_WDT will_MD give_VB GlaxoSmithKline_NNP 23_CD TIME_NNP ZONES_NNPS AND_CC 100_CD MONETARY_JJ CURRENCIES_NNS ._.
a_DT clear_JJ advantage_NN in_IN the_DT marketplace_NN and_CC ultimately_RB EMPLOYING_VBG NEARLY_RB 12,000_CD PEOPLE_NNP ,_, OUR_NNP US_NNP MANUFACTURING_NNP SITES_NNP IN_IN 38_CD COUNTRIES_NNS ._.
help_NN millions_NNS of_IN people_NNS around_IN PHARMACEUTICAL_NNP COMPANY_NNP IS_VBZ A_DT LEADER_NN IN_IN FOUR_NNP the_DT world_NN to_TO live_VB longer_RB ,_, MAJOR_NNP THERAPEUTIC_NNP AREAS_NNP IN_IN THE_DT USA_NNP happier_JJR ,_, healthier_RBR lives_NNS ._.
ANTI-INFECTIVES_NNS ,_, CENTRAL_NNP NERVOUS_NNP SYSTEM_NNP ,_, RESPIRATORY_NNP AND_CC METABOLIC_NNPS AND_CC GASTRO-INTESTINAL_NNP ._.
JP_NNP GARNIER_NNP ,_, Chief_NNP Executive_NNP Officer_NNP ANNUAL_NNP REVIEW_NNP 2002_CD 12_CD |_NN 13_CD And_CC over_IN 100,000_CD people_NNS are_VBP working_VBG at_IN GlaxoSmithKline_NNP to_TO ensure_VB excellence_NN and_CC success_NN today_NN ._.
Comprising_VBG one_CD global_JJ workforce_NN in_IN business_NN areas_NNS as_IN diverse_JJ as_IN R&D_NNP ,_, manufacturing_NN and_CC supply_NN ,_, sales_NNS ,_, marketing_NN and_CC distribution_NN ,_, GlaxoSmithKline_NNP people_NNS are_VBP committed_VBN to_TO bringing_VBG innovative_JJ medicines_NNS ,_, vaccines_NNS and_CC consumer_NN healthcare_NN products_NNS to_TO people_NNS throughout_IN the_DT world_NN ._.
CORPORATE_JJ AND_CC SOCIAL_JJ RESPONSIBILITY_NN GlaxoSmithKline_NN is_VBZ committed_VBN to_TO enhancing_VBG its_PRP$ position_NN as_IN a_DT responsible_JJ corporate_JJ citizen_NN and_CC to_TO building_VBG community_NN partnerships_NNS ._.
CORPORATE_JJ AND_CC SOCIAL_JJ RESPONSIBILITY_NN Lymphatic_JJ filariasis_NN GlaxoSmithKline_NNP aims_VBZ to_TO be_VB a_DT valued_VBN The_DT mosquito-borne_JJ lymphatic_JJ filariasis_NN corporate_JJ citizen_NN wherever_WRB it_PRP does_VBZ business_NN ._.
LF_NNP or_CC elephantiasis_NN is_VBZ one_CD of_IN the_DT worlds_NNS most_RBS disabling_JJ diseases_NNS ._.
We_PRP are_VBP committed_JJ We_PRP make_VBP a_DT significant_JJ and_CC positive_JJ to_TO continuing_VBG as_IN an_DT active_JJ member_NN of_IN contribution_NN to_TO society_NN through_IN our_PRP$ the_DT Global_JJ Alliance_NNP to_TO Eliminate_VB Lymphatic_JJ medicines_NNS ,_, vaccines_NNS and_CC healthcare_NN products_NNS ._.
In_IN 2002_CD ,_, the_DT fourth_JJ year_NN of_IN the_DT Our_PRP$ products_NNS must_MD improve_VB peoples_NNS lives_VBZ program_NN ,_, 66_CD million_CD tablets_NNS ,_, worth_JJ to_TO ensure_VB a_DT profitable_JJ and_CC sustainable_JJ 8.7_CD million_CD at_IN wholesale_JJ acquisition_NN future_NN for_IN our_PRP$ business_NN ._.
Understandably_RB ,_, cost_NN were_VBD donated_VBN to_TO 31_CD countries_NNS ._.
stakeholders_NNS including_VBG employees_NNS want_VBP to_TO know_VB how_WRB we_PRP make_VBP this_DT profit_NN ._.
HIV_NNP AIDS_NNP Through_IN Positive_NNP Action_NNP ,_, GlaxoSmithKline_NNP We_PRP publish_VB a_DT separate_JJ report_NN on_IN corporate_JJ works_NNS in_IN partnership_NN with_IN networks_NNS of_IN and_CC social_JJ responsibility_NN ,_, including_VBG access_NN people_NNS living_VBG with_IN HIV_NNP AIDS_NNP ,_, community_NN to_TO medicines_NNS in_IN the_DT developing_VBG world_NN ,_, groups_NNS ,_, international_JJ agencies_NNS ,_, and_CC nonR_NNP &_CC D_NNP for_IN diseases_NNS of_IN the_DT developing_VBG world_NN ,_, governmental_JJ organizations_NNS to_TO intensify_VB preferential_JJ pricing_NN arrangements_NNS and_CC community_NN responses_NNS to_TO HIV_NNP AIDS_NNP ._.
environmental_JJ ,_, health_NN and_CC safety_NN performance_NN ._.
Our_PRP$ program_NN of_IN HIV_NNP education_NN ,_, care_NN and_CC community_NN support_NN marked_VBD its_PRP$ tenth_NN COMMUNITY_NNP PROGRAMMES_NNPS AND_CC anniversary_NN in_IN 2002_CD ._.
During_IN the_DT year_NN ,_, Positive_NNP Action_NNP supported_VBD 25_CD international_JJ CORPORATE_JJ DONATIONS_NNS Many_JJ of_IN our_PRP$ community_NN programs_NNS are_VBP programs_NNS in_IN partnership_NN with_IN 22_CD long-term_JJ commitments_NNS that_WDT help_VBP bring_VB community-based_JJ organizations_NNS in_IN about_IN sustainable_JJ change_NN ._.
spent_VBN 239_CD million_CD in_IN support_NN of_IN community_NN programs_NNS ,_, product_NN donations_NNS and_CC Malaria_NN charitable_JJ contributions_NNS ._.
In_IN 2002_CD ,_, we_PRP launched_VBD the_DT African_JJ Malaria_NNP Partnership_NNP to_TO help_VB combat_VB a_DT disease_NN that_WDT These_DT activities_NNS are_VBP focused_VBN on_IN disease_NN kills_VBZ more_JJR than_IN one_CD million_CD people_NNS every_DT programs_NNS ,_, regional_JJ community_NN initiatives_NNS ,_, year_NN ._.
Three_CD behavioural_JJ development_NN education_NN ,_, product_NN donations_NNS and_CC employee_NN programs_NNS in_IN seven_CD countries_NNS will_MD share_VB involvement_NN ._.
Three_CD of_IN our_PRP$ largest_JJS programs_NNS grants_NNS of_IN 1.0_CD million_CD over_IN the_DT next_JJ three_CD are_VBP major_JJ initiatives_NNS in_IN public_JJ health_NN :_: years_NNS and_CC will_MD benefit_VB nearly_RB two_CD million_CD people_NNS in_IN malaria-endemic_JJ communities_NNS ._.
In_IN 2002_CD ,_, the_DT Personal_NNP Hygiene_NNP and_CC Sanitation_NNP Education_NNP project_NN in_IN Africa_NNP and_CC South_NNP America_NNP won_VBD an_DT award_NN for_IN International_NNP Corporate_NNP Citizenship_NNP ._.
In_IN seven_CD years_NNS ,_, GlaxoSmithKline_NNP has_VBZ provided_VBN more_JJR than_IN 2.7_CD million_CD to_TO the_DT Barretstown_NNP Gang_NN in_IN Ireland_NNP which_WDT offers_VBZ therapeutic_JJ recreation_NN for_IN seriously_RB ill_JJ children_NNS ._.
Positive_JJ Action_NNP funds_NNS a_DT program_NN to_TO assist_VB the_DT scale-up_NN of_IN HIV_NNP AIDS_NNP voluntary_JJ organizations_NNS in_IN Africa_NNP ._.
ANNUAL_JJ REVIEW_NNP 2002_CD 14_CD |_NN 15_CD PRODUCT_NN PORTFOLIO_NN Across_IN the_DT Groups_NNS portfolio_NN of_IN products_NNS ,_, six_CD major_JJ therapeutic_JJ areas_NNS experienced_VBD double-digit_JJ percentage_NN growth_NN for_IN 2002_CD including_VBG the_DT fast_JJ growing_VBG franchises_NNS of_IN central_JJ nervous_JJ system_NN 17_CD %_NN ,_, respiratory_JJ 16_CD %_NN ,_, anti-virals_JJ 12_CD %_NN and_CC vaccines_NNS 16_CD %_NN ._.
TR_NNP Top_NNP 10_CD pharmaceutical_JJ products_NNS SEROXAT_NNP PAXIL_NNP SERETIDE_NNP ADVAIR_NNP AUGMENTIN_NNP WELLBUTRIN_NNP AVANDIA_NNP 2.1_CD bn_NN $_$ 3.1_CD bn_NN 1.6_CD bn_NN $_$ 2.4_CD bn_NN 1.2_CD bn_NN $_$ 1.8_CD bn_NN 882m_CD $_$ 1.3_CD bn_NN 809m_CD $_$ 1.2_CD bn_NN Central_NNP Nervous_NNP System_NNP Respiratory_NNP Anti-bacterials_NNPS CNS_NNP Metabolic_NNP &_CC CNS_NNP A_NNP combination_NN of_IN Serevent_NNP An_DT antibiotic_JJ for_IN the_DT An_DT anti-depressant_JJ available_JJ gastro-intestinal_JJ A_DT selective_JJ serotonin_NN and_CC Flixotide_NNP that_WDT offers_VBZ treatment_NN of_IN most_JJS in_IN the_DT USA_NNP in_IN normal_JJ tablet_NN A_DT member_NN of_IN the_DT newest_JJS re-uptake_NN inhibitor_NN for_IN a_DT long-acting_JJ bronchodilator_NN common_JJ respiratory_JJ or_CC sustained_VBN release_NN tablet_NN class_NN of_IN oral_JJ treatments_NNS the_DT treatment_NN of_IN depression_NN and_CC an_DT anti-inflammatory_JJ tract_NN infections_NNS ._.
IMIGRAN_NNP IMITREX_NNP FLIXOTIDE_NNP FLOVENT_NNP ZOFRAN_NNP COMBIVIR_NNP FLIXONASE_NNP FLONASE_NNP 798m_VBD $_$ 1.2_CD bn_NN 783m_CD $_$ 1.2_CD bn_NN 708m_CD $_$ 1.1_CD bn_NN 588m_CD $_$ 882m_CD 534m_CD $_$ 801m_CD CNS_NNP Respiratory_NNP Oncology_NNP &_CC emesis_NN Anti-virals_NNS Respiratory_NNP A_NNP 5HT_NNP receptor_NN agonist_NN An_DT inhaled_JJ steroid_NN for_IN the_DT Used_VBN to_TO prevent_VB nausea_NN A_DT combination_NN of_IN Retrovir_NNP An_DT intra-nasal_JJ 1_CD for_IN the_DT treatment_NN of_IN severe_JJ treatment_NN of_IN inflammation_NN and_CC vomiting_VBG associated_VBN and_CC Epivir_NNP which_WDT reduces_VBZ preparation_NN for_IN the_DT or_CC frequent_JJ migraine_NN and_CC associated_VBN with_IN respiratory_JJ with_IN chemotherapy_JJ and_CC the_DT pill_NN burden_NN faced_VBN by_IN treatment_NN of_IN perennial_JJ cluster_NN headaches_NNS ._.
HIV_NNP patients_NNS with_IN multiple_JJ and_CC seasonal_JJ rhinitis_NN ._.
Major_JJ launches_NNS in_IN 2002_CD Vaccines_NNS PAXIL_NNP CR_NNP AVANDAMET_NNP AUGMENTIN_NNP XR_NNP HEPATITIS_NNP VACCINES_NNPS INFANRIX_NNP CNS_NNP Metabolic_NNP &_CC Anti-bacterials_NNP 483m_CD $_$ 725m_CD 254m_CD $_$ 381m_CD Launched_VBN in_IN the_DT USA_NNP in_IN gastro-intestinal_JJ A_DT new_JJ enhanced_JJ A_DT range_NN of_IN treatments_NNS A_DT range_NN of_IN vaccines_NNS April_NNP ,_, Paxil_NNP CR_NNP combines_VBZ Avandamet_NNP was_VBD launched_VBN formulation_NN of_IN protecting_VBG against_IN hepatitis_NN for_IN diphtheria_NN ,_, tetanus_NN the_DT efficacy_NN of_IN Paxil_NNP with_IN in_IN the_DT USA_NNP in_IN November_NNP ,_, Augmentin_NNP for_IN adults_NNS A_DT Havrix_NNP and_CC hepatitis_NNP B_NNP and_CC whooping_JJ cough_NN ._.
a_DT controlled_JJ release_NN combining_VBG Avandia_NNP ,_, which_WDT to_TO treat_VB communityEngerix-B_NN ._.
The_DT first_JJ technology_NN for_IN the_DT targets_NNS insulin_NN resistance_NN ,_, acquired_VBD pneumonia_NN ,_, combined_VBN hepatitis_NNP A_NNP and_CC B_NNP treatment_NN of_IN major_JJ and_CC metformin_NN ,_, an_DT oral_JJ acute_JJ bacterial_JJ sinusitis_NN vaccine_NN Twinrix_NNP protects_VBZ depressive_JJ disorder_NN diabetes_NN therapy_NN ,_, in_IN one_CD and_CC chronic_JJ bronchitis_NNS ._.
against_IN both_DT diseases_NNS in_IN and_CC panic_VB disorder_NN ._.
Top_JJ 5_CD consumer_NN healthcare_NN products_NNS AQUAFRESH_NNP LUCOZADE_NNP NICODERM_NNP CQ_NNP SENSODYNE_NNP RIBENA_NNP 344m_CD $_$ 516m_CD 214m_CD $_$ 321m_CD NIQUITIN_NNP CQ_NNP NICABATE_NNP 192m_CD $_$ 288m_CD 192m_CD $_$ 288m_CD One_CD of_IN the_DT worlds_NNS The_DT glucose_NN energy_NN 193m_CD $_$ 290m_CD A_DT toothpaste_NN which_WDT A_DT range_NN of_IN juice_NN drinks_NNS largest_JJS toothpaste_NN drink_NN which_WDT provides_VBZ Nicotine_JJ replacement_NN addresses_NNS dental_JJ sensitivity_NN rich_JJ in_IN vitamin_NN C._NNP and_CC toothbrush_JJ brands_NNS ._.
nutrients_NNS to_TO complement_VB therapy_NN available_JJ as_IN a_DT patch_NN and_CC pain_NN ._.
THE_DT BOARD_NNP The_NNP Board_NNP of_IN Directors_NNS is_VBZ ultimately_RB accountable_JJ for_IN the_DT Groups_NNS activities_NNS ,_, strategy_NN and_CC financial_JJ performance_NN ._.
BDFH_NNP DHJ_NNP SIR_NNP CHRISTOPHER_NNP HOGG_NNP JOHN_NNP MCARTHUR_NNP Non-Executive_NNP Director_NNP Aged_VBD 68_CD Non-Executive_NNP Chairman_NNP Aged_VBD 66_CD Sir_NNP Christopher_NNP was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP Mr_NNP McArthur_NNP was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP of_IN Glaxo_NNP Wellcome_NNP plc._NN ._.
He_PRP is_VBZ a_DT Non-Executive_JJ of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
He_PRP is_VBZ Non-Executive_JJ Chairman_NN of_IN Reuters_NNP Group_NNP PLC_NNP ,_, and_CC a_DT member_NN Director_NNP of_IN BCE_NNP Inc._NNP ._.
BCE_NNP Emergis_NNP Inc._NNP ._.
Cabot_NNP Corporation_NNP ,_, HCA_NNP Corporation_NNP Koc_NNP Holdings_NNP A._NNP S._NNP of_IN the_DT Supervisory_NNP Board_NNP of_IN Air_NNP Liquide_NNP S._NNP A._NN and_CC Chairman_NN of_IN The_DT Royal_NNP National_NNP Theatre_NNP ._.
Rohm_NNP and_CC Haas_NNP Company_NNP ,_, Telsat_NNP Canada_NNP and_CC The_DT AES_NNP Corporation_NNP ._.
He_PRP is_VBZ also_RB Senior_JJ Advisor_NNP DHJ_NNP SIR_NNP ROGER_NNP HURN_NNP to_TO the_DT President_NNP of_IN the_DT World_NNP Bank_NNP ._.
Non-Executive_JJ Deputy_NNP Chairman_NNP Aged_VBD 64_CD DEH_NNP Sir_NNP Roger_NNP was_VBD appointed_VBN a_DT Non-Executive_JJ Director_NNP DONALD_NNP MCHENRY_NNP of_IN Glaxo_NNP Wellcome_NNP plc_NN in_IN 1996_CD and_CC Deputy_NNP Chairman_NNP Non-Executive_NNP Director_NNP Aged_VBD 66_CD Mr_NNP McHenry_NNP was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP in_IN 1997_CD ._.
He_PRP is_VBZ a_DT Non-Executive_JJ Director_NNP of_IN Cazenove_NNP Group_NNP plc._NN ._.
He_PRP is_VBZ also_RB Chairman_NNP of_IN the_DT Court_NNP of_IN of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
He_PRP is_VBZ a_DT Distinguished_NNP Professor_NNP in_IN the_DT Practice_NNP of_IN Diplomacy_NNP at_IN the_DT School_NNP Governors_NNP of_IN Henley_NNP College_NNP ._.
of_IN Foreign_NNP Service_NNP at_IN Georgetown_NNP University_NNP D_NNP DR_NNP JEAN-PIERRE_NNP GARNIER_NNP and_CC President_NNP of_IN the_DT IRC_NNP Group_NNP ,_, LLC_NNP ._.
His_PRP$ other_JJ Chief_NNP Executive_NNP Officer_NNP Aged_VBD 55_CD Non-Executive_JJ directorships_NNS include_VBP The_DT Coca-Cola_NNP Dr_NNP Garnier_NNP was_VBD appointed_VBN an_DT Executive_NNP Director_NNP Company_NNP ,_, FleetBoston_NNP Financial_NNP Corporation_NNP ,_, of_IN SmithKline_NNP Beecham_NNP plc_NN in_IN 1992_CD ,_, and_CC became_VBD International_NNP Paper_NNP Company_NNP and_CC AT&T_NNP Corporation_NNP ._.
Chief_NNP Executive_NNP Officer_NNP in_IN April_NNP 2000_CD ._.
He_PRP is_VBZ a_DT He_PRP previously_RB served_VBD as_IN Ambassador_NNP and_CC US_NNP Non-Executive_NNP Director_NNP of_IN United_NNP Technologies_NNPS Permanent_NNP Representative_NNP to_TO the_DT United_NNP Nations_NNPS ._.
Corporation_NNP and_CC a_DT member_NN of_IN the_DT Board_NNP of_IN Trustees_NNPS BDG_NNP of_IN the_DT Eisenhower_NNP Exchange_NNP Fellowships_NNP ._.
He_PRP holds_VBZ SIR_NNP IAN_NNP PROSSER_NNP Non-Executive_NNP Director_NNP Aged_VBD 59_CD a_DT PhD_NNP in_IN pharmacology_NN from_IN the_DT University_NNP of_IN Sir_NNP Ian_NNP was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP Louis_NNP Pasteur_NNP in_IN France_NNP and_CC an_DT MBA_NNP from_IN Stanford_NNP of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
He_PRP is_VBZ Executive_NNP University_NNP in_IN the_DT USA_NNP ._.
Chairman_NNP of_IN Six_CD Continents_NNP PLC_NNP and_CC the_DT World_NNP D_NNP JOHN_NNP COOMBE_NNP Travel_NNP &_CC Tourism_NNP Council_NNP and_CC Non-Executive_NNP Deputy_NNP Chief_NNP Financial_NNP Officer_NNP Aged_VBD 57_CD Chairman_NNP of_IN BP_NNP plc._FW ._.
He_PRP is_VBZ a_DT member_NN of_IN the_DT CBI_NNP Mr_NNP Coombe_NNP was_VBD formerly_RB an_DT Executive_NNP Director_NNP Presidents_NNP Committee_NNP ._.
of_IN Glaxo_NNP Wellcome_NNP plc_NN where_WRB he_PRP was_VBD responsible_JJ AD_NNP for_IN Finance_NNP and_CC Investor_NNP Relations_NNPS ._.
He_PRP is_VBZ a_DT member_NN DR_NNP RONALDO_NNP SCHMITZ_NNP Non-Executive_NNP Director_NNP Aged_VBD 64_CD of_IN the_DT Supervisory_NNP Board_NNP of_IN Siemens_NNP AG_NNP ,_, the_DT UK_NNP Accounting_NNP Standards_NNP Board_NNP and_CC the_DT Code_NNP Dr_NNP Schmitz_NNP was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP of_IN Glaxo_NNP Wellcome_NNP plc._NN ._.
He_PRP is_VBZ a_DT Non-Executive_JJ Director_NNP Committee_NNP of_IN the_DT UK_NNP Takeover_NN Panel_NN ._.
of_IN Legal_NNP &_CC General_NNP Group_NNP plc_NN and_CC a_DT member_NN of_IN the_DT DI_NNP PAUL_NNP ALLAIRE_NNP Board_NNP of_IN Directors_NNS of_IN Rohm_NNP and_CC Haas_NNP Company_NNP and_CC Non-Executive_NNP Director_NNP Aged_NNP 64_CD Cabot_NNP Corporation_NNP ._.
Mr_NNP Allaire_NNP was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP DF_NNP of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
He_PRP is_VBZ a_DT Non-Executive_JJ DR_NNP LUCY_NNP SHAPIRO_NNP Director_NNP of_IN Lucent_NNP Technologies_NNPS Inc._NNP and_CC priceline_NN ._.
com_NN Non-Executive_NNP Director_NNP Aged_VBD 62_CD Dr_NNP Shapiro_NNP was_VBD formerly_RB a_DT Non-Executive_NNP Director_NNP Inc._NNP ._.
He_PRP is_VBZ Chairman_NNP of_IN The_DT Ford_NNP Foundation_NNP ._.
She_PRP is_VBZ Ludwig_NNP Professor_NNP DFJ_NNP DR_NNP MICHLE_NNP BARZACH_NNP of_IN Cancer_NNP Research_NNP in_IN the_DT Department_NNP of_IN Non-Executive_NNP Director_NNP Aged_VBD 59_CD Developmental_JJ Biology_NN and_CC Director_NNP of_IN the_DT Beckman_NNP Dr_NNP Barzach_NNP was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP Centre_NNP for_IN Molecular_NNP and_CC Genetic_NNP Medicine_NNP at_IN the_DT of_IN Glaxo_NNP Wellcome_NNP plc._NN ._.
She_PRP is_VBZ a_DT member_NN of_IN the_DT Stanford_NNP University_NNP School_NNP of_IN Medicine_NNP ._.
She_PRP holds_VBZ International_NNP Cooperation_NNP High_NNP Council_NNP ,_, Chairman_NNP a_DT PhD_NNP in_IN molecular_JJ biology_NN from_IN the_DT Albert_NNP Einstein_NNP of_IN the_DT Board_NNP of_IN Equilibres_NNPS et_FW Populations_NNPS and_CC Director_NNP College_NNP of_IN Medicine_NNP ._.
of_IN the_DT Board_NNP of_IN Project_NNP Hope_NNP ._.
International_NNP consultant_NN on_IN health_NN strategy_NN ,_, she_PRP was_VBD formerly_RB French_JJ Minister_NNP Other_JJ Directors_NNS of_IN Health_NNP and_CC the_DT Family_NNP ._.
Sir_NNP Richard_NNP Sykes_NNP ,_, Non-Executive_NNP Chairman_NNP ,_, BDJ_NNP Sir_NNP Peter_NNP Walters_NNP ,_, Non-Executive_NNP Deputy_NNP Chairman_NNP ,_, SIR_NNP PETER_NNP JOB_NNP and_CC Mr_NNP John_NNP Young_NNP ,_, Non-Executive_NNP Director_NNP ,_, Non-Executive_NNP Director_NNP Aged_VBD 61_CD all_DT retired_VBN from_IN the_DT Board_NNP on_IN 20th_JJ May_NNP 2002_CD ._.
Sir_NNP Peter_NNP was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP of_IN Glaxo_NNP Wellcome_NNP plc._NN ._.
He_PRP is_VBZ a_DT Non-Executive_JJ Director_NNP of_IN Schroders_NNP plc_NN ,_, Shell_NNP Transport_NNP and_CC Trading_NNP Company_NNP plc_NN ,_, TIBCO_NNP Software_NNP Inc_NNP ,_, Instinet_NNP Group_NNP Inc._NNP and_CC Multex_NNP ._.
He_PRP is_VBZ also_RB a_DT member_NN of_IN the_DT Supervisory_NNP Boards_NNPS of_IN Deutsche_NNP Bank_NNP AG_NNP and_CC Bertelsmann_NNP AG_NNP ._.
Membership_NN of_IN Board_NNP committees_NNS is_VBZ indicated_VBN by_IN the_DT following_VBG symbols_NNS :_: CHAIRMAN_NNP MEMBER_NNP Audit_NNP A_NNP B_NNP Corporate_NNP Administration_NNP D_NNP &_CC Transactions_NNS Corporate_JJ Social_NNP Responsibility_NNP E_NNP F_NN Financial_NNP Results_NNS D_NNP Nominations_NNPS G_NNP H_NNP Remuneration_NNP I_PRP J_NNP ANNUAL_NNP REVIEW_NNP 2002_CD 16_CD |_NN 17_CD CORPORATE_JJ EXECUTIVE_NN The_DT executive_NN management_NN of_IN the_DT Group_NNP is_VBZ through_IN the_DT TEAM_NNP Corporate_NNP Executive_NNP Team_NNP CET_NNP ,_, comprising_VBG the_DT Chief_NNP Executive_NNP Officer_NNP ,_, the_DT Chief_NNP Financial_NNP Officer_NNP and_CC other_JJ senior_JJ managers_NNS ._.
JP_NNP GARNIER_NNP DAVID_NNP STOUT_NNP Chief_NNP Executive_NNP Officer_NNP President_NNP As_IN Chief_NNP Executive_NNP Officer_NNP ,_, JP_NNP is_VBZ the_DT link_NN between_IN Pharmaceutical_NNP Operations_NNP David_NNP was_VBD President_NNP of_IN US_NNP Pharmaceuticals_NNP until_IN the_DT Board_NNP and_CC staff_NN ,_, and_CC oversees_VBZ all_DT operational_JJ aspects_NNS including_VBG establishing_VBG policies_NNS ,_, objectives_NNS he_PRP was_VBD appointed_VBN to_TO his_PRP$ current_JJ position_NN in_IN January_NNP 2003_CD ._.
He_PRP is_VBZ responsible_JJ for_IN the_DT global_JJ pharmaceuticals_NNS and_CC initiatives_NNS ,_, and_CC directing_VBG long_JJ term_NN strategy_NN ._.
He_PRP was_VBD formerly_RB Chief_NNP Executive_NNP Officer_NNP of_IN SmithKline_NNP business_NN as_RB well_RB as_IN the_DT global_JJ vaccines_NNS business_NN ._.
He_PRP joined_VBD SmithKline_NNP Beecham_NNP in_IN 1996_CD as_IN head_NN Beecham_NNP ,_, having_VBG joined_VBN the_DT Group_NNP in_IN 1990_CD ._.
of_IN its_PRP$ US_NNP Sales_NNS and_CC Marketing_NNP function_NN ,_, and_CC in_IN 1998_CD RUPERT_NNP BONDY_NNP became_VBD President_NNP ,_, Pharmaceuticals_NNP ,_, North_NNP America_NNP ._.
Senior_JJ Vice_NNP President_NNP and_CC General_NNP Counsel_NNP Rupert_NNP is_VBZ responsible_JJ for_IN legal_JJ matters_NNS across_IN the_DT CHRIS_NNP VIEHBACHER_NNP President_NNP Group_NNP ,_, together_RB with_IN environmental_JJ ,_, health_NN and_CC US_NNP Pharmaceuticals_NNP safety_NN issues_NNS ,_, insurance_NN and_CC security_NN ._.
He_PRP was_VBD a_DT lawyer_NN Responsible_JJ for_IN European_JJ pharmaceuticals_NNS operations_NNS in_IN private_JJ practice_NN before_IN joining_VBG SmithKline_NNP Beecham_NNP until_IN the_DT end_NN of_IN 2002_CD ,_, Chris_NNP took_VBD over_RP the_DT US_NNP in_IN 1995_CD as_IN Senior_JJ Counsel_NNP ._.
FORD_NNP CALHOUN_NNP He_PRP joined_VBD Wellcome_NNP in_IN 1988_CD and_CC became_VBD Director_NNP ,_, Chief_NNP Information_NNP Officer_NNP Continental_NNP Europe_NNP ,_, at_IN Glaxo_NNP Wellcome_NNP in_IN 1999_CD ._.
Ford_NNP is_VBZ responsible_JJ for_IN information_NN technology_NN ,_, ANDREW_NNP WITTY_VBD a_DT global_JJ function_NN that_WDT enables_VBZ key_JJ business_NN processes_VBZ President_NNP across_IN all_DT parts_NNS of_IN the_DT Group_NNP ._.
With_IN doctoral_JJ and_CC Pharmaceuticals_NNP Europe_NNP post-doctoral_JJ training_NN in_IN microbiology_NN ,_, genetics_NNS ,_, Andrew_NNP is_VBZ responsible_JJ for_IN the_DT Groups_NNS pharmaceuticals_NNS biomathematics_NNS and_CC computer_NN science_NN ,_, Ford_NNP joined_VBD operations_NNS in_IN Europe_NNP ,_, a_DT post_NN he_PRP took_VBD up_RP in_IN January_NNP Smith_NNP Kline_NNP &_CC French_NNP in_IN 1984_CD ._.
2003_CD when_WRB he_PRP was_VBD appointed_VBN to_TO the_DT CET_NNP ._.
Andrew_NNP JOHN_NNP COOMBE_NNP joined_VBD Glaxo_NNP in_IN 1985_CD and_CC at_IN GlaxoSmithKline_NNP was_VBD Chief_NNP Financial_NNP Officer_NNP Senior_NNP Vice_NNP President_NNP ,_, Asia_NNP Pacific_NNP ,_, until_IN his_PRP$ As_IN head_NN of_IN the_DT finance_NN function_NN ,_, John_NNP is_VBZ responsible_JJ current_JJ post_NN ._.
for_IN activities_NNS such_JJ as_IN financial_JJ reporting_NN and_CC control_NN ,_, TACHI_NNP YAMADA_NNP tax_NN and_CC treasury_NN ,_, investor_NN relations_NNS ,_, finance_NN systems_NNS ,_, Chairman_NNP internal_JJ audit_NN and_CC real_JJ estate_NN ._.
He_PRP joined_VBD Glaxo_NNP in_IN Research_NNP &_CC Development_NNP 1986_CD as_IN Group_NNP Financial_NNP Controller_NNP and_CC was_VBD Tachi_NNP leads_VBZ the_DT Groups_NNS complex_JJ business_NN of_IN drug_NN appointed_VBN Group_NNP Finance_NNP Director_NNP in_IN 1992_CD ._.
discovery_NN and_CC development_NN creating_VBG new_JJ medicines_NNS DAN_NNP PHELAN_NNP through_IN research_NN ._.
He_PRP joined_VBD SmithKline_NNP Beecham_NNP in_IN Senior_NNP Vice_NNP President_NNP 1994_CD as_IN a_DT Non-Executive_JJ member_NN of_IN the_DT Board_NNP and_CC Human_NNP Resources_NNPS became_VBD Chairman_NNP ,_, R&D_NNP ,_, Pharmaceuticals_NNP in_IN 1999_CD ._.
Dan_NNP is_VBZ responsible_JJ for_IN benefits_NNS ,_, compensation_NN ,_, JENNIE_NNP YOUNGER_NNP recruitment_NN ,_, organization_NN development_NN ,_, leadership_NN Senior_JJ Vice_NNP President_NNP development_NN and_CC succession_NN planning_NN ,_, human_JJ Corporate_JJ Communications_NNPS &_CC Community_NNP resource_NN information_NN systems_NNS and_CC employee_NN health_NN Partnerships_NNS management_NN ._.
He_PRP joined_VBD Smith_NNP Kline_NNP &_CC French_NNP in_IN 1981_CD Jennie_NNP is_VBZ responsible_JJ for_IN the_DT Groups_NNS internal_JJ and_CC and_CC in_IN 1994_CD was_VBD appointed_VBN Senior_JJ Vice_NNP President_NNP and_CC external_JJ communications_NNS ,_, its_PRP$ image_NN and_CC partnerships_NNS Director_NNP ,_, Human_NNP Resources_NNPS ,_, SmithKline_NNP Beecham_NNP ._.
with_IN communities_NNS of_IN the_DT world_NN ._.
She_PRP joined_VBD Glaxo_NNP HOWARD_NNP PIEN_NNP Wellcome_NNP in_IN 1996_CD as_IN Director_NNP of_IN Investor_NNP Relations_NNPS ._.
President_NNP JACK_NNP ZIEGLER_NNP Pharmaceuticals_NNP International_NNP President_NNP Howard_NNP leads_VBZ the_DT pharmaceutical_JJ operations_NNS outside_IN Consumer_NNP Healthcare_NNP the_DT USA_NNP and_CC most_JJS of_IN Europe_NNP ,_, covering_VBG more_JJR than_IN Jack_NNP is_VBZ head_NN of_IN the_DT global_JJ Consumer_NN Healthcare_NNP 100_CD countries_NNS that_WDT account_VBP for_IN over_IN 82_CD per_IN cent_NN business_NN ,_, which_WDT produces_VBZ oral_JJ healthcare_NN ,_, overof_VBP the_DT worlds_NNS population_NN ._.
He_PRP joined_VBD SmithKline_NNP the-counter_NN medicines_NNS and_CC nutritional_JJ healthcare_NN Beecham_NNP in_IN 1991_CD and_CC in_IN 1998_CD was_VBD appointed_VBN products_NNS ._.
He_PRP joined_VBD SmithKline_NNP Beecham_NNP in_IN 1991_CD President_NNP ,_, Pharmaceuticals_NNP ._.
and_CC in_IN 1998_CD was_VBD appointed_VBN President_NNP of_IN the_DT DAVID_NNP PULMAN_NNP Consumer_NNP Healthcare_NNP business_NN ._.
President_NNP Global_NNP Manufacturing_NNP &_CC Supply_NNP Other_JJ members_NNS Appointed_VBN to_TO the_DT post_NN in_IN December_NNP 2002_CD ,_, David_NNP James_NNP Palmer_NNP and_CC Tim_NNP Tyson_NNP left_VBD the_DT Group_NNP on_IN is_VBZ responsible_JJ for_IN the_DT global_JJ manufacturing_NN and_CC 1st_CD December_NNP 2002_CD to_TO pursue_VB other_JJ roles_NNS in_IN the_DT supply_NN chain_NN network_NN ._.
He_PRP joined_VBD Glaxo_NNP in_IN 1978_CD pharmaceutical_JJ industry_NN ._.
Bob_NNP Ingram_NNP retired_VBD on_IN and_CC prior_RB to_TO his_PRP$ most_RBS recent_JJ posting_VBG was_VBD responsible_JJ 31st_CD December_NNP 2002_CD but_CC will_MD continue_VB to_TO work_VB for_IN the_DT North_JJ American_JJ supply_NN network_NN ,_, manufacturing_VBG part-time_JJ as_IN Vice_NNP Chairman_NNP of_IN Pharmaceuticals_NNP ,_, acting_VBG as_IN a_DT special_JJ advisor_NN to_TO the_DT Group_NNP and_CC will_MD strategy_NN and_CC logistics_NNS ._.
attend_VB CET_NNP meetings_NNS in_IN that_DT capacity_NN ._.
BUSINESS_NN OPERATING_NN GlaxoSmithKline_NN continues_VBZ to_TO deliver_VB strong_JJ financial_JJ REVIEW_NNP performance_NN ,_, providing_VBG a_DT sound_JJ platform_NN for_IN the_DT future_NN ._.
Total_JJ pharmaceutical_JJ sales_NNS grew_VBD eight_CD per_IN cent_NN to_TO 18_CD billion_CD of_IN which_WDT new_JJ product_NN sales_NNS totalled_VBD 4.8_CD billion_CD ,_, an_DT increase_NN of_IN 36_CD per_IN cent_NN ._.
PHARMACEUTICALS_NNS Anti-viral_JJ sales_NNS grew_VBD across_IN all_DT regions_NNS Within_IN vaccines_NNS ,_, the_DT Hepatitis_NNP franchise_NN In_IN the_DT central_JJ nervous_JJ system_NN therapy_NN area_NN ,_, and_CC totalled_VBD 2.3_CD billion_CD ,_, up_RB 12_CD per_IN cent_NN ._.
grew_VBD 12_CD per_IN cent_NN with_IN sales_NNS in_IN Europe_NNP sales_NNS of_IN GlaxoSmithKlines_NNP leading_VBG product_NN Sales_NNS of_IN Trizivir_NNP ,_, GlaxoSmithKlines_NNP new_JJ growing_VBG ten_NN per_IN cent_NN ._.
Vaccine_NN sales_NNS in_IN the_DT for_IN depression_NN and_CC anxiety_NN disorders_NNS ,_, triple_JJ combination_NN therapy_NN for_IN HIV_NNP ,_, grew_VBD USA_NNP were_VBD up_RB 16_CD per_IN cent_NN benefiting_VBG from_IN Seroxat_NNP Paxil_NNP ,_, were_VBD up_RB 18_CD per_IN cent_NN in_IN the_DT 95_CD per_IN cent_NN to_TO 315_CD million_CD ._.
Valtrex_NNP for_IN the_DT launch_NN of_IN Twinrix_NNP and_CC continued_VBD growth_NN USA_NNP ._.
Paxil_NNP CR_NNP ,_, launched_VBN in_IN the_DT USA_NNP in_IN April_NNP ,_, herpes_VBZ achieved_VBN strong_JJ sales_NNS growth_NN of_IN in_IN Havrix_NNP ,_, driven_VBN by_IN new_JJ state_NN mandates_VBZ continues_VBZ to_TO gain_VB acceptance_NN due_JJ to_TO its_PRP$ 26_CD per_IN cent_NN worldwide_NN ._.
In_IN September_NNP 2002_CD ,_, requiring_VBG Hepatitis_NNP A_NNP vaccination_NN for_IN school_NN strong_JJ tolerability_NN profile_NN ._.
International_NNP Valtrex_NNP was_VBD approved_VBN by_IN the_DT FDA_NNP for_IN the_DT age_NN children_NNS ._.
In_IN the_DT USA_NNP ,_, GlaxoSmithKlines_NNP sales_NNS of_IN Paxil_NNP grew_VBD 27_CD per_IN cent_NN led_VBN by_IN treatment_NN of_IN cold_JJ sores_NNS in_IN healthy_JJ adults_NNS new_JJ Pediarix_NNP vaccine_NN was_VBD launched_VBN in_IN continued_VBN strong_JJ growth_NN in_IN Japan_NNP ,_, where_WRB and_CC in_IN October_NNP 2002_CD ,_, GlaxoSmithKline_NNP filed_VBD January_NNP 2003_CD ._.
the_DT product_NN was_VBD launched_VBN only_RB two_CD years_NNS a_DT further_JJ application_NN for_IN Valtrex_NNP seeking_VBG ago_RB ._.
Sales_NNS of_IN Wellbutrin_NNP ,_, for_IN depression_NN ,_, the_DT first-ever_JJ indication_NN to_TO reduce_VB the_DT risk_NN In_IN oncology_NN ,_, Zofran_NNP sales_NNS grew_VBD 22_CD per_IN cent_NN grew_VBD 42_CD per_IN cent_NN ,_, reflecting_VBG increased_VBN of_IN transmission_NN of_IN genital_JJ herpes_NNS ._.
to_TO 708_CD million_CD driven_VBN by_IN a_DT strong_JJ US_NNP physician_NN awareness_NN of_IN the_DT products_NNS performance_NN ,_, up_IN 28_CD per_IN cent_NN to_TO 525_CD million_CD ._.
outstanding_JJ efficacy_NN and_CC favourable_JJ side_NN Anti-bacterial_JJ sales_NNS declined_VBD 12_CD per_IN cent_NN effect_NN profile_NN ._.
Lamictal_NNP ,_, for_IN epilepsy_NN ,_, worldwide_NN and_CC 22_CD per_IN cent_NN in_IN the_DT USA_NNP In_IN July_NNP ,_, GlaxoSmithKline_NNP received_VBD approval_NN continued_VBD to_TO grow_VB across_IN all_DT regions_NNS ._.
as_IN a_DT result_NN of_IN generic_JJ competition_NN for_IN from_IN the_DT Swedish_JJ regulatory_JJ authorities_NNS In_IN January_NNP 2003_CD ,_, the_DT US_NNP FDA_NNP approved_VBD Augmentin_NNP and_CC Ceftin_NNP ._.
In_IN the_DT USA_NNP ,_, for_IN Avodart_NNP dutasteride_NN ,_, a_DT DHT_NNP inhibitor_NN the_DT use_NN of_IN Lamictal_NNP for_IN the_DT treatment_NN of_IN GlaxoSmithKlines_NNPS two_CD new_JJ antibiotics_NNS ,_, for_IN the_DT treatment_NN of_IN symptomatic_JJ benign_JJ partial_JJ seizures_NNS in_IN paediatric_JJ patients_NNS aged_VBN Augmentin_NNP ES_NNP for_IN children_NNS and_CC Augmentin_NNP prostatic_JJ hyperplasia_NN ._.
GlaxoSmithKline_NNP two_CD years_NNS and_CC above_IN ._.
XR_NNP for_IN adults_NNS are_VBP performing_VBG well_RB ._.
plans_NNS to_TO market_NN Avodart_NNP in_IN all_DT major_JJ European_JJ markets_NNS with_IN launches_NNS in_IN the_DT In_NNP respiratory_NN ,_, GlaxoSmithKline_NNP continues_VBZ In_IN metabolic_JJ and_CC gastro-intestinal_JJ the_DT first_JJ half_NN of_IN 2003_CD ._.
to_TO be_VB the_DT global_JJ leader_NN with_IN sales_NNS of_IN its_PRP$ Avandia_NNP franchise_NN ,_, Avandia_NNP and_CC Avandamet_NNP ,_, three_CD key_JJ products_NNS Seretide_NNP Advair_NNP ,_, grew_VBD 19_CD per_IN cent_NN for_IN the_DT year_NN and_CC Avandia_NNP Levitra_NNP vardenafil_NN a_DT new_JJ agent_NN for_IN the_DT Flixotide_NNP and_CC Serevent_NNP amounting_VBG to_TO is_VBZ now_RB approved_VBN in_IN 81_CD countries_NNS ._.
Avandamet_NNP treatment_NN of_IN erectile_JJ dysfunction_NN has_VBZ nearly_RB 3_CD billion_CD ,_, up_RB 25_CD per_IN cent_NN ._.
Sales_NNS Avandia_NNP and_CC metformin_JJ HCI_NNP ,_, launched_VBD received_VBN approval_NN for_IN marketing_NN in_IN Europe_NNP of_IN Seretide_NNP Advair_NNP grew_VBD 96_CD per_IN cent_NN and_CC in_IN the_DT fourth_JJ quarter_NN ,_, is_VBZ the_DT first_JJ treatment_NN and_CC launches_NNS are_VBP planned_VBN for_IN March_NNP 2003_CD ._.
Advair_NNP is_VBZ now_RB the_DT market_NN leader_NN in_IN the_DT for_IN type_NN 2_CD diabetes_NN that_WDT targets_VBZ insulin_NN Levitra_NNP was_VBD researched_VBN and_CC developed_VBN by_IN US_NNP asthma_NN market_NN in_IN new_JJ prescriptions_NNS resistance_NN and_CC decreases_VBZ glucose_NN production_NN Bayer_NNP AG_NNP and_CC will_MD be_VB co-promoted_VBN with_IN after_RB less_JJR than_IN two_CD years_NNS on_IN the_DT market_NN ._.
The_DT Group_NNP expects_VBZ European_JJ marketing_NN authorisation_NN within_IN the_DT next_JJ few_JJ months_NNS for_IN the_DT use_NN of_IN Seretide_NNP as_IN a_DT new_JJ treatment_NN for_IN Chronic_NNP Obstructive_NNP Pulmonary_NNP Disease_NNP ._.
GlaxoSmithKline_NNP aims_VBZ to_TO be_VB the_DT world_NN leader_NN in_IN consumer_NN healthcare_NN offering_NN products_NNS in_IN oral_JJ healthcare_NN ,_, over-thecounter_JJ medicines_NNS and_CC nutritional_JJ healthcare_NN ._.
A_DT dynamic_JJ R&D_NNP organization_NN of_IN over_IN 15,000_CD employees_NNS based_VBN at_IN more_JJR than_IN 20_CD sites_NNS in_IN eight_CD countries_NNS providing_VBG a_DT leading_VBG position_NN in_IN genomics_NNS genetics_NNS and_CC new_JJ drug_NN discovery_NN techniques_NNS ._.
A_DT manufacturing_NN and_CC supply_NN network_NN comprising_VBG over_IN 1,200_CD different_JJ products_NNS created_VBN at_IN 95_CD sites_NNS in_IN 38_CD countries_NNS ._.
ANNUAL_JJ REVIEW_NNP 2002_CD 18_CD |_NN 19_CD CONSUMER_NN HEALTHCARE_NN IMPLEMENTATION_NN OF_IN NEW_NNP FINANCIAL_NNP LEGAL_NNP PROCEEDINGS_NNS Over-the-counter_JJ sales_NNS were_VBD 1.6_CD billion_CD ,_, The_DT Group_NNP is_VBZ involved_VBN in_IN various_JJ legal_JJ REPORTING_NNP STANDARD_NNP up_IN four_CD per_IN cent_NN ,_, reflecting_VBG strong_JJ growth_NN The_DT Group_NNP has_VBZ implemented_VBN Financial_NNP and_CC administrative_JJ proceedings_NNS principally_RB in_IN the_DT smoking_NN control_NN franchise_NN ._.
Nutritional_NNP Reporting_NNP Standard_NNP 19_CD Deferred_JJ tax_NN intellectual_JJ property_NN cases_NNS ,_, product_NN liability_NN healthcare_NN grew_VBD three_CD per_IN cent_NN due_JJ to_TO in_IN 2002_CD which_WDT requires_VBZ deferred_VBN tax_NN to_TO and_CC government_NN investigations_NNS ._.
Descriptions_NNS strong_JJ growth_NN in_IN Europe_NNP for_IN Lucozade_NNP and_CC be_VB accounted_VBN for_IN on_IN a_DT full_JJ provision_NN basis_NN ,_, of_IN the_DT most_RBS significant_JJ of_IN those_DT are_VBP described_VBN Ribena_NNP ,_, partly_RB offset_VBN by_IN the_DT performance_NN rather_RB than_IN a_DT partial_JJ provision_NN basis_NN as_IN under_IN Legal_NNP proceedings_NNS in_IN the_DT Notes_NNS to_TO of_IN Horlicks_NNP in_IN international_JJ markets_NNS ._.
Comparative_JJ information_NN has_VBZ been_VBN the_DT financial_JJ statements_NNS in_IN the_DT companys_NNS care_VBP sales_NNS were_VBD down_RB two_CD per_IN cent_NN to_TO restated_VBN as_RB necessary_JJ ._.
The_DT effect_NN in_IN 2001_CD Annual_JJ Report_NNP for_IN 2002_CD ._.
1.1_CD billion_CD as_IN growth_NN from_IN Sensodyne_NNP ,_, is_VBZ to_TO increase_VB the_DT business_NN performance_NN Polident_NNP and_CC Poligrip_NNP was_VBD offset_VBN by_IN weak_JJ tax_NN charge_NN by_IN 8_CD million_CD and_CC the_DT overall_JJ CAUTIONARY_NNP STATEMENT_NN sales_NNS for_IN Aquafresh_NNP ._.
The_DT net_JJ deferred_VBN Under_IN the_DT safe_JJ harbor_NN provisions_NNS of_IN the_DT tax_NN asset_NN at_IN 31st_CD December_NNP 2001_CD has_VBZ been_VBN US_NNP Private_NNP Securities_NNP Litigation_NNP Reform_NNP Act_NNP TRADING_NN PROFIT_NN AND_CC EARNINGS_NNS reduced_VBN by_IN 127_CD million_CD ._.
of_IN 1995_CD ,_, the_DT company_NN cautions_VBZ investors_NNS that_IN any_DT forward-looking_JJ statements_NNS or_CC PER_NNP SHARE_NNP Business_NNP performance_NN trading_NN profit_NN was_VBD THE_DT SARBANES-OXLEY_NN ACT_NNP 2002_CD projections_NNS made_VBN by_IN the_DT company_NN ,_, including_VBG 6.7_CD billion_CD with_IN a_DT growth_NN of_IN 15_CD per_IN cent_NN ,_, Following_VBG a_DT number_NN of_IN corporate_JJ and_CC those_DT made_VBN in_IN this_DT Annual_JJ Review_NNP ,_, are_VBP greater_JJR than_IN sales_NNS growth_NN of_IN seven_CD per_IN cent_NN ,_, accounting_VBG scandals_NNS in_IN the_DT USA_NNP ,_, Congress_NNP subject_NN to_TO risks_NNS and_CC uncertainties_NNS that_WDT may_MD demonstrating_VBG an_DT improved_JJ trading_NN margin_NN passed_VBD the_DT Sarbanes-Oxley_NNP Act_NNP 2002_CD cause_NN actual_JJ results_NNS to_TO differ_VB materially_RB from_IN of_IN 2.1_CD points_NNS to_TO 31.6_CD per_IN cent_NN compared_VBN Sarbanes-Oxley_NNP which_WDT took_VBD effect_NN on_IN those_DT projected_VBN ._.
Factors_NNS that_WDT may_MD affect_VB with_IN 2001_CD ._.
This_DT is_VBZ mainly_RB due_JJ to_TO cost_VB 30th_JJ July_NNP 2002_CD ._.
Sarbanes-Oxley_NNP establishes_VBZ the_DT Groups_NNS operations_NNS are_VBP described_VBN under_IN savings_NNS derived_VBN from_IN merger_NN integration_NN ,_, new_JJ or_CC enhanced_JJ standards_NNS for_IN corporate_JJ Risk_NNP factors_NNS in_IN the_DT Operating_NN and_CC financial_JJ manufacturing_NN restructuring_NN and_CC other_JJ accountability_NN in_IN the_DT USA_NNP ._.
A_DT number_NN review_NN and_CC prospects_NNS in_IN the_DT companys_NNS initiatives_NNS ._.
Statutory_JJ trading_NN profit_NN was_VBD of_IN provisions_NNS of_IN Sarbanes-Oxley_NNP apply_VB Annual_JJ Report_NNP on_IN Form_NN 20-F_NN ,_, filed_VBN with_IN the_DT 5.7_CD billion_CD with_IN a_DT growth_NN of_IN 26_CD per_IN cent_NN ._.
to_TO GlaxoSmithKline_NNP and_CC ,_, although_IN the_DT US_NNP Securities_NNPS and_CC Exchange_NNP Commission_NNP ._.
companys_NNS corporate_JJ governance_NN structure_NN Full_NNP year_NN business_NN performance_NN earnings_NNS is_VBZ believed_VBN to_TO be_VB robust_JJ and_CC in_IN line_NN with_IN per_IN share_NN EPS_NNP of_IN 78.3_CD pence_NN increased_VBD best_JJS practice_NN ,_, certain_JJ changes_NNS were_VBD 13_CD per_IN cent_NN and_CC eight_CD per_IN cent_NN in_IN sterling_NN necessary_JJ to_TO ensure_VB compliance_NN ._.
These_DT terms_NNS reflecting_VBG a_DT weakening_NN of_IN the_DT US_NNP are_VBP described_VBN under_IN Corporate_JJ governance_NN dollar_NN and_CC other_JJ currencies_NNS ._.
Full_JJ year_NN in_IN the_DT companys_NNS Annual_JJ Report_NNP for_IN 2002_CD ._.
statutory_JJ EPS_NNP was_VBD 66.2_CD pence_NN ,_, an_DT increase_NN of_IN 38_CD per_IN cent_NN ._.
Business_NNP performance_NN ,_, which_WDT is_VBZ the_DT primary_JJ Pharmaceutical_NNP sales_NNS by_IN therapeutic_JJ area_NN performance_NN measure_NN used_VBN by_IN management_NN ,_, 2002_CD 2001_CD %_NN CER_NNP is_VBZ presented_VBN after_IN excluding_VBG merger_NN items_NNS ,_, integration_NN and_CC restructuring_NN costs_NNS and_CC disposal_NN m_NN m_NN GROWTH_NN of_IN businesses_NNS ._.
Management_NNP believes_VBZ that_IN CNS_NNP 4,511_CD 4,007_CD 17_CD exclusion_NN of_IN these_DT non-recurring_JJ items_NNS provides_VBZ Respiratory_NNP 3,987_CD 3,537_CD 16_CD a_DT better_JJR comparison_NN of_IN business_NN performance_NN Anti-virals_NNS 2,299_CD 2,128_CD 12_CD for_IN the_DT periods_NNS presented_VBN ._.
Statutory_JJ results_NNS Anti-bacterials_JJ 2,210_CD 2,604_CD 12_CD include_VBP these_DT non-recurring_JJ items_NNS ._.
Metabolic_NNP and_CC gastro-intestinal_JJ 1,429_CD 1,480_CD 1_CD In_IN order_NN to_TO illustrate_VB underlying_VBG performance_NN ,_, Vaccines_NNP 1,080_CD 948_CD 16_CD it_PRP is_VBZ the_DT Groups_NNS practice_NN to_TO discuss_VB the_DT results_NNS Oncology_NNP and_CC emesis_NN 977_CD 838_CD 21_CD in_IN terms_NNS of_IN constant_JJ exchange_NN rates_NNS CER_NNP Cardiovascular_NNP 655_CD 591_CD 14_CD growth_NN ._.
This_DT represents_VBZ growth_NN calculated_VBN as_IN Arthritis_NNP 23_CD 156_CD 84_CD if_IN the_DT exchange_NN rates_NNS used_VBN to_TO determine_VB the_DT Other_JJ 824_CD 916_CD 5_CD results_NNS of_IN overseas_JJ companies_NNS in_IN sterling_NN had_VBD Total_JJ 17,995_CD 17,205_CD 8_CD remained_VBD unchanged_JJ from_IN those_DT used_VBN in_IN the_DT previous_JJ period_NN ._.
Growth_NN rates_NNS are_VBP therefore_RB at_IN CER_NNP unless_IN otherwise_RB stated_VBN ._.
RESPONSIBILITY_NN STATEMENTS_NNS Annual_JJ Review_NNP The_DT Annual_JJ Review_NNP ,_, including_VBG Summary_NNP financial_JJ statements_NNS ,_, has_VBZ The_DT Annual_JJ Review_NNP is_VBZ a_DT summary_NN report_NN and_CC does_VBZ not_RB contain_VB been_VBN approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS and_CC signed_VBN on_IN its_PRP$ behalf_NN by_IN sufficient_JJ information_NN to_TO allow_VB as_IN full_JJ an_DT understanding_NN of_IN the_DT results_NNS and_CC state_NN of_IN affairs_NNS of_IN the_DT Group_NNP as_IN is_VBZ provided_VBN by_IN the_DT full_JJ Annual_JJ Sir_NNP Christopher_NNP Hogg_NNP ,_, Report_NNP ._.
Shareholders_NNS requiring_VBG more_JJR detailed_JJ information_NN may_MD Chairman_NNP obtain_VB ,_, free_JJ of_IN charge_NN ,_, a_DT copy_NN of_IN the_DT Annual_JJ Report_NNP for_IN 2002_CD 10th_JJ March_NNP 2003_CD and_CC may_MD also_RB elect_VB to_TO receive_VB a_DT copy_NN of_IN the_DT Annual_JJ Report_NNP in_IN future_JJ years_NNS refer_VBP to_TO Shareholder_NN information_NN ._.
Independent_NNP auditors_NNS statement_NN to_TO the_DT members_NNS The_DT Independent_NNP Auditors_NNS report_VBP on_IN the_DT full_JJ financial_JJ statements_NNS of_IN GlaxoSmithKline_NNP plc_NN of_IN the_DT Group_NNP for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2002_CD is_VBZ unqualified_JJ We_PRP have_VBP examined_VBN the_DT Summary_NNP financial_JJ statements_NNS which_WDT comprise_VBP and_CC does_VBZ not_RB contain_VB any_DT statement_NN concerning_VBG inadequate_JJ the_DT Summary_NNP consolidated_JJ profit_NN and_CC loss_NN account_NN ,_, balance_NN sheet_NN and_CC accounting_NN records_NNS or_CC failure_NN to_TO obtain_VB necessary_JJ information_NN cash_NN flow_NN statement_NN and_CC the_DT summarised_VBN Directors_NNS report_VBP including_VBG and_CC explanations_NNS ._.
Summary_JJ financial_JJ statements_NNS Respective_JJ responsibilities_NNS of_IN Directors_NNS and_CC auditors_NNS A_DT columnar_NN presentation_NN has_VBZ been_VBN adopted_VBN in_IN the_DT Summary_NNP The_NNP Directors_NNS are_VBP responsible_JJ for_IN preparing_VBG the_DT Annual_JJ Review_NNP consolidated_JJ profit_NN and_CC loss_NN account_NN in_IN order_NN to_TO illustrate_VB business_NN in_IN accordance_NN with_IN applicable_JJ law_NN ._.
Our_PRP$ responsibility_NN is_VBZ to_TO report_VB performance_NN which_WDT is_VBZ the_DT primary_JJ measure_NN used_VBN by_IN management_NN ._.
to_TO you_PRP our_PRP$ opinion_NN on_IN the_DT consistency_NN of_IN the_DT Summary_NNP financial_JJ For_IN this_DT purpose_NN certain_JJ items_NNS are_VBP identified_VBN separately_RB and_CC are_VBP statements_NNS within_IN the_DT Annual_JJ Review_NNP with_IN the_DT Annual_JJ financial_JJ excluded_VBN from_IN business_NN performance_NN ._.
These_DT comprise_VBP merger_NN items_NNS ,_, statements_NNS ,_, the_DT Directors_NNS report_NN and_CC the_DT Directors_NNS remuneration_NN including_VBG merger_NN related_VBN product_NN divestments_NNS ,_, costs_NNS relating_VBG report_NN ,_, and_CC its_PRP$ compliance_NN with_IN the_DT relevant_JJ requirements_NNS of_IN Section_NN to_TO previously_RB announced_VBN manufacturing_NN and_CC other_JJ restructuring_NN ,_, 251_CD of_IN the_DT United_NNP Kingdom_NNP Companies_NNP Act_NNP 1985_CD and_CC the_DT regulations_NNS and_CC disposal_NN of_IN businesses_NNS ._.
Business_NNP performance_NN is_VBZ discussed_VBN made_VBN thereunder_RB ._.
We_PRP also_RB read_VBD the_DT other_JJ information_NN contained_VBN in_IN the_DT Business_NN operating_VBG review_NN ._.
in_IN the_DT Annual_JJ Review_NNP and_CC consider_VB the_DT implications_NNS for_IN our_PRP$ report_NN if_IN we_PRP become_VBP aware_JJ of_IN any_DT apparent_JJ misstatements_NNS or_CC material_NN Information_NN is_VBZ provided_VBN for_IN US_NNP shareholders_NNS in_IN accordance_NN with_IN inconsistencies_NNS with_IN the_DT Summary_NNP financial_JJ statements_NNS ._.
the_DT requirements_NNS of_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP ._.
The_DT Summary_NNP financial_JJ statements_NNS under_IN UK_NNP Generally_RB Accepted_JJ Accounting_NN This_DT statement_NN ,_, including_VBG the_DT opinion_NN ,_, has_VBZ been_VBN prepared_VBN for_IN and_CC only_RB Principles_NNPS GAAP_NNP are_VBP presented_VBN in_IN US$_$ as_RB well_RB as_IN in_IN sterling_NN ._.
for_IN the_DT companys_NNS members_NNS as_IN a_DT body_NN in_IN accordance_NN with_IN Section_NN 251_CD Earnings_NNS and_CC shareholders_NNS funds_NNS are_VBP also_RB restated_VBN in_IN accordance_NN of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC for_IN no_DT other_JJ purpose_NN ._.
in_IN giving_VBG this_DT opinion_NN ,_, accept_VB or_CC assume_VB responsibility_NN for_IN any_DT other_JJ purpose_NN or_CC to_TO any_DT other_JJ person_NN to_TO whom_WP this_DT statement_NN is_VBZ shown_VBN Statement_NN by_IN the_DT Directors_NNS or_CC into_IN whose_WP$ hands_NNS it_PRP may_MD come_VB save_IN where_WRB expressly_RB agreed_VBN by_IN The_DT Annual_JJ Review_NNP 2002_CD is_VBZ the_DT Summary_NNP Directors_NNS report_NN and_CC our_PRP$ prior_JJ consent_NN in_IN writing_VBG ._.
includes_VBZ the_DT Summary_NNP financial_JJ statements_NNS of_IN GlaxoSmithKline_NNP plc_NN for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2002_CD ,_, which_WDT is_VBZ published_VBN in_IN Basis_NN of_IN opinion_NN hard-copy_JJ printed_VBN form_NN and_CC on_IN the_DT website_NN ._.
The_DT Business_NN operating_NN We_PRP conducted_VBD our_PRP$ work_NN in_IN accordance_NN with_IN Bulletin_NNP 1999_CD 6_CD ,_, review_NN ,_, the_DT Summary_NNP financial_JJ statements_NNS ,_, the_DT Summary_NNP remuneration_NN The_DT auditors_NNS statement_NN on_IN the_DT Summary_NNP financial_JJ statement_NN issued_VBN report_NN and_CC the_DT Statement_NN on_IN corporate_JJ governance_NN are_VBP summaries_NNS by_IN the_DT Auditing_NNP Practices_NNPS Board_NNP for_IN use_NN in_IN the_DT United_NNP Kingdom_NNP ._.
of_IN information_NN in_IN the_DT Annual_JJ Report_NNP ._.
Opinion_NN The_DT Directors_NNS are_VBP responsible_JJ for_IN the_DT maintenance_NN and_CC integrity_NN In_IN our_PRP$ opinion_NN the_DT Summary_NNP financial_JJ statements_NNS are_VBP consistent_JJ with_IN of_IN the_DT Annual_JJ Review_NNP on_IN the_DT website_NN in_IN accordance_NN with_IN the_DT UK_NNP the_DT Annual_JJ financial_JJ statements_NNS ,_, the_DT Directors_NNS report_NN and_CC the_DT Directors_NNS legislation_NN governing_VBG the_DT preparation_NN and_CC dissemination_NN of_IN financial_JJ remuneration_NN report_NN of_IN GlaxoSmithKline_NNP plc_NN for_IN the_DT year_NN ended_VBD statements_NNS ._.
Access_NN to_TO the_DT website_NN is_VBZ available_JJ from_IN outside_IN the_DT UK_NNP ,_, 31st_CD December_NNP 2002_CD and_CC complies_VBZ with_IN the_DT applicable_JJ requirements_NNS where_WRB comparable_JJ legislation_NN may_MD be_VB different_JJ ._.
of_IN Section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
Corporate_JJ governance_NN The_DT Combined_NNP Code_NNP Principles_NNPS of_IN Good_JJ Governance_NN and_CC Code_NNP of_IN LLP_NNP Best_JJS Practice_NN is_VBZ specified_VBN by_IN the_DT Listing_NNP Rules_NNP of_IN the_DT Financial_NNP Services_NNPS Chartered_NNP Accountants_NNPS and_CC Registered_NNP Auditors_NNS Authority_NNP for_IN the_DT guidance_NN of_IN listed_VBN companies_NNS ._.
The_DT Board_NNP considers_VBZ Southwark_NNP Towers_NNP ,_, London_NNP ,_, England_NNP ,_, 10th_JJ March_NNP 2003_CD that_WDT throughout_IN 2002_CD and_CC up_RB to_TO the_DT date_NN of_IN approval_NN of_IN this_DT review_NN ,_, GlaxoSmithKline_NNP plc_NN applied_VBD the_DT principles_NNS of_IN the_DT Combined_NNP Code_NNP and_CC ,_, with_IN the_DT exception_NN of_IN matters_NNS where_WRB the_DT companys_NNS position_NN is_VBZ described_VBN in_IN the_DT Annual_JJ Report_NNP ,_, complied_VBN with_IN the_DT provisions_NNS of_IN the_DT Combined_NNP Code_NNP ,_, and_CC the_DT guidance_NN on_IN internal_JJ control_NN issued_VBN by_IN the_DT Turnbull_NNP Committee_NNP ._.
ANNUAL_JJ REVIEW_NNP 2002_CD 20_CD |_NN 21_CD CORPORATE_JJ GOVERNANCE_NNP Governance_NNP and_CC policy_NN The_DT Board_NNP and_CC Executive_NNP The_NNP Directors_NNS listed_VBN under_IN The_DT Board_NNP on_IN page_NN 16_CD were_VBD appointed_VBN The_DT Remuneration_NNP Committee_NNP determines_VBZ the_DT terms_NNS of_IN service_NN on_IN 23rd_JJ May_NNP 2000_CD and_CC have_VBP served_VBN since_IN that_DT date_NN ._.
and_CC remuneration_NN of_IN the_DT Executive_NNP Directors_NNS and_CC Corporate_JJ Executives_NNS and_CC with_IN the_DT assistance_NN of_IN external_JJ independent_JJ advisors_NNS The_DT Board_NNP of_IN GlaxoSmithKline_NNP plc_NN is_VBZ responsible_JJ for_IN the_DT Groups_NNS it_PRP evaluates_VBZ and_CC makes_VBZ recommendations_NNS to_TO the_DT Board_NNP on_IN the_DT system_NN of_IN corporate_JJ governance_NN and_CC is_VBZ ultimately_RB accountable_JJ remuneration_NN of_IN Non-Executive_JJ Directors_NNS ._.
The_DT Committee_NNP consists_VBZ for_IN the_DT Groups_NNS activities_NNS ,_, strategy_NN and_CC financial_JJ performance_NN ._.
It_PRP meets_VBZ four_CD times_NNS a_DT year_NN and_CC otherwise_RB as_RB necessary_JJ ._.
The_DT Chairman_NNP and_CC CEO_NNP attend_VBP the_DT meetings_NNS The_DT Board_NNP comprises_VBZ Executive_NNP and_CC Non-Executive_NNP Directors_NNS ._.
except_IN when_WRB their_PRP$ own_JJ remuneration_NN is_VBZ being_VBG considered_VBN ._.
The_DT Senior_JJ The_DT role_NN of_IN Non-Executive_JJ Directors_NNS is_VBZ to_TO bring_VB independent_JJ Vice_NNP President_NNP ,_, Human_NNP Resources_NNPS ,_, also_RB attends_VBZ each_DT meeting_NN ._.
judgement_NN to_TO Board_NNP deliberations_NNS and_CC decisions_NNS ._.
The_DT Board_NNP considers_VBZ each_DT of_IN the_DT Non-Executive_JJ Directors_NNS to_TO be_VB independent_JJ ._.
The_DT Nominations_NNPS Committee_NNP reviews_VBZ the_DT structure_NN ,_, size_NN and_CC composition_NN of_IN the_DT Board_NNP and_CC the_DT appointment_NN of_IN Corporate_JJ Sir_NNP Christopher_NNP Hogg_NNP was_VBD appointed_VBN Non-Executive_NNP Chairman_NNP Executives_NNS and_CC new_JJ Board_NNP members_NNS and_CC makes_VBZ recommendations_NNS following_VBG the_DT retirement_NN of_IN Sir_NNP Richard_NNP Sykes_NNP on_IN 20th_JJ May_NNP 2002_CD ,_, to_TO the_DT Board_NNP as_IN appropriate_JJ ._.
The_DT Committee_NNP will_MD also_RB review_VB the_DT and_CC Dr_NNP Jean-Pierre_NNP Garnier_NNP is_VBZ Chief_NNP Executive_NNP Officer_NNP ._.
Sir_NNP Roger_NNP Hurn_NNP managements_NNS succession_NN plan_NN to_TO ensure_VB its_PRP$ adequacy_NN ._.
The_DT Committee_NNP is_VBZ Non-Executive_JJ Deputy_NNP Chairman_NNP and_CC Senior_NNP Independent_NNP Director_NNP ._.
consists_VBZ entirely_RB of_IN Non-Executive_JJ Directors_NNS and_CC meets_VBZ at_IN least_JJS once_RB a_DT year_NN to_TO consider_VB succession_NN planning_NN and_CC otherwise_RB as_RB necessary_JJ ._.
Board_NNP process_NN The_NNP Board_NNP meets_VBZ at_IN least_JJS six_CD times_NNS a_DT year_NN ._.
It_PRP has_VBZ a_DT formal_JJ schedule_NN The_DT Corporate_NNP Administration_NNP &_CC Transactions_NNS Committee_NNP of_IN matters_NNS reserved_VBN to_TO it_PRP for_IN decision_NN but_CC otherwise_RB delegates_NNS reviews_NNS and_CC approves_VBZ matters_NNS in_IN connection_NN with_IN the_DT administration_NN specific_JJ responsibilities_NNS to_TO Board_NNP committees_NNS ,_, as_IN described_VBN below_IN ._.
of_IN the_DT Groups_NNS business_NN ,_, and_CC of_IN certain_JJ corporate_JJ transactions_NNS ._.
The_DT Board_NNP works_VBZ to_TO an_DT agreed_VBN agenda_NN in_IN reviewing_VBG the_DT key_JJ The_DT Committee_NNP consists_VBZ of_IN the_DT Directors_NNS ,_, CET_NNP members_NNS and_CC activities_NNS of_IN the_DT business_NN ,_, and_CC receives_VBZ papers_NNS and_CC presentations_NNS the_DT Company_NN Secretary_NNP ._.
The_DT Committee_NNP meets_VBZ as_RB necessary_JJ ._.
to_TO enable_VB it_PRP to_TO do_VB so_RB effectively_RB ._.
The_DT Board_NNP considers_VBZ and_CC reviews_VBZ the_DT work_NN undertaken_VBN by_IN its_PRP$ Committees_NNS ._.
The_DT Corporate_JJ Social_NNP Responsibility_NNP Committee_NNP consists_VBZ entirely_RB of_IN Non-Executive_JJ Directors_NNS and_CC provides_VBZ a_DT Board_NNP level_NN forum_NN for_IN the_DT The_NNP Company_NNP Secretary_NNP is_VBZ responsible_JJ to_TO the_DT Board_NNP and_CC is_VBZ regular_JJ review_NN of_IN external_JJ issues_NNS that_WDT have_VBP the_DT potential_NN for_IN serious_JJ available_JJ to_TO individual_JJ Directors_NNS in_IN respect_NN of_IN Board_NNP procedures_NNS ._.
impact_NN upon_IN the_DT Groups_NNS business_NN and_CC reputation_NN ._.
The_DT Committee_NNP The_NNP Company_NNP Secretary_NNP is_VBZ Simon_NNP Bicknell_NNP who_WP was_VBD appointed_VBN is_VBZ also_RB responsible_JJ for_IN annual_JJ governance_NN oversight_NN of_IN the_DT Groups_NNS in_IN May_NNP 2000_CD ._.
He_PRP is_VBZ a_DT barrister_NN and_CC joined_VBD the_DT Group_NNP in_IN 1984_CD ._.
worldwide_JJ donations_NNS and_CC community_NN support_NN ._.
The_DT Committee_NNP meets_VBZ He_PRP is_VBZ secretary_NN to_TO all_PDT the_DT Board_NNP Committees_NNS ._.
formally_RB twice_RB a_DT year_NN and_CC has_VBZ further_JJ meetings_NNS and_CC consultations_NNS as_IN required_VBN ._.
Board_NNP committees_VBZ The_DT Audit_NNP Committee_NNP reviews_VBZ the_DT financial_JJ and_CC internal_JJ reporting_NN Corporate_NNP Executive_NNP Team_NNP process_NN ,_, the_DT system_NN of_IN internal_JJ control_NN and_CC management_NN of_IN risks_NNS The_DT executive_NN management_NN of_IN the_DT Group_NNP is_VBZ the_DT responsibility_NN of_IN and_CC the_DT external_JJ and_CC internal_JJ audit_NN process_NN ._.
The_DT Committee_NNP also_RB the_DT CEO_NNP and_CC other_JJ senior_JJ managers_NNS ,_, who_WP form_VBP the_DT CET_NNP which_WDT meets_VBZ proposes_VBZ to_TO the_DT shareholders_NNS the_DT appointment_NN of_IN the_DT external_JJ 11_CD times_NNS a_DT year_NN ._.
The_DT members_NNS of_IN the_DT CET_NNP and_CC their_PRP$ responsibilities_NNS auditors_NNS and_CC is_VBZ directly_RB responsible_JJ for_IN their_PRP$ remuneration_NN and_CC are_VBP given_VBN on_IN page_NN 17_CD ._.
oversight_NN of_IN their_PRP$ work_NN ._.
The_DT Committee_NNP consists_VBZ entirely_RB of_IN Non-Executive_JJ Directors_NNS ._.
It_PRP meets_VBZ at_IN least_JJS four_CD times_NNS a_DT year_NN with_IN the_DT Remuneration_NNP of_IN Directors_NNS Chief_NNP Executive_NNP Officer_NNP CEO_NNP ,_, the_DT Chief_NNP Financial_NNP Officer_NNP CFO_NNP ,_, Information_NNP on_IN the_DT remuneration_NN of_IN Directors_NNS is_VBZ given_VBN in_IN the_DT Summary_NNP the_DT General_NNP Counsel_NNP ,_, the_DT heads_NNS of_IN global_JJ internal_JJ audit_NN and_CC remuneration_NN report_NN on_IN pages_NNS 25_CD to_TO 27_CD ._.
corporate_JJ compliance_NN and_CC representatives_NNS of_IN the_DT external_JJ auditors_NNS in_IN attendance_NN ._.
With_IN effect_NN from_IN 1st_CD January_NNP 2003_CD the_DT Committee_NNP Share_NN buy-back_NN program_NN is_VBZ responsible_JJ for_IN pre-approving_VBG all_DT non-audit_JJ services_NNS to_TO be_VB In_IN October_NNP 2002_CD ,_, following_VBG the_DT completion_NN of_IN the_DT 4_CD billion_CD share_NN provided_VBN by_IN external_JJ auditors_NNS ._.
buy-back_JJ program_NN announced_VBN in_IN 2001_CD ,_, the_DT company_NN announced_VBD plans_NNS for_IN a_DT new_JJ 4_CD billion_CD share_NN buy-back_JJ program_NN ._.
The_DT Financial_NNP Results_NNS Committee_NNP reviews_VBZ and_CC approves_VBZ ,_, on_IN behalf_NN of_IN the_DT Board_NNP ,_, the_DT Annual_JJ Report_NNP on_IN Form_NN 20-F_NN and_CC Annual_JJ The_DT program_NN covers_VBZ purchases_NNS by_IN the_DT company_NN of_IN shares_NNS for_IN Review_NNP and_CC the_DT convening_VBG of_IN the_DT Annual_JJ General_NNP Meeting_VBG together_RB cancellation_NN ,_, in_IN accordance_NN with_IN the_DT authority_NN given_VBN by_IN shareholders_NNS with_IN the_DT preliminary_JJ and_CC quarterly_JJ statements_NNS of_IN trading_NN results_NNS ._.
at_IN the_DT Annual_JJ General_NNP Meetings_NNS in_IN 2001_CD and_CC 2002_CD ._.
Each_DT Director_NNP is_VBZ a_DT member_NN of_IN the_DT committee_NN and_CC the_DT quorum_NN for_IN a_DT meeting_NN is_VBZ any_DT three_CD members_NNS ._.
To_TO be_VB quorate_JJ ,_, each_DT meeting_NN In_IN total_JJ 2.2_CD billion_CD was_VBD spent_VBN during_IN 2002_CD ._.
In_IN May_NNP 2002_CD the_DT must_MD include_VB the_DT Chairman_NNP or_CC the_DT Chairman_NNP of_IN the_DT Audit_NNP company_NN was_VBD authorised_VBN to_TO purchase_VB a_DT maximum_NN of_IN 617_CD million_CD Committee_NNP and_CC the_DT CEO_NNP or_CC the_DT CFO_NNP ._.
shares_NNS 623_CD million_CD shares_NNS in_IN May_NNP 2001_CD and_CC 156_CD million_CD shares_NNS were_VBD purchased_VBN for_IN cancellation_NN during_IN 2002_CD ._.
The_DT exact_JJ amount_NN and_CC timing_NN of_IN future_JJ purchases_NNS will_MD be_VB determined_VBN by_IN the_DT company_NN and_CC is_VBZ dependent_JJ on_IN market_NN conditions_NNS and_CC other_JJ factors_NNS ._.
SUMMARY_NN FINANCIAL_NNP STATEMENTS_NNS for_IN the_DT year_NN to_TO 31st_CD December_NNP 2002_CD Merger_NNP ,_, restructuring_NN and_CC Business_NN performance_NN disposal_NN of_IN subsidiaries_NNS Statutory_NNP 2001 2001 2001 2002_CD restated_VBN 2002_CD restated_VBN 2002_CD restated_VBN Summary_NNP consolidated_JJ profit_NN and_CC loss_NN account_NN m_NN m_NN CER_NNP %_NN m_NN m_FW m_FW m_FW Sales_NNS Pharmaceuticals_NNS 17,995_CD 17,205_CD 8_CD 17,995_CD 17,205_CD Consumer_NN Healthcare_NNP 3,217_CD 3,284_CD 2_CD 3,217_CD 3,284_CD Total_JJ sales_NNS 21,212_CD 20,489_CD 7_CD 21,212_CD 20,489_CD Cost_NN of_IN sales_NNS 4,243_CD 4,430_CD 2_CD 366_CD 303_CD 4,609_CD 4,733_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenditure_NN 7,543_CD 7,451_CD 5_CD 498_CD 957_CD 8,041_CD 8,408_CD Research_NNP and_CC development_NN expenditure_NN 2,732_CD 2,555_CD 9_CD 168_CD 96_CD 2,900_CD 2,651_CD Trading_NN profit_NN 6,694_CD 6,053_CD 15_CD 1,032_CD 1,356_CD 5,662_CD 4,697_CD Other_JJ income_NN and_CC expenses_NNS 111_CD 37_CD 21_CD 296_CD 90_CD 259_CD Income_NN from_IN associates_NNS 75_CD 167_CD 75_CD 167_CD Net_JJ interest_NN payable_JJ 141_CD 88_CD 141_CD 88_CD Profit_NN before_IN taxation_NN 6,517_CD 6,169_CD 11_CD 1,011_CD 1,652_CD 5,506_CD 4,517_CD Taxation_NNP 1,760_CD 1,655_CD 299_CD 322_CD 1,461_CD 1,333_CD Profit_NN after_IN taxation_NN 4,757_CD 4,514_CD 712_CD 1,330_CD 4,045_CD 3,184_CD Minority_NNP interests_NNS 110_CD 97_CD 110_CD 97_CD Preference_NN share_NN dividends_NNS 20_CD 34_CD 20_CD 34_CD Earnings_NNS 4,627_CD 4,383_CD 11_CD 712_CD 1,330_CD 3,915_CD 3,053_CD Earnings_NNS per_IN share_NN 78.3_CD p_VBP 72.3_CD p_JJ 13_CD 66.2_CD p_NN 50.3_CD p_NN Dividends_NNS 2,346_CD 2,356_CD To_TO illustrate_VB Business_NNP performance_NN ,_, which_WDT is_VBZ the_DT primary_JJ measure_NN used_VBN by_IN management_NN ,_, merger_NN items_NNS ,_, integration_NN and_CC restructuring_NN costs_NNS and_CC disposal_NN of_IN businesses_NNS have_VBP been_VBN excluded_VBN and_CC an_DT adjusted_JJ EPS_NNP presented_VBD ._.
Business_NNP performance_NN growth_NN is_VBZ at_IN constant_JJ exchange_NN rates_NNS ._.
2001_CD 2002_CD restated_VBN Summary_NNP consolidated_JJ balance_NN sheet_NN m_NN m_NN Fixed_VBN assets_NNS 11,578_CD 11,920_CD Current_JJ assets_NNS 10,749_CD 10,423_CD Creditors_NNPS :_: amounts_NNS due_JJ within_IN one_CD year_NN 8,808_CD 9,430_CD Net_JJ current_JJ assets_NNS 1,941_CD 993_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 13,519_CD 12,913_CD Creditors_NNPS :_: amounts_NNS due_RB after_IN one_CD year_NN 3,298_CD 2,298_CD Provision_NNP for_IN liabilities_NNS and_CC charges_NNS 2,833_CD 2,363_CD Net_JJ assets_NNS 7,388_CD 8,252_CD Equity_NNP shareholders_NNS funds_NNS 6,581_CD 7,390_CD Minority_NNP interests_NNS 807_CD 862_CD Capital_NN employed_VBN 7,388_CD 8,252_CD 2002_CD 2001_CD Summary_NNP consolidated_JJ cash_NN flow_NN statement_NN m_NN m_NN Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 7,255_CD 6,507_CD Dividends_NNS from_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 2_CD Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN 237_CD 191_CD Taxation_NNP paid_VBD 1,633_CD 1,717_CD Capital_NN expenditure_NN and_CC financial_JJ investment_NN 1,120_CD 1,779_CD Acquisitions_NNS and_CC disposals_NNS 20_CD 657_CD Equity_NNP dividends_NNS paid_VBD 2,327_CD 2,325_CD Management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN 1,515_CD 450_CD Increase_VBP decrease_NN in_IN cash_NN in_IN the_DT year_NN 405_CD 612_CD ANNUAL_JJ REVIEW_NNP 2002_CD 22_CD |_NN 23_CD SUMMARY_NNP FINANCIAL_NNP STATEMENTS_NNP IN_IN US_NNP DOLLARS_NNPS for_IN the_DT year_NN to_TO 31st_CD December_NNP 2002_CD Merger_NNP ,_, restructuring_NN and_CC Business_NN performance_NN disposal_NN of_IN subsidiaries_NNS Statutory_NNP 2001 2001 2001 2002_CD restated_VBN 2002_CD restated_VBN 2002_CD restated_VBN Summary_NNP consolidated_JJ profit_NN and_CC loss_NN account_VBP $_$ m_CD $_$ m_CD CER_CD %_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Sales_NNS Pharmaceuticals_NNP 26,993_CD 24,775_CD 8_CD 26,993_CD 24,775_CD Consumer_NN Healthcare_NNP 4,826_CD 4,729_CD 2_CD 4,826_CD 4,729_CD Total_JJ sales_NNS 31,819_CD 29,504_CD 7_CD 31,819_CD 29,504_CD Cost_NN of_IN sales_NNS 6,364_CD 6,379_CD 2_CD 549_CD 437_CD 6,913_CD 6,816_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenditure_NN 11,315_CD 10,730_CD 5_CD 747_CD 1,378_CD 12,062_CD 12,108_CD Research_NNP and_CC development_NN expenditure_NN 4,098_CD 3,679_CD 9_CD 252_CD 138_CD 4,350_CD 3,817_CD Trading_NN profit_NN 10,042_CD 8,716_CD 15_CD 1,548_CD 1,953_CD 8,494_CD 6,763_CD Other_JJ income_NN and_CC expenses_NNS 167_CD 54 31 426 136_CD 372_CD Income_NN from_IN associates_NNS 113 240 113 240_CD Net_JJ interest_NN payable_JJ 212 127 212 127_CD Profit_NN before_IN taxation_NN 9,776_CD 8,883_CD 11_CD 1,517_CD 2,379_CD 8,259_CD 6,504_CD Taxation_NNP 2,640_CD 2,383_CD 449_CD 464_CD 2,191_CD 1,919_CD Profit_NN after_IN taxation_NN 7,136_CD 6,500_CD 10_CD 1,068_CD 1,915_CD 6,068_CD 4,585_CD Minority_NNP interests_NNS 165 140 165 140_CD Preference_NN share_NN dividends_NNS 30_CD 49_CD 30_CD 49_CD Earnings_NNS 6,941_CD 6,311_CD 11_CD 1,068_CD 1,915_CD 5,873_CD 4,396_CD Earnings_NNS per_IN ADS_NNPS $_$ 2.35_CD $_$ 2.08_CD 13_CD $_$ 1.99_CD $_$ 1.45_CD Dividends_NNPS 3,519_CD 3,393_CD To_TO illustrate_VB Business_NNP performance_NN ,_, which_WDT is_VBZ the_DT primary_JJ measure_NN used_VBN by_IN management_NN ,_, merger_NN items_NNS ,_, integration_NN and_CC restructuring_NN costs_NNS and_CC disposal_NN of_IN businesses_NNS have_VBP been_VBN excluded_VBN and_CC an_DT adjusted_JJ EPS_NNP presented_VBD ._.
2001_CD 2002_CD restated_VBN Summary_NNP consolidated_JJ balance_NN sheet_NN $_$ m_CD $_$ m_CD Fixed_VBN assets_NNS 18,641_CD 17,284_CD Current_JJ assets_NNS 17,306_CD 15,114_CD Creditors_NNPS :_: amounts_NNS due_JJ within_IN one_CD year_NN 14,181_CD 13,674_CD Net_JJ current_JJ assets_NNS 3,125_CD 1,440_CD Total_JJ assets_NNS less_RBR current_JJ liabilities_NNS 21,766_CD 18,724_CD Creditors_NNPS :_: amounts_NNS due_RB after_IN one_CD year_NN 5,310_CD 3,332_CD Provision_NNP for_IN liabilities_NNS and_CC charges_NNS 4,561_CD 3,426_CD Net_JJ assets_NNS 11,895_CD 11,966_CD Equity_NNP shareholders_NNS funds_NNS 10,596_CD 10,716_CD Minority_NNP interests_NNS 1,299_CD 1,250_CD Capital_NN employed_VBN 11,895_CD 11,966_CD 2002_CD 2001_CD Summary_NNP consolidated_JJ cash_NN flow_NN statement_NN $_$ m_CD $_$ m_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 10,882_CD 9,370_CD Dividends_NNS from_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 3_CD Returns_NNS on_IN investments_NNS and_CC servicing_NN of_IN finance_NN 355_CD 275_CD Taxation_NNP paid_VBD 2,449_CD 2,472_CD Capital_NN expenditure_NN and_CC financial_JJ investment_NN 1,680_CD 2,562_CD Acquisitions_NNS and_CC disposals_NNS 30_CD 946_CD Equity_NNP dividends_NNS paid_VBD 3,491_CD 3,348_CD Management_NN of_IN liquid_JJ resources_NNS and_CC financing_NN 2,272_CD 648_CD Increase_VBP decrease_NN in_IN cash_NN in_IN the_DT year_NN 608_CD 881_CD The_DT Summary_NNP financial_JJ statements_NNS above_IN have_VBP been_VBN provided_VBN in_IN US$_$ for_IN the_DT convenience_NN of_IN US_NNP shareholders_NNS ._.
The_DT profit_NN and_CC loss_NN account_NN and_CC cash_NN flow_NN statement_NN have_VBP been_VBN translated_VBN at_IN the_DT average_JJ exchange_NN rate_NN 1_CD US$_$ 1.50_CD 2001_CD :_: 1_CD US$_$ 1.44_CD ,_, and_CC the_DT balance_NN sheet_NN at_IN the_DT year_NN end_NN exchange_NN rate_NN 1_CD US$_$ 1.61_CD 2001_CD :_: 1_CD US$_$ 1.45_CD ._.
SUMMARY_NN INFORMATION_NN UNDER_IN US_NNP GAAP_NNP for_IN the_DT year_NN to_TO 31st_CD December_NNP 2002_CD The_DT following_NN is_VBZ a_DT summary_NN of_IN the_DT material_NN adjustments_NNS to_TO profit_VB and_CC shareholders_NNS funds_NNS which_WDT would_MD be_VB required_VBN if_IN US_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNPS GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP ._.
These_DT adjustments_NNS have_VBP been_VBN reflected_VBN in_IN the_DT income_NN statements_NNS and_CC balance_NN sheet_NN presented_VBN in_IN accordance_NN with_IN US_NNP GAAP_NNP ._.
2001_CD 2002_CD restated_VBN Profit_NN m_NN m_NN Profit_NN attributable_JJ to_TO shareholders_NNS under_IN UK_NNP GAAP_NNP 3,915_CD 3,053_CD US_NNP GAAP_NNP adjustments_NNS :_: Fixed_JJ assets_NNS 45_CD 15_CD Intangible_JJ assets_NNS and_CC goodwill_NN 4,252_CD 3,667_CD Inventory_NNP 298_CD Disposal_NNP of_IN investments_NNS ,_, subsidiaries_NNS and_CC products_NNS 7_CD 87_CD Employee_NN costs_NNS 469_CD 174_CD Provision_NNP against_IN ESOT_NNP shares_NNS 51_CD 108_CD Derivative_JJ instruments_NNS 8_CD 15_CD Restructuring_NN 37_CD 182_CD Taxation_NNP 1,169_CD 827_CD Impairment_NN of_IN equity_NN investments_NNS 8_CD 75_CD Net_JJ income_NN loss_NN under_IN US_NNP GAAP_NNP before_IN cumulative_JJ changes_NNS in_IN accounting_NN principles_NNS 503_CD 143_CD Cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 90_CD Net_JJ income_NN loss_NN under_IN US_NNP GAAP_NNP after_IN cumulative_JJ effect_NN of_IN changes_NNS in_IN accounting_NN principles_NNS 413_CD 143_CD Basic_JJ and_CC diluted_JJ loss_NN per_IN share_NN under_IN US_NNP GAAP_NNP :_: Net_JJ income_NN loss_NN before_IN cumulative_JJ changes_NNS in_IN accounting_NN principles_NNS 8.5_CD p_NN 2.4_CD p_NN Changes_NNS in_IN accounting_NN principles_NNS 1.5_CD p_NN Net_JJ income_NN loss_NN after_IN changes_NNS in_IN accounting_NN principles_NNS 7.0_CD p_NN 2.4_CD p_NN 2001_CD 2002_CD restated_VBN Equity_NNP shareholders_NNS funds_NNS m_VBP m_NN Equity_NN shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP 6,581_CD 7,390_CD US_NNP GAAP_NNP adjustments_NNS :_: Fixed_JJ assets_NNS 215_CD 170_CD Investments_NNP 829_CD 879_CD Intangible_JJ assets_NNS and_CC goodwill_NN 36,141_CD 40,478_CD Unrealised_JJ gains_NNS on_IN marketable_JJ securities_NNS 113_CD 163_CD Employee_NN costs_NNS 1,198_CD 299_CD Employee_NNP Share_NNP Ownership_NNP Trust_NNP 2,826_CD 2,936_CD Restructuring_NN costs_NNS 6_CD 46_CD Derivative_JJ instruments_NNS 98_CD 29_CD Dividends_NNPS 754_CD 718_CD Deferred_JJ taxation_NN 5,779_CD 7,037_CD Shareholders_NNS equity_NN under_IN US_NNP GAAP_NNP 34,922_CD 40,107_CD Certain_NNP items_NNS for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2001_CD have_VBP been_VBN reclassified_VBN for_IN comparative_JJ purposes_NNS ._.
A_DT summary_NN of_IN the_DT material_NN differences_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP that_IN apply_VB to_TO the_DT Group_NNP is_VBZ set_VBN out_RP in_IN the_DT Annual_JJ Report_NNP 2002_CD ._.
Changes_NNS arising_VBG in_IN 2002_CD are_VBP as_IN follows_VBZ :_: During_IN 2002_CD FRS_NNP 19_CD Deferred_JJ tax_NN has_VBZ been_VBN implemented_VBN by_IN the_DT Group_NNP under_IN UK_NNP GAAP_NNP ._.
This_DT FRS_NNP requires_VBZ deferred_JJ tax_NN to_TO be_VB accounted_VBN for_IN on_IN a_DT full_JJ provision_NN basis_NN ,_, rather_RB than_IN a_DT partial_JJ provision_NN basis_NN as_IN in_IN 2001_CD and_CC earlier_JJR years_NNS ._.
This_DT change_NN has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT prior_JJ period_NN adjustment_NN for_IN UK_NNP GAAP_NNP purposes_NNS and_CC comparative_JJ adjustments_NNS to_TO arrive_VB at_IN US_NNP GAAP_NNP have_VBP been_VBN restated_VBN as_RB necessary_JJ ._.
This_DT change_NN has_VBZ had_VBN no_DT impact_NN on_IN US_NNP GAAP_NNP results_NNS ._.
The_DT Group_NNP adopted_VBD SFAS_NNP 142_CD ,_, Goodwill_NNP and_CC other_JJ Intangible_NNP Assets_NNPS as_IN of_IN 1st_CD January_NNP 2002_CD ._.
The_DT implementation_NN of_IN SFAS_NNP 142_CD resulted_VBD in_IN no_DT impairment_NN of_IN the_DT Groups_NNS goodwill_NN and_CC a_DT revised_VBN initial_JJ impairment_NN of_IN 173_CD million_CD 127_CD million_CD net_NN of_IN tax_NN on_IN indefinite_JJ lived_VBD assets_NNS ._.
This_DT is_VBZ shown_VBN as_IN a_DT cumulative_JJ effect_NN of_IN an_DT accounting_NN change_NN ._.
In_IN addition_NN ,_, during_IN 2002_CD the_DT Group_NNP decided_VBD to_TO align_VB the_DT measurement_NN date_NN for_IN all_DT of_IN its_PRP$ pension_NN plans_NNS ._.
The_DT impact_NN ,_, reflected_VBD as_IN a_DT cumulative_JJ effect_NN of_IN an_DT accounting_NN change_NN ,_, was_VBD a_DT 37_CD million_CD credit_NN ,_, net_NN of_IN tax_NN ,_, to_TO income_NN ._.
ANNUAL_JJ REVIEW_NNP 2002_CD 24_CD |_NN 25_CD SUMMARY_NNP REMUNERATION_NNP REPORT_NNP for_IN the_DT year_NN to_TO 31st_CD December_NNP 2002_CD The_DT Summary_NNP remuneration_NN report_NN sets_VBZ out_RP the_DT annual_JJ remuneration_NN earned_VBN in_IN 2002_CD together_RB with_IN any_DT gains_NNS under_IN long-term_JJ incentive_NN arrangements_NNS ._.
It_PRP also_RB describes_VBZ the_DT background_NN to_TO and_CC outlines_VBZ the_DT Groups_NNS remuneration_VBP policy_NN together_RB with_IN the_DT performance_NN graph_NN as_IN required_VBN by_IN schedule_NN 7A_NN of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, The_DT Directors_NNS Remuneration_NNP report_NN Regulations_NNPS 2002_CD ,_, schedule_NN 7A_NN ._.
Annual_JJ remuneration_NN 2002_CD 2001_CD Total_JJ Total_JJ Fees_NNS and_CC Other_JJ Annual_JJ annual_JJ annual_JJ salary_NN benefits_NNS bonus_NN remuneration_NN remuneration_NN Directors_NNS of_IN GlaxoSmithKline_NNP 000 000 000 000_CD 000_CD Dr_NNP J_NNP P_NNP Garnier_NNP 967_CD 132_CD 1,353_CD 2,452_CD 3,450_CD Mr_NNP J_NNP D_NNP Coombe_NNP 475 15 457 947_CD 1,326_CD Executive_NNP Directors_NNS 1,442_CD 147_CD 1,810_CD 3,399_CD 4,776_CD Sir_NNP Richard_NNP Sykes_NNP 154_CD 8_CD 162_CD 414_CD Sir_NNP Christopher_NNP Hogg_NNP 252_CD 252_CD 63_CD Sir_NNP Roger_NNP Hurn_NNP 121 121 135_CD Sir_NNP Peter_NNP Walters_NNP 51_CD 2_CD 53_CD 136_CD Mr_NNP P_NNP A_NNP Allaire_NNP 68_CD 68_CD 68_CD Dr_NN M_NNP Barzach_NNP 100 100 102_CD Mr_NNP D_NNP C_NNP Bonham_NNP 5_CD 5_CD 29_CD Sir_NNP Peter_NNP Job_NNP 59_CD 59_CD 63_CD Mr_NNP J_NNP H_NNP McArthur_NNP 62_CD 62_CD 73_CD Mr_NNP D_NNP F_NN McHenry_NNP 62_CD 62_CD 68_CD Sir_NNP Ian_NNP Prosser_NNP 59_CD 59_CD 63_CD Dr_NN R_NN Schmitz_NNP 69_CD 69_CD 70_CD Dr_NN L_NNP Shapiro_NNP 62_CD 62_CD 68_CD Mr_NNP J_NNP A_NNP Young_NNP 29_CD 2_CD 31_CD 80_CD Non-Executive_JJ Directors_NNS 1,148_CD 17_CD 1,165_CD 1,432_CD Total_JJ remuneration_NN 2,590_CD 164_CD 1,810_CD 4,564_CD 6,208_CD Sir_NNP Richard_NNP Sykes_NNP ,_, Sir_NNP Peter_NNP Walters_NNP and_CC Mr_NNP Young_NNP retired_VBD from_IN the_DT Board_NNP at_IN the_DT Annual_JJ General_NNP Meeting_VBG on_IN 20th_JJ May_NNP 2002_CD ._.
Following_VBG their_PRP$ retirement_NN they_PRP received_VBD the_DT value_NN of_IN their_PRP$ shares_NNS and_CC ADSs_NNS as_IN awarded_VBN under_IN the_DT Non-Executive_NNP Directors_NNS share_VBP arrangements_NNS and_CC equivalent_JJ SmithKline_NNP Beecham_NNP arrangements_NNS ._.
As_IN at_IN 20th_JJ May_NNP 2002_CD they_PRP had_VBD been_VBN awarded_VBN shares_NNS and_CC ADSs_NNS with_IN a_DT total_JJ value_NN at_IN the_DT date_NN of_IN award_NN ,_, as_IN indicated_VBN :_: Sir_NNP Richard_NNP Sykes_NNP 135,530_CD :_: Sir_NNP Peter_NNP Walters_NNP 249,876_CD :_: Mr_NNP Young_NNP 187,034_CD ._.
On_IN 20th_JJ May_NNP 2002_CD the_DT value_NN of_IN the_DT shares_NNS and_CC ADSs_NNS paid_VBN to_TO them_PRP was_VBD :_: Sir_NNP Richard_NNP Sykes_NNP 122,860_CD :_: Sir_NNP Peter_NNP Walters_NNP 241,468_CD :_: Mr_NNP Young_NNP 174,354_CD ._.
The_DT change_NN in_IN value_NN is_VBZ attributable_JJ to_TO dividends_NNS re-invested_JJ and_CC the_DT change_NN in_IN share_NN price_NN between_IN the_DT dates_NNS of_IN award_NN and_CC 20th_JJ May_NNP 2002_CD ._.
Mr_NNP Young_NNP has_VBZ elected_VBN to_TO receive_VB the_DT value_NN of_IN shares_NNS and_CC ADSs_NNS in_IN three_CD equal_JJ annual_JJ instalments_NNS and_CC ,_, accordingly_RB ,_, received_VBD 58,118_CD in_IN 2002_CD ._.
Following_VBG Sir_NNP Richard_NNP Sykes_NNP retirement_NN from_IN the_DT Board_NNP ,_, and_CC in_IN recognition_NN of_IN his_PRP$ services_NNS to_TO the_DT Company_NN ,_, the_DT Board_NNP decided_VBD to_TO make_VB an_DT augmentation_NN payment_NN to_TO the_DT pension_NN plan_NN of_IN 300,000_CD in_IN respect_NN of_IN Sir_NNP Richard_NNP ._.
It_PRP was_VBD also_RB agreed_VBN that_IN for_IN a_DT period_NN of_IN two_CD years_NNS from_IN 1st_CD June_NNP 2002_CD Sir_NNP Richard_NNP be_VB appointed_VBN Senior_JJ Advisor_NNP to_TO the_DT company_NN ,_, at_IN a_DT salary_NN of_IN 49,000_CD per_IN annum_NN and_CC he_PRP received_VBD 28,583_CD in_IN respect_NN of_IN the_DT period_NN from_IN 1st_CD June_NNP 2002_CD to_TO 31st_CD December_NNP 2002_CD in_IN addition_NN to_TO the_DT fees_NNS and_CC salary_NN above_IN ._.
Mr_NNP Bonham_NNP resigned_VBD as_IN a_DT Non-Executive_JJ Director_NNP on_IN 21st_CD May_NNP 2001_CD ._.
During_IN 2002_CD Mr_NNP Bonham_NNP received_VBD 5,000_CD in_IN respect_NN of_IN 2001_CD and_CC the_DT value_NN of_IN his_PRP$ shares_NNS ,_, as_RB at_IN 21st_CD May_NNP 2001_CD ,_, as_IN allocated_VBN under_IN the_DT Non-Executive_NNP Directors_NNS share_VBP arrangements_NNS ._.
As_IN at_IN 21st_CD May_NNP 2001_CD he_PRP had_VBD been_VBN awarded_VBN shares_NNS valued_VBN at_IN 4,539_CD at_IN the_DT date_NN of_IN award_NN ._.
On_IN 21st_CD May_NNP 2001_CD these_DT shares_NNS were_VBD worth_JJ 4,860_CD ._.
The_DT change_NN in_IN value_NN is_VBZ attributable_JJ to_TO dividends_NNS re-invested_JJ and_CC the_DT change_NN in_IN share_NN price_NN between_IN the_DT date_NN of_IN award_NN and_CC 21st_JJ May_NNP 2001_CD ._.
As_IN set_VBN out_RP on_IN page_NN 27_CD ,_, Non-Executive_JJ Directors_NNS are_VBP required_VBN to_TO receive_VB a_DT significant_JJ part_NN of_IN their_PRP$ fees_NNS in_IN the_DT form_NN of_IN shares_NNS and_CC ADSs_NNS and_CC may_MD also_RB elect_VB to_TO invest_VB part_NN or_CC all_DT of_IN the_DT balance_NN of_IN their_PRP$ fees_NNS in_IN the_DT form_NN of_IN shares_NNS and_CC ADSs_NNS ._.
The_DT value_NN of_IN these_DT shares_NNS and_CC ADSs_NNS at_IN the_DT dates_NNS of_IN award_NN are_VBP included_VBN in_IN fees_NNS and_CC salary_NN above_IN ._.
These_DT shares_NNS and_CC ADSs_NNS are_VBP not_RB paid_VBN out_RP until_IN the_DT Directors_NNS retirement_NN from_IN the_DT Board_NNP ._.
In_IN addition_NN to_TO annual_JJ compensation_NN ,_, GlaxoSmithKline_NNP operates_VBZ share-based_JJ schemes_NNS to_TO provide_VB incentives_NNS to_TO Executive_NNP Directors_NNS to_TO achieve_VB longer-term_JJ growth_NN in_IN shareholder_NN value_NN ._.
Gains_NNS under_IN such_JJ schemes_NNS are_VBP recognized_VBN on_IN exercise_NN or_CC award_NN ,_, but_CC reflect_VBP value_NN earned_VBN over_IN a_DT period_NN of_IN years_NNS ._.
The_DT timing_NN of_IN exercise_NN is_VBZ normally_RB at_IN the_DT discretion_NN of_IN the_DT Director_NNP ._.
Realised_VBN gains_NNS in_IN 2002_CD on_IN exercise_NN of_IN options_NNS were_VBD :_: share_NN option_NN schemes_NNS nil_VBP 2001_CD 2,408,992_CD :_: long-term_JJ incentive_NN plan_NN 293,370_CD 2001_CD 3,307,203_CD ._.
In_IN previous_JJ years_NNS ,_, Dr_NNP Garniers_NNP fees_NNS and_CC salary_NN included_VBD GlaxoSmithKlines_NNP match_NN on_IN compensation_NN that_WDT is_VBZ deferred_VBN ._.
For_IN 2002_CD this_DT has_VBZ been_VBN included_VBN within_IN contributions_NNS to_TO money_NN purchase_NN schemes_NNS ._.
Dr_NNP Garniers_NNPS fees_NNS and_CC salary_NN for_IN 2001_CD have_VBP been_VBN restated_VBN by_IN 58,419_CD ,_, reflecting_VBG GlaxoSmithKlines_NNP match_NN in_IN 2001_CD ,_, in_IN order_NN to_TO provide_VB consistent_JJ presentation_NN ._.
The_DT accrued_VBN annual_JJ benefits_NNS under_IN the_DT defined_VBN benefit_NN schemes_NNS operated_VBN by_IN the_DT Group_NNP were_VBD :_: Dr_VB J_NNP P_NNP Garnier_NNP 929,193_CD :_: Mr_NNP J_NNP D_NNP Coombe_NNP 290,834_CD :_: Sir_NNP Richard_NNP Sykes_NNP 729,046_CD ._.
In_IN addition_NN ,_, Dr_NNP J_NNP P_NNP Garnier_NNP is_VBZ also_RB a_DT member_NN of_IN a_DT money_NN purchase_NN scheme_NN into_IN which_WDT contributions_NNS of_IN 92,800_CD were_VBD paid_VBN ._.
None_NN of_IN the_DT above_JJ Directors_NNS received_VBD expenses_NNS during_IN the_DT year_NN requiring_VBG separate_JJ disclosure_NN as_IN defined_VBN by_IN schedule_NN 7A_NN ._.
SUMMARY_NN REMUNERATION_NNP REPORT_NNP continued_VBD for_IN the_DT year_NN to_TO 31st_CD December_NNP 2002_CD The_DT Remuneration_NNP Committee_NNP The_NNP majority_NN of_IN these_DT are_VBP US-based_JJ companies_NNS which_WDT operate_VBP In_IN reviewing_VBG governance_NN arrangements_NNS ,_, the_DT Board_NNP decided_VBD during_IN globally_RB ._.
These_DT companies_NNS are_VBP competing_VBG for_IN the_DT same_JJ talent_NN and_CC the_DT year_NN to_TO separate_VB the_DT roles_NNS of_IN the_DT former_JJ Remuneration_NNP and_CC any_DT perceived_VBN shortfall_NN in_IN GlaxoSmithKlines_NNP competitive_JJ position_NN Nominations_NNS R&N_NNP Committee_NNP in_IN order_NN to_TO give_VB a_DT separate_JJ individual_NN could_MD lead_VB to_TO a_DT loss_NN of_IN key_JJ talent_NN to_TO competitor_NN companies_NNS ._.
Board_NNP focus_NN to_TO both_DT functions_NNS ._.
Accordingly_RB ,_, a_DT Remuneration_NNP Committee_NNP ,_, with_IN terms_NNS of_IN reference_NN revised_VBN to_TO take_VB into_IN account_NN GlaxoSmithKlines_NNS remuneration_VBP policy_NN was_VBD set_VBN out_RP at_IN the_DT time_NN latest_JJS governance_NN standards_NNS ,_, assumed_VBD the_DT remuneration_NN of_IN the_DT merger_NN ,_, endorsed_VBN by_IN shareholders_NNS then_RB ,_, and_CC has_VBZ made_VBN responsibilities_NNS of_IN the_DT previous_JJ R&N_NNP Committee_NNP in_IN October_NNP 2002_CD ._.
a_DT major_JJ contribution_NN to_TO the_DT success_NN of_IN the_DT merger_NN ._.
The_DT members_NNS of_IN the_DT Remuneration_NNP Committee_NNP are_VBP set_VBN out_RP on_IN page_NN 16_CD ._.
Remuneration_NNP policy_NN GlaxoSmithKlines_NNP remuneration_NN policy_NN is_VBZ to_TO pay_VB at_IN industry_NN Remit_NNP of_IN the_DT Remuneration_NNP Committee_NNP competitive_JJ levels_NNS with_IN a_DT heavy_JJ emphasis_NN on_IN pay_NN for_IN performance_NN The_DT Remuneration_NNP Committee_NNP considers_VBZ and_CC regularly_RB reviews_NNS and_CC at_IN risk_NN remuneration_NN ._.
The_DT policy_NN is_VBZ designed_VBN to_TO :_: the_DT Groups_NNS policy_NN on_IN Executive_NNP remuneration_NN for_IN approval_NN by_IN the_DT Board_NNP and_CC determines_VBZ the_DT individual_JJ remuneration_NN packages_NNS focus_VB on_IN long-term_JJ sustained_VBN success_NN of_IN the_DT members_NNS of_IN the_DT CET_NNP ._.
focus_NN on_IN shareholder_NN value_NN through_IN a_DT strong_JJ emphasis_NN on_IN share_NN plans_NNS Towers_NNP Perrin_NNP ,_, a_DT leading_JJ firm_NN of_IN remuneration_NN and_CC benefits_NNS set_VBP high_JJ levels_NNS of_IN minimum_JJ achievement_NN consultants_NNS ,_, advises_VBZ the_DT Remuneration_NNP Committee_NNP with_IN regard_NN ensure_VB integrated_VBN performance_NN assessment_NN throughout_IN the_DT to_TO the_DT remuneration_NN of_IN senior_JJ executive_JJ management_NN and_CC the_DT management_NN team_NN to_TO deliver_VB concerted_JJ action_NN towards_IN success_NN Non-Executive_NNP Directors_NNS ._.
In_IN 2003_CD ,_, the_DT Remuneration_NNP Committee_NNP provide_VBP opportunities_NNS to_TO earn_VB globally_RB competitive_JJ rewards_NNS ,_, engaged_VBD Deloitte_NNP &_CC Touche_NNP to_TO conduct_VB an_DT additional_JJ independent_JJ but_CC only_RB if_IN performance_NN is_VBZ delivered_VBN ._.
review_NN of_IN GlaxoSmithKlines_NNP current_JJ remuneration_NN policy_NN ._.
GlaxoSmithKlines_NNS executive_JJ remuneration_NN consists_VBZ of_IN four_CD Background_NN components_NNS :_: salary_NN ,_, performance_NN bonus_NN ,_, long-term_JJ incentives_NNS GlaxoSmithKline_NNP is_VBZ one_CD of_IN the_DT worlds_NNS leading_VBG research-based_JJ and_CC benefits_NNS ._.
The_DT relative_JJ importance_NN for_IN the_DT Executive_NNP Directors_NNS pharmaceutical_JJ and_CC healthcare_NN companies_NNS ._.
As_IN such_JJ ,_, it_PRP has_VBZ to_TO of_IN the_DT fixed_VBN and_CC variable_JJ elements_NNS of_IN pay_NN is_VBZ illustrated_VBN in_IN the_DT be_VB global_JJ in_IN outlook_NN and_CC operations_NNS ._.
The_DT Group_NNP employs_VBZ over_IN table_NN below_IN :_: 100,000_CD people_NNS in_IN over_IN 100_CD countries_NNS ._.
Over_IN 90_CD per_IN cent_NN of_IN Fixed_NNP Performance-related_JJ its_PRP$ sales_NNS are_VBP generated_VBN outside_IN the_DT UK_NNP ._.
Short-term_JJ incentives_NNS Long-term_JJ incentives_NNS Base_NNP pay_NN Performance_NNP bonus_NN Share_NN option_NN Performance_NNP The_NNP USA_NNP is_VBZ the_DT largest_JJS pharmaceutical_JJ market_NN in_IN the_DT world_NN plan_NN share_NN plan_NN and_CC is_VBZ fundamental_JJ to_TO GlaxoSmithKlines_NNP success_NN and_CC profitability_NN ._.
Measures_NNS More_JJR than_IN 50_CD per_IN cent_NN of_IN GlaxoSmithKlines_NNP pharmaceutical_JJ Operating_NN financial_JJ EPS_NNP growth_NN of_IN 9_CD TSR_NNP vs_NNS FTSE_NNP 100_CD sales_NNS are_VBP in_IN the_DT USA_NNP ._.
The_DT CEO_NNP is_VBZ based_VBN there_RB ,_, along_IN with_IN another_DT measures_NNS percentage_NN points_NNS EPS_NNP growth_NN of_IN 9_CD eight_CD of_IN the_DT thirteen_VBN person_NN CET_NNP ._.
greater_JJR than_IN Retail_NNP percentage_NN points_NNS Performance_NNP against_IN Price_NNP Index_NNP RPI_NNP greater_JJR than_IN RPI_NNP individual_JJ objectives_NNS over_IN 3_CD years_NNS over_IN 3_CD years_NNS The_DT pharmaceutical_JJ industry_NN is_VBZ international_JJ ,_, highly_RB specialised_VBN and_CC is_VBZ characterised_VBN by_IN a_DT handful_NN of_IN global_JJ companies_NNS which_WDT 15-25_CD %_NN 75-85_CD %_NN compete_VBP as_IN intensely_RB for_IN talent_NN as_IN they_PRP do_VBP for_IN business_NN ._.
The_DT industrys_NNS top_JJ managers_NNS and_CC scientists_NNS are_VBP very_RB much_RB in_IN To_TO provide_VB appropriate_JJ incentives_NNS for_IN exceptional_JJ performance_NN ,_, the_DT demand_NN ,_, widely_RB known_VBN in_IN the_DT industry_NN and_CC are_VBP internationally_RB Committees_NNS policy_NN is_VBZ to_TO provide_VB market_NN referenced_VBD opportunities_NNS and_CC corporately_JJ mobile_JJ ._.
The_DT way_NN all_DT managers_NNS and_CC scientists_NNS beyond_IN this_DT for_IN truly_RB outstanding_JJ performance_NN ._.
However_RB ,_, the_DT in_IN GlaxoSmithKline_NNP are_VBP rewarded_VBN and_CC developed_VBN therefore_RB has_VBZ Committee_NNP is_VBZ aware_JJ that_IN current_JJ levels_NNS of_IN long-term_JJ incentives_NNS to_TO be_VB industry-competitive_JJ ._.
It_PRP is_VBZ crucial_JJ to_TO their_PRP$ retention_NN and_CC do_VB not_RB deliver_VB this_DT policy_NN ._.
Independent_JJ market_NN data_NNS demonstrate_VBP effectiveness_NN ._.
Key_NNP market_NN data_NNS with_IN regard_NN to_TO remuneration_VB that_DT GlaxoSmithKlines_NNPS top_JJ management_NN remuneration_NN is_VBZ currently_RB for_IN senior_JJ management_NN ,_, science_NN based_VBN positions_NNS and_CC sales_NNS uncompetitive_JJ with_IN regard_NN to_TO long-term_JJ incentives_NNS ._.
As_IN a_DT result_NN is_VBZ provided_VBN by_IN a_DT survey_NN which_WDT covers_VBZ the_DT following_JJ group_NN of_IN their_PRP$ total_JJ remuneration_NN opportunity_NN for_IN 2002_CD was_VBD well_RB below_IN global_JJ pharmaceutical_JJ companies_NNS the_DT competitor_NN panel_NN :_: the_DT industry_NN median_NN ._.
Abbott_NNP Laboratories_NNP US_NNP Novartis_NNP Switzerland_NNP The_NNP Remuneration_NNP Committee_NNP will_MD continue_VB to_TO monitor_VB closely_RB AstraZeneca_NNP UK_NNP Pfizer_NNP US_NNP the_DT quantum_NN and_CC trend_NN of_IN our_PRP$ competitors_NNS awards_NNS and_CC will_MD consider_VB Aventis_NNP France_NNP Pharmacia_NNP US_NNP what_WDT should_MD be_VB done_VBN in_IN the_DT best_JJS interests_NNS of_IN the_DT company_NN and_CC Bristol-Myers_NNP Squibb_NNP US_NNP Roche_NNP Switzerland_NNP its_PRP$ shareholders_NNS ._.
Eli_NNP Lilly_NNP US_NNP Schering-Plough_NNP US_NNP Johnson_NNP &_CC Johnson_NNP US_NNP Wyeth_NNP US_NNP The_NNP vesting_NN of_IN options_NNS granted_VBN to_TO Executive_NNP Directors_NNS is_VBZ subject_JJ Merck_NNP US_NNP to_TO the_DT performance_NN condition_NN that_WDT business_NN performance_NN earnings_NNS per_IN share_NN EPS_NNP growth_NN ,_, excluding_VBG currency_NN and_CC exceptional_JJ items_NNS ,_, should_MD be_VB at_IN least_JJS nine_CD percentage_NN points_NNS more_RBR than_IN the_DT increase_NN in_IN the_DT UK_NNP Retail_NNP Price_NNP Index_NNP over_IN any_DT three_CD year_NN measurement_NN period_NN ._.
ANNUAL_JJ REVIEW_NNP 2002_CD 26_CD |_NN 27_CD SUMMARY_NNP REMUNERATION_NNP REPORT_NNP continued_VBD SHAREHOLDER_NNP INFORMATION_NNP for_IN the_DT year_NN to_TO 31st_CD December_NNP 2002_CD Vesting_NNP of_IN awards_NNS granted_VBN under_IN the_DT performance_NN share_NN plan_NN are_VBP Ordinary_JJ shares_NNS subject_JJ to_TO two_CD performance_NN conditions_NNS each_DT relating_VBG to_TO half_DT of_IN the_DT The_DT companys_NNS shares_NNS are_VBP listed_VBN on_IN the_DT London_NNP Stock_NNP Exchange_NNP ._.
awards_NNS ,_, business_NN performance_NN EPS_NNP growth_NN as_IN for_IN share_NN options_NNS and_CC Total_JJ Shareholder_NN Return_NN TSR_NNP whereby_WRB GlaxoSmithKlines_NNP TSR_NNP Registrar_NNP is_VBZ compared_VBN to_TO the_DT TSR_NNP of_IN companies_NNS in_IN the_DT UK_NNP FTSE_NNP 100_CD Index_NNP The_DT companys_NNS share_VBP register_NN is_VBZ administered_VBN by_IN Lloyds_NNP TSB_NNP Registrars_NNPS ,_, over_IN the_DT same_JJ period_NN ._.
Even_RB if_IN these_DT performance_NN conditions_NNS are_VBP met_VBN ,_, who_WP also_RB provide_VBP the_DT following_JJ services_NNS :_: vesting_NN of_IN these_DT awards_NNS made_VBD to_TO the_DT CET_NNP is_VBZ subject_JJ to_TO approval_NN by_IN the_DT Remuneration_NNP Committee_NNP ._.
These_DT conditions_NNS were_VBD selected_VBN at_IN GlaxoSmithKline_NNP Investment_NNP Plan_NNP enables_VBZ shareholders_NNS to_TO the_DT time_NN of_IN the_DT merger_NN and_CC aim_NN to_TO achieve_VB a_DT balance_NN between_IN the_DT reinvest_VBP quarterly_JJ dividends_NNS and_CC or_CC make_VB monthly_JJ investments_NNS in_IN expectations_NNS of_IN UK_NNP institutional_JJ investors_NNS and_CC global_JJ market_NN practice_NN ._.
the_DT company_NN 's_POS ordinary_JJ shares_NNS using_VBG a_DT special_JJ dealing_NN arrangement_NN ._.
Executive_NNP Directors_NNS are_VBP employed_VBN under_IN service_NN contracts_NNS in_IN which_WDT GlaxoSmithKline_NNP Individual_NNP Savings_NNP Account_NNP is_VBZ a_DT the_DT employing_VBG company_NN is_VBZ required_VBN to_TO give_VB 24_CD calendar_NN months_NNS tax-efficient_JJ way_NN to_TO invest_VB in_IN the_DT companys_NNS ordinary_JJ shares_NNS ._.
notice_NN of_IN termination_NN and_CC the_DT Executive_NNP Directors_NNS are_VBP required_VBN to_TO give_VB 12_CD calendar_NN months_NNS notice_VBP ._.
Dr_NNP JP_NNP Garniers_NNP service_NN agreement_NN GlaxoSmithKline_NNP Corporate_NNP Sponsored_NNP Nominee_NNP provides_VBZ expires_VBZ on_IN 31st_CD October_NNP 2007_CD and_CC Mr_NNP Coombes_NNPS expires_VBZ on_IN a_DT facility_NN for_IN shareholders_NNS to_TO hold_VB shares_NNS without_IN the_DT need_NN 31st_CD March_NNP 2005_CD ._.
The_DT compensation_NN to_TO be_VB paid_VBN in_IN the_DT event_NN for_IN share_NN certificates_NNS ._.
Shareholders_NNS details_NNS will_MD not_RB be_VB held_VBN of_IN termination_NN includes_VBZ salary_NN ,_, incentives_NNS and_CC pensions_NNS ._.
on_IN the_DT main_JJ share_NN register_NN ,_, and_CC so_RB will_MD remain_VB confidential_JJ ._.
Non-Executive_JJ Directors_NNS of_IN GlaxoSmithKline_NNP do_VBP not_RB have_VB service_NN Shareview_NNP service_NN provides_VBZ shareholders_NNS with_IN information_NN contracts_NNS but_CC instead_RB have_VBP letters_NNS of_IN appointment_NN ._.
To_TO enhance_VB on_IN their_PRP$ investment_NN in_IN the_DT company_NN ._.
Shareholders_NNS may_MD register_VB the_DT link_NN between_IN Directors_NNS and_CC shareholders_NNS ,_, GlaxoSmithKline_NNP for_IN this_DT service_NN at_IN www_NN ._.
co._FW uk_FW requires_VBZ Non-Executive_NNP Directors_NNS to_TO receive_VB a_DT significant_JJ part_NN of_IN their_PRP$ fees_NNS in_IN the_DT form_NN of_IN shares_NNS allocated_VBN to_TO a_DT share_NN account_NN and_CC Share_NN dealing_VBG facility_NN offers_VBZ the_DT opportunity_NN to_TO invest_VB part_NN or_CC all_DT of_IN the_DT balance_NN of_IN fees_NNS NatWest_NNP Stockbrokers_NNS Limited_JJ offers_VBZ a_DT share_NN dealing_VBG service_NN on_IN in_IN a_DT share_NN account_NN ._.
These_DT shares_NNS are_VBP not_RB paid_VBN out_RP until_IN the_DT Directors_NNS behalf_NN of_IN the_DT company_NN to_TO shareholders_NNS wishing_VBG to_TO buy_VB or_CC sell_VB retirement_NN from_IN the_DT Board_NNP ,_, or_CC at_IN a_DT later_JJ date_NN ,_, on_IN the_DT basis_NN of_IN the_DT companys_NNS shares_NNS ._.
dividends_NNS being_VBG reinvested_VBN in_IN the_DT interim_NN ._.
Share_NN price_NN information_NN Performance_NNP graph_NN Share_NN price_NN information_NN is_VBZ available_JJ on_IN the_DT companys_NNS website_VBP at_IN The_DT new_JJ regulations_NNS covering_VBG Directors_NNS remuneration_NN require_VBP that_IN www_NN ._.
Information_NNP made_VBD available_JJ on_IN the_DT website_NN does_VBZ not_RB a_DT graph_NN be_VB presented_VBN showing_VBG the_DT companys_NNS total_JJ shareholder_NN return_NN constitute_VBP part_NN of_IN this_DT Annual_JJ Review_NNP ._.
Information_NN is_VBZ also_RB available_JJ on_IN TSR_NNP against_IN the_DT TSR_NNP performance_NN of_IN a_DT broad_JJ equity_NN market_NN index_NN ._.
Ceefax_NNP ,_, Teletext_NNP ,_, and_CC from_IN FT_NNP Cityline_NNP by_IN calling_VBG 0906 003 5694_CD or_CC The_DT following_JJ graph_NN shows_VBZ GlaxoSmithKlines_NNP TSR_NNP performance_NN 0906 843 5694_CD calls_VBZ charged_VBN at_IN 60p_CD a_DT minute_NN plus_CC VAT_NNP at_IN all_DT times_NNS ._.
against_IN the_DT FTSE_NNP 100_CD which_WDT has_VBZ been_VBN chosen_VBN because_IN it_PRP is_VBZ the_DT principal_JJ index_NN in_IN which_WDT the_DT companys_NNS shares_NNS are_VBP quoted_VBN and_CC American_JJ Depositary_NNP Shares_NNP against_IN the_DT competition_NN panel_NN set_VBN out_RP on_IN page_NN 26_CD which_WDT indicates_VBZ The_DT companys_NNS shares_NNS are_VBP listed_VBN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP GlaxoSmithKlines_NNP relative_JJ performance_NN against_IN its_PRP$ peers_NNS ._.
in_IN the_DT form_NN of_IN American_JJ Depositary_NNP Shares_NNP ADSs_NNP and_CC these_DT are_VBP evidenced_VBN by_IN American_JJ Depositary_NNP Receipts_NNPS ADRs_NNPS ,_, each_DT one_CD of_IN which_WDT represents_VBZ two_CD ordinary_JJ shares_NNS ._.
100_CD ADR_NNP program_NN administrator_NN 90_CD The_DT ADR_NNP program_NN is_VBZ administered_VBN by_IN The_DT Bank_NNP of_IN New_NNP York_NNP as_IN 80_CD well_RB as_IN Global_JJ BuyDIRECT_NNP ,_, a_DT direct_JJ ADS_NNPS purchase_NN sale_NN and_CC dividend_NN reinvestment_NN plan_NN for_IN ADR_NNP holders_NNS ._.
70_CD 60_CD Annual_JJ General_NNP Meeting_VBG 2003_CD 31_CD 12_CD 00_CD 31_CD 12_CD 01_CD 31_CD 12_CD 02_CD The_DT Annual_JJ General_NNP Meeting_VBG will_MD be_VB held_VBN at_IN the_DT Queen_NNP Elizabeth_NNP II_NNP GSK_NNP Total_NNP Return_NN Index_NNP GSK_NNP Pharma_NNP Peers_NNP Return_NN Index_NNP FTSE_NNP 100_CD Total_JJ Return_NN Index_NNP Conference_NNP Centre_NNP ,_, Broad_NNP Sanctuary_NNP ,_, Westminster_NNP ,_, London_NNP SW1P_NNP 3EE_NNP Notes_NNP on_IN 19th_JJ May_NNP 2003_CD ._.
The_DT TSR_NNP graph_NN above_IN starts_NNS at_IN the_DT beginning_NN of_IN the_DT first_JJ accounting_NN year_NN following_VBG the_DT formation_NN of_IN GlaxoSmithKline_NNP and_CC uses_VBZ ,_, as_IN a_DT base_NN ,_, the_DT share_NN SmithKline_NNP Beecham_NNP plc_NN Floating_VBG Rate_NNP Unsecured_JJ price_NN on_IN 31st_CD December_NNP 2000_CD ._.
Calculations_NNS for_IN the_DT graph_NN are_VBP based_VBN on_IN spot_NN Loan_NNP Stock_NNP 1990_CD 2010_CD prices_NNS at_IN the_DT beginning_NN and_CC end_NN of_IN each_DT year_NN as_IN required_VBN by_IN the_DT Directors_NNS The_DT loan_NN stock_NN is_VBZ not_RB listed_VBN on_IN any_DT exchange_NN but_CC holders_NNS may_MD Remuneration_NNP Report_NNP Regulations_NNPS 2002_CD ,_, whereas_IN GlaxoSmithKlines_NNP performance_NN conditions_NNS use_VBP average_JJ prices_NNS over_IN a_DT period_NN of_IN a_DT year_NN ._.
require_VB SmithKline_NNP Beecham_NNP plc_NN to_TO redeem_VB their_PRP$ loan_NN stock_NN at_IN par_NN ,_, Therefore_RB the_DT above_JJ graph_NN should_MD not_RB be_VB taken_VBN as_IN an_DT indication_NN of_IN the_DT likely_JJ i._NN e._FW 1_CD for_IN every_DT 1_CD of_IN loan_NN stock_NN held_VBN ,_, on_IN the_DT first_JJ business_NN day_NN of_IN vesting_NN of_IN awards_NNS granted_VBN under_IN GlaxoSmithKlines_NNP Performance_NNP Share_NNP Plan_NNP ._.
March_NNP ,_, June_NNP ,_, September_NNP and_CC December_NNP ._.
Holders_NNS wishing_VBG to_TO redeem_VB The_DT average_JJ price_NN method_NN was_VBD selected_VBN because_IN it_PRP smoothes_VBZ out_RP volatility_NN and_CC reduces_VBZ the_DT impact_NN of_IN any_DT particularly_RB large_JJ temporary_JJ price_NN movements_NNS all_DT or_CC part_NN of_IN their_PRP$ loan_NN stock_NN should_MD complete_VB the_DT notice_NN on_IN the_DT back_NN at_IN either_CC the_DT beginning_NN or_CC end_NN of_IN the_DT performance_NN period_NN ._.
of_IN their_PRP$ loan_NN stock_NN certificate_NN and_CC return_VB it_PRP to_TO the_DT registrar_NN ,_, to_TO arrive_VB 2_CD ._.
Past_JJ performance_NN should_MD not_RB be_VB taken_VBN as_IN a_DT guide_NN to_TO future_JJ performance_NN ._.
at_IN least_JJS 30_CD days_NNS before_IN the_DT relevant_JJ redemption_NN date_NN ._.
SHAREHOLDER_NN INFORMATION_NN continued_VBD Financial_JJ reporting_NN Market_NN capitalization_NN The_DT market_NN capitalization_NN of_IN GlaxoSmithKline_NNP at_IN 31st_CD December_NNP 2002_CD Financial_NNP reporting_VBG calendar_NN 2003_CD was_VBD 72_CD billion_CD ._.
At_IN that_DT date_NN GlaxoSmithKline_NNP was_VBD the_DT third_JJ largest_JJS company_NN by_IN market_NN capitalization_NN in_IN the_DT FTSE_NNP index_NN ._.
Announcement_NN of_IN 1st_CD Quarter_NN Results_NNS 30th_JJ April_NNP 2003_CD Announcement_NN of_IN 2nd_CD Quarter_NN Results_NNS 23rd_JJ July_NNP 2003_CD Dividends_NNPS Announcement_NN of_IN 3rd_CD Quarter_NN Results_NNS 22nd_JJ October_NNP 2003_CD GlaxoSmithKline_NNP pays_VBZ dividends_NNS quarterly_RB ._.
At_IN present_JJ it_PRP is_VBZ expected_VBN Preliminary_JJ Announcement_NN of_IN Annual_JJ Results_NNS 12th_JJ February_NNP 2004_CD that_IN there_EX will_MD be_VB a_DT level_NN dividend_NN for_IN each_DT of_IN the_DT first_JJ three_CD quarters_NNS ,_, Publication_NN of_IN Annual_JJ Report_NNP Review_NNP March_NNP 2004_CD with_IN a_DT higher_JJR dividend_NN in_IN the_DT fourth_JJ quarter_NN ._.
Each_DT quarters_NNS dividend_NN is_VBZ announced_VBN at_IN the_DT time_NN of_IN the_DT quarterly_JJ Results_NNS Announcement_NN ._.
Results_NNS Announcements_NNS Results_NNS Announcements_NNS are_VBP issued_VBN to_TO the_DT London_NNP Stock_NNP Exchange_NNP LSE_NNP ,_, The_NNP Board_NNP has_VBZ declared_VBN dividends_NNS for_IN 2002_CD as_IN follows_VBZ :_: and_CC made_VBN available_JJ on_IN the_DT LSE_NNP news_NN service_NN ,_, and_CC at_IN the_DT same_JJ time_NN ,_, or_CC 2002_CD 2001_CD Dividends_NNPS per_IN share_NN pence_NN pence_NN shortly_RB afterwards_RB ,_, are_VBP issued_VBN to_TO the_DT media_NNS ,_, are_VBP made_VBN available_JJ on_IN the_DT companys_NNS website_VBP and_CC are_VBP filed_VBN in_IN the_DT USA_NNP with_IN the_DT Securities_NNPS and_CC First_NNP interim_JJ paid_VBN 4th_JJ July_NNP 2002_CD 9_CD 9_CD Exchange_NNP Commission_NNP and_CC the_DT New_NNP York_NNP Stock_NNP Exchange_NNP ._.
Second_JJ interim_JJ paid_VBN 3rd_CD October_NNP 2002_CD 9_CD 9_CD Third_NNP interim_JJ paid_VBN 3rd_CD January_NNP 2003_CD 9_CD 9_CD Fourth_JJ interim_JJ payable_JJ 17th_JJ April_NNP 2003_CD 13_CD 12_CD Financial_JJ reports_NNS The_DT company_NN publishes_VBZ an_DT Annual_JJ Report_NNP and_CC ,_, for_IN the_DT investor_NN Total_JJ 40_CD 39_CD not_RB needing_VBG the_DT full_JJ detail_NN of_IN the_DT Report_NNP ,_, an_DT Annual_JJ Review_NNP ._.
These_DT are_VBP available_JJ from_IN the_DT date_NN of_IN publication_NN on_IN the_DT GlaxoSmithKline_NNP website_NN ._.
The_DT Annual_JJ Review_NNP is_VBZ sent_VBN to_TO all_DT shareholders_NNS on_IN the_DT date_NN Dividends_NNPS ADSs_NNPS of_IN publication_NN ._.
Shareholders_NNS may_MD also_RB elect_VB to_TO receive_VB the_DT Report_NNP As_IN a_DT guide_NN to_TO holders_NNS of_IN ADRs_NNS ,_, the_DT tables_NNS below_IN set_VBN out_RP the_DT dividends_NNS by_IN writing_VBG to_TO the_DT Companys_NNPS registrars_NNS ._.
Alternatively_RB shareholders_NNS paid_VBD per_IN ADS_NNPS in_IN US_NNP dollars_NNS in_IN the_DT last_JJ five_CD years_NNS ._.
The_DT dividends_NNS are_VBP may_MD elect_VB to_TO receive_VB notification_NN by_IN email_NN of_IN the_DT publication_NN of_IN adjusted_VBN for_IN UK_NNP tax_NN credit_NN less_RBR withholding_VBG tax_NN ,_, where_WRB applicable_JJ ,_, financial_JJ reports_NNS by_IN registering_VBG on_IN www_NN ._.
Copies_NNS and_CC are_VBP translated_VBN into_IN US_NNP dollars_NNS at_IN applicable_JJ exchange_NN rates_NNS ._.
of_IN previous_JJ financial_JJ reports_NNS are_VBP available_JJ on_IN the_DT companys_NNS website_VBP ._.
Printed_NNP copies_NNS can_MD be_VB obtained_VBN from_IN the_DT companys_NNS registrar_NN in_IN the_DT Since_IN 6th_JJ April_NNP 1999_CD ,_, claims_VBZ for_IN refunds_NNS of_IN tax_NN credits_NNS on_IN dividends_NNS UK_NNP and_CC from_IN the_DT companys_NNS Customer_NN Response_NNP Center_NNP in_IN the_DT USA_NNP ._.
from_IN the_DT UK_NNP tax_NN authorities_NNS are_VBP of_IN negligible_JJ benefit_NN to_TO US_NNP shareholders_NNS ._.
Year_NN GSK_NNP $_$ GW_CD $_$ SB_CD $_$ Publications_NNPS 2002_CD 1.24_CD This_DT year_NN GlaxoSmithKline_NNP has_VBZ again_RB produced_VBN a_DT separate_JJ report_NN 2001_CD 1.11_CD covering_VBG the_DT Groups_NNS contribution_NN to_TO society_NN ._.
The_DT 2002_CD Corporate_JJ 2000_CD 1.10_CD 0.87_CD and_CC Social_NNP Responsibility_NNP Report_NNP covers_VBZ the_DT issues_NNS that_WDT are_VBP of_IN primary_JJ 1999_CD 1.14_CD 0.86_CD interest_NN to_TO stakeholders_NNS ,_, including_VBG the_DT contribution_NN to_TO society_NN ,_, business_NN 1998_CD 1.19_CD 0.81_CD ethics_NNS and_CC integrity_NN ,_, access_NN to_TO medicines_NNS ,_, R&D_NNP ,_, community_NN investment_NN ,_, the_DT environment_NN and_CC health_NN and_CC safety_NN ._.
The_DT report_NN is_VBZ available_JJ from_IN Dividends_NNPS paid_VBD to_TO Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP ADR_NNP the_DT Secretariat_NNP at_IN the_DT companys_NNS head_VBP office_NN and_CC the_DT website_NN at_IN holders_NNS are_VBP expressed_VBN as_IN dividends_NNS per_IN GlaxoSmithKline_NNP ADS_NNPS ._.
Dividend_NN calendar_NN Share_NN price_NN 2002_CD 2001_CD Fourth_JJ quarter_NN 2002_CD Share_NN price_NN Ex-dividend_NN date_NN 19th_JJ February_NNP 2003_CD At_IN 1st_CD January_NNP 17.23_CD 18.90_CD Record_NNP date_NN 21st_CD February_NNP 2003_CD High_NNP during_IN the_DT year_NN 17.80_CD 20.32_CD Payable_JJ 17th_JJ April_NNP 2003_CD Low_NNP during_IN the_DT year_NN 10.57_CD 16.26_CD At_IN 31st_CD December_NNP 11.92_CD 17.23_CD First_JJ quarter_NN 2003_CD Decrease_NN over_IN year_NN 31_CD %_NN 9_CD %_NN Ex-dividend_NN date_NN 7th_JJ May_NNP 2003_CD Record_NNP date_NN 9th_CD May_NNP 2003_CD The_DT table_NN sets_VBZ out_RP the_DT middle_JJ market_NN closing_NN prices_NNS derived_VBN from_IN Payable_JJ 3rd_CD July_NNP 2003_CD the_DT LSE_NNP Daily_NNP Official_NNP List_NN ._.
The_DT companys_NNS share_VBP price_NN declined_VBD by_IN 31_CD per_IN cent_NN in_IN 2002_CD from_IN a_DT price_NN of_IN 17.23_CD at_IN 1st_CD January_NNP 2002_CD Second_JJ quarter_NN 2003_CD to_TO 11.92_CD at_IN 31st_CD December_NNP 2002_CD ._.
This_DT compares_VBZ with_IN a_DT decrease_NN Ex-dividend_NN date_NN 30th_JJ July_NNP 2003_CD in_IN the_DT FTSE_NNP 100_CD index_NN of_IN 24_CD per_IN cent_NN during_IN the_DT year_NN ._.
In_IN the_DT two_CD years_NNS Record_NNP date_NN 1st_CD August_NNP 2003_CD since_IN the_DT merger_NN ,_, the_DT share_NN price_NN has_VBZ declined_VBN by_IN 37_CD per_IN cent_NN from_IN Payable_JJ 2nd_JJ October_NNP 2003_CD 18.90_CD at_IN 1st_CD January_NNP 2001_CD which_WDT is_VBZ in_IN line_NN with_IN a_DT similar_JJ decrease_NN Third_JJ quarter_NN 2003_CD in_IN the_DT FTSE_NNP 100_CD index_NN over_IN the_DT same_JJ period_NN ._.
Ex-dividend_NN date_NN 29th_JJ October_NNP 2003_CD Record_NNP date_NN 31st_CD October_NNP 2003_CD Payable_JJ 6th_JJ January_NNP 2004_CD ANNUAL_NNP REVIEW_NNP 2002_CD 28_CD |_NN 29_CD Internet_NNP United_NNP Kingdom_NNP United_NNP States_NNPS of_IN America_NNP Information_NNP for_IN investors_NNS and_CC about_IN the_DT Investor_NNP relations_NNS Investor_NNP relations_NNS company_NN is_VBZ available_JJ on_IN GlaxoSmithKlines_NNP 980_CD Great_NNP West_NNP Road_NNP One_CD Franklin_NNP Plaza_NNP corporate_JJ website_NN at_IN www_NN ._.
com_NN Brentford_NNP PO_NNP Box_NNP 7929_CD Middlesex_NNP TW8_NNP 9GS_NNP Philadelphia_NNP Head_NNP Office_NNP and_CC Registered_NNP Office_NNP Tel_NNP :_: 44_CD 0_CD 20 8047 5557 5558_CD Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ Fax_NN :_: 44_CD 0_CD 20 8047 7807_CD Tel_NNP :_: 1_CD 215 751 7003_CD outside_IN the_DT USA_NNP GlaxoSmithKline_NNP plc_NN Fax_NNP :_: 1_CD 215 751 3233 980_CD Great_NNP West_NNP Road_NNP Registrar_NNP Brentford_NNP Lloyds_NNP TSB_NNP Registrars_NNPS ADR_NNP program_NN administrator_NN Middlesex_NNP TW8_NNP 9GS_NNP The_NNP Causeway_NNP The_NNP Bank_NNP of_IN New_NNP York_NNP Tel_NNP :_: 44_CD 0_CD 20 8047 5000_CD Worthing_NNP Shareholder_NN Relations_NNP West_NNP Sussex_NNP BN99_NNP 6DA_NNP PO_NNP Box_NNP 11258_CD www_NN ._.
co._FW uk_FW Church_NNP Street_NNP Station_NNP New_NNP York_NNP NY_NNP 10286-1258_CD General_NNP enquiries_NNS ,_, Annual_JJ Report_NNP www_NN ._.
com_NN orderline_NN and_CC Corporate_JJ Nominee_NN service_NN Tel_NNP :_: 1_CD 877 353 1154_CD toll_NN free_JJ Tel_NNP :_: 0870 600 3991_CD inside_IN the_DT UK_NNP Tel_NNP :_: 1_CD 610 312 5315_CD outside_IN the_DT USA_NNP Tel_NNP :_: 44_CD 0_CD 121 415 7067_CD outside_IN the_DT UK_NNP Customer_NN Response_NNP Center_NNP Shareholder_NN Investment_NN Plans_NNS Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ Dividend_NN Re-investment_JJ queries_NNS Tel_NNP :_: 0870 241 3018_CD inside_IN the_DT UK_NNP Tel_NNP :_: 44_CD 0_CD 1903 604 516_CD outside_IN the_DT UK_NNP Monthly_JJ Savings_NNPS Plan_NNP queries_VBZ Tel_NNP :_: 0870 606 0268_CD inside_IN the_DT UK_NNP Tel_NNP :_: 44_CD 0_CD 131 527 3746_CD outside_IN the_DT UK_NNP ISA_NNP enquiries_VBZ Tel_NNP :_: 0870 242 4244_CD inside_IN the_DT UK_NNP Tel_NNP :_: 44_CD 0_CD 1903 604 594_CD outside_IN the_DT UK_NNP Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP corporate_JJ PEPs_NNS The_DT Share_NN Centre_NNP Limited_NNP Oxford_NNP House_NNP Oxford_NNP Road_NNP Aylesbury_NNP Produced_NNP by_IN Corporate_NNP Communications_NNPS ,_, Bucks_NNPS HP21_NNP 8SZ_NNP GlaxoSmithKline_NNP plc._NN ._.
Tel_NNP :_: 44_CD 0_CD 1296 414 144_CD Design_NN consultancy_NN by_IN salterbaxter_NN ._.
Corporate_JJ share_NN dealing_VBG facility_NN Printed_NNP in_IN the_DT UK_NNP by_IN Waddies_NNP ._.
The_DT paper_NN used_VBN NatWest_NNP Stockbrokers_NNS in_IN the_DT production_NN of_IN this_DT document_NN is_VBZ made_VBN from_IN pulps_NNS harvested_VBN from_IN sustainable_JJ forests_NNS ,_, also_RB Corporate_NNP &_CC Employee_NNP Service_NNP using_VBG sawmill_NN residues_NNS and_CC forest_NN thinnings_NNS ._.
55_CD Mansell_NNP Street_NNP It_PRP is_VBZ elemental_JJ chlorine-free_NN ._.
London_NNP E1_NNP 8AN_NNP Product_NNP names_NNS throughout_IN this_DT publication_NN are_VBP Tel_NNP :_: 0870 600 3080_CD inside_IN the_DT UK_NNP indicated_VBD in_IN italics_NNS and_CC are_VBP trade_NN marks_NNS of_IN GlaxoSmithKline_NNP plc_NN ,_, its_PRP$ subsidiaries_NNS or_CC associated_VBN Tel_NNP :_: 44_CD 0_CD 20 7895 5923_CD outside_IN the_DT UK_NNP companies_NNS ,_, with_IN the_DT exception_NN of_IN Levitra_NNP a_DT trade_NN Email_NNP :_: contactces@natwest_JJS ._.
com_NN quoting_VBG GSK_NNP mark_NN of_IN Bayer_NNP AG_NNP and_CC Nicoderm_NNP ,_, a_DT trade_NN mark_NN of_IN Aventis_NNP SA_NNP ,_, all_DT of_IN which_WDT is_VBZ used_VBN under_IN licence_NN Shareholders_NNP Service_NNP by_IN the_DT Group_NNP ._.
ANNUAL_JJ REVIEW_NNP ANNUAL_NNP REPORT_NNP CORPORATE_JJ AND_CC SOCIAL_JJ A_DT review_NN of_IN major_JJ The_DT full_JJ Financial_NNP RESPONSIBILITY_NNP REPORT_NNP communication_NN statements_NNS for_IN the_DT A_NNP review_NN of_IN our_PRP$ themes_NNS for_IN 2002_CD year_NN ended_VBD 31st_CD commitment_NN to_TO society_NN and_CC an_DT abridged_JJ December_NNP 2002_CD ._.
and_CC the_DT environment_NN ._.
version_NN of_IN the_DT financial_JJ results_NNS ._.
